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Creating an Effective Routine Surveillance System for Drug-Resistant Tuberculosis 
Among Previously Treated Patients in Tanzania. 
 
Basra Esmail Doulla 
 
Introduction: Tuberculosis routine surveillance is an essential tool for scrutinising the 
effectiveness of TB Programmes and especially for monitoring drug resistance. This 
study sought to understand the effectiveness of the existing Routine Surveillance 
System for drug-resistant Tuberculosis amongst previously treated TB patients  in 
Tanzania, identify weaknesses and interventions leading to improvements, and then 
pilot these interventions.  
Methods: Both quantitative and qualitative methods were used to gather the current 
Routine Surveillance System information among previously treated tuberculosis 
patients. Quantitative data were collected from the routine laboratory databases 
over a three-year period (2011-2013). Qualitative data were collected using key 
informant interviews and focus group discussions. Based on the results, an 
intervention to improve the Routine Surveillance System was designed and a pilot 
study was implemented in Mwanza region. The intervention considered the 
implementation of rapid molecular techniques such as Xpert MTB/RIF and Line Probe 
Assay at the Central Tuberculosis Reference Laboratory. Revised communication 
measures and request form completion strategies were also included. A further 
qualitative study was undertaken for comparison after implementation.   
Results: The initial quantitative analysis showed that, over the surveyed period, 2,750 
specimens were received at the reference laboratory from across the country. This 
was only 32% of the anticipated numbers, although it reached 61% in 2013. The 
median and interquartile ranges of turnaround times for microscopy, culture and 
drug sensitivity testing were: 1(1, 1), 61(43, 71) and 129(72, 170) days respectively. 






analysis showed a mixed picture; the system of sending specimens via post was seen 
to be efficient, though many challenges were noted, in particular: inadequate 
supplies, poor completion of forms, staff shortages and demotivation. Delays in the 
transportation of specimens were associated with inadequate funding, training and 
poor supervision. A revised routine surveillance system for drug-resistant 
tuberculosis amongst previously treated tuberculosis patients in Tanzania was 
designed to address many of the identified shortfalls. The revised system, piloted in 
Mwanza, increased the volume of specimens received from 75 in 2016 to 185 in 2017. 
The system reduced the time it took for specimens to reach the reference laboratory 
by 22% (from 9 to 7 days). The median time for results getting back to the requesters 
was shortened by 36% (from 11 to 7 days).  Overall, the number of drug resistant 
cases increased by 67% (from 12 to 20). In the qualitative analysis undertaken 
following the pilot, stakeholders identified earlier diagnosis, timely feedback of 
results, strengthened communication and reliable specimen transportation 
arrangements as key gains.  
Conclusion: The routine surveillance system is critical to the effectiveness of the 
Tuberculosis Programme in Tanzania. The existing routine surveillance policy was 
poorly executed and lacked new technology, which led to long delays, specimen 
inertness, discontentment and compromised patient care. A revised routine 
surveillance system can overcome these weaknesses and increase MDR-TB detection. 
These lessons are highly relevant to other resource-limited settings, including 
elsewhere in sub-Saharan Africa.  
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Short title: Routine surveillance for control of tuberculosis drug resistance in 
Tanzania 
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Definitions   
Drug susceptibility testing: Refers to in vitro testing using either phenotypic methods to determine 
susceptibility or molecular techniques to detect resistance. This entails testing to find out which 
drugs will be effective against certain TB bacteria. 
Drug Susceptible Tuberculosis: If someone is infected with TB bacteria that are fully susceptible, it 
means that all the TB drugs will be effective so long as they are taken properly.  
Drug Resistant Tuberculosis: Is the resistance to anti-TB drugs, meaning that the disease does not 
respond to standard TB drug treatment. This can occur when first-line drugs are misused or 
mismanaged. 
Extensively drug resistant TB (XDR-TB): Is a rare type of MDR-TB that is resistant to isoniazid and 
rifampicin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., 
amikacin, kanamycin, or capreomycin). 
Extra-Pulmonary Tuberculosis: Extra-pulmonary tuberculosis (EPTB) occurs when the bacteria 
spread outside of the lung and cause disease.  Except for laryngeal TB, EPTB is not usually infectious.  
Patients with EPTB disease often also have TB disease in the lungs.  EPTB usually occurs in people 
with weak immune systems such as those who are PLHIV, DM or infants.  
Genotypic DST (molecular DST): Genotypic testing detects mutations in the TB genome associated 
with specific drug resistance. (Note: genotypic testing is also used to identify M. tuberculosis by 
detecting the presence of TB-specific mycobacterial DNA). 
Molecular Detection of Drug Resistance: Is a method to identify multidrug-resistant TB (MDR-TB) 
rapidly. This service uses Deoxyribonucleic Acid (DNA) sequencing for detection of mutations most 
often associated with rifampicin and isoniazid drug resistance. Added testing will be conducted to 
identify mutations associated with resistance to the most effective second-line drugs; 






Mono-resistance: resistance to one first-line anti-TB drug only. 
Multidrug-Resistant Tuberculosis (MDR-TB): is a form of TB caused by organisms that are resistant 
to at least two of the most effective anti TB drugs, isoniazid and rifampicin.  
New case: Is a newly registered episode of TB in a patient who had never been treated for TB or 
reports having taken anti-TB drugs for less than one month. 
Phenotypic DST (conventional DST): Phenotypic testing determines if an isolate is resistant to an 
anti-TB drug by evaluating growth (or metabolic activity) in the presence of the drug.  
Poly-resistance: resistance to more than one first-line anti-TB drug, other than both isoniazid and 
rifampicin. 
Presumptive TB case: a patient who presents with symptoms or signs suggestive of TB. 
Previously-treated case: Is a registered patient who has reported having received one month or 
more of anti-TB drugs in the past. Previously treated cases (also referred to as “retreatment cases”) 
are a heterogeneous group composed of several subcategories. i.e. Relapse, Treatment after failure, 
Treatment after loss to follow-up and Previously-treated other. 
Proportion method: is used for testing the susceptibility of M. TB complex isolates. It differentiates 
the proportion of resistant organisms within a particular strain that is used to determine clinically 
significant in particular anti TB drugs. 
Pulmonary Tuberculosis (PTB): This is the most frequent type, accounting for about 80% of TB cases. 
PTB is infectious. Symptoms include a cough for two or more weeks and sputum production. Patients 
may have cavities in the lung that are rich in bacilli.  
Purposive sampling (also known as judgment, selective or subjective sampling): is a sampling 
technique in which researcher relies on his or her own judgment when choosing members of 






Rifampicin resistance (RR): resistance to rifampicin detected using phenotypic or genotypic 
methods, with or without resistance to other anti-TB drugs. This includes any resistance to 
rifampicin, in the form of mono-resistance, poly-resistance, MDR or XDR. 
Relapse patients: have previously been treated for TB, were declared cured or treatment completed 
at the end of their most recent course of treatment and have now been diagnosed with a recurrent 
episode of TB (either a true relapse or a new episode of TB caused by reinfection).  
Routine Surveillance System: Is a surveillance system based on routine drug susceptibility testing of 
TB cases.  
Sampling: is a process used in statistical analysis in which a predetermined number of observations 
are taken from a larger population. The methodology used to sample from a larger population 
depends on the type of analysis being performed, but it may include simple random sampling or 
systematic sampling.  
Surveillance systems based on routine drug susceptibility testing: A surveillance system based on 
routine DST of all TB cases is able to provide continuous information on drug resistance patterns 
among patient groups, and is therefore able to accurately detect trends, as well as localized 
outbreaks. 
Transit time: the time from specimen collection in the peripheral health facilities to the time the 
specimen is received at a site where DST can take place time. 
Treatment after failure: patients are those who have previously been treated for TB and whose 
treatment failed at the end of their most recent course of treatment. 
Treatment after loss to follow-up: patients have previously been treated for TB and were declared 
lost to follow-up at the end of their most recent course of treatment (previously known as treatment 
after default patients). 
Tuberculosis (TB): is a disease caused by bacteria Mycobacterium tuberculosis that is spread from 






Turnaround time (TAT): The time from specimen receipt at the CTRL to the time the DST results are 
sent back to the requesting clinician 
Xpert MTB/RIF (Xpert): a rapid molecular technology for detection of MTB and rifampicin 






Chapter 1 Introduction 
1.1 Global Tuberculosis burden  
Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide (1). The disease remains a 
global emergency which was first declared by the World Health Organisation (WHO) in 1993 and 
endorsed by the Africa Union through the Maputo declaration in 2005 (2). TB is an infectious disease 
caused by the bacillus Mycobacterium tuberculosis (MTB). It typically affects the lungs (pulmonary 
TB or PTB) but can also affect other parts of the body (extrapulmonary TB or EPTB). The mode of 
transmission of the bacilli is mainly by infected aerosol in tiny droplets when talking, coughing, 
laughing or sneezing (3,4). Between 2000 and 2017 there was significant progress in global TB control 
and in fighting the disease (5,6). TB treatment alone averted an estimated 45 million deaths and TB 
treatment supported by Antiretroviral Therapy (ART) averted an additional 9 million deaths among 
Human Immunodeficiency Virus (HIV) positive people (5,6). According to WHO estimates, there were 
10.0 million new incident cases of TB disease in 2017, of which 5.8 million were men, 3.2 million 
were women and 1.0 million were children (aged< 15 years). People living with HIV accounted for 
an estimated 9% total (7). In addition, about one-quarter of the world's population has latent TB.  
This refers to people who have been infected by TB bacteria but who have not (yet) become ill with 
the disease and cannot transmit the disease (8). People infected with TB bacteria have about 5 to 
15% lifetime risk of falling ill with TB. People with compromised immune systems, such as people 
living with HIV, malnutrition or diabetes, or people who use tobacco, have a much higher risk of 
falling ill (8).  
The emergence and global spread of Multidrug-Resistant TB (MDR-TB) has become a priority public 
health issue (9). MDR-TB is TB disease that is resistant to at least isoniazid (INH) and rifampicin (RIF), 
the two most potent first line drugs (FLD) for TB treatment. According to the 2016 WHO Global 
Report there were an estimated 480,000 cases of MDR-TB globally. It can be argued these figures 
are an underestimate of the true burden of MDR-TB (9). It is because these estimates are based on 
the number of notifications, but in resource constrained settings many TB and MDR-TB cases are still 






routine surveillance, diagnosis, and lack of robust data leading to the WHO inability to accurately 
estimate the burden. 
 Furthermore, nearly one in ten of the MDR-TB cases are categorised as Extensively Drug-Resistant 
TB (XDR-TB). Most recently, totally drug-resistant TB (TDR-TB) has emerged in various parts of the 
world. XDR-TB is a rare type of MDR TB that is resistant to INH and RIF, plus any fluoroquinolone and 
at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin). Both 
MDR-TB and XDR-TB require long-term treatment regimens with toxic second-line anti-TB drugs that 
are associated with serious side effects leading to non-adherence and high mortality (9).  
Effective TB control measures require early identification of the TB infected persons followed by 
timely tailored therapies (10). In resource-constrained countries there are often many patient and 
healthcare system-related delays between the onset of TB symptoms and diagnosis and treatment. 
Such delays provide more opportunities for transmission of the disease, which adversely affects the 
public (11,12).  
Diagnosis of active TB in Low-and Middle-Income Countries (LMIC) is still mainly based on the 
detection of MTB through sputum smear microscopy examination and occasionally culture (10). 
Culture methods are more sensitive and specific than microscopy but are slower (e.g. 3-8 weeks in 
the Löwenstein-Jensen (LJ) medium and 2-3 weeks for liquid culture) and prone to contamination. 
Both methods are complex requiring skilled personnel, good laboratory standards and infrastructure 
(Biosafety level 2 for solid culture and level 3 for liquid culture), and  continuous power supply 
(13,14).  
Difficulty in specimen transportation between remote locations and reference laboratories are also 
contributing factors to diagnostic delay, particularly for drug resistance testing (8,15). In 2010, the 
WHO endorsed the use of the Xpert MTB/RIF (Xpert) assay, a rapid molecular technology for 
detection of MTB and rifampicin resistance (RR). The assay operates on the GeneXpert system 
(Cepheid, CA, USA), and has the potential to revolutionise the detection of TB and MDR-TB in LMIC 
(15,16). TB programmes need to make the right decision about which of these new tools to 






decisions are difficult as the new tools are often expensive to implement and use, and until recently 
the health system and patient effects were uncertain (17).  The need for reliable drug-susceptibility 
testing (DST) has increased with the growth in the prevalence of MDR-TB. This has also lead to an 
increased demand for appropriate treatment for MDR-TB and an expansion of anti-TB Drug 
Resistance Surveys (DRS) (18).   
In summary, urgent action is required to improve the quality of diagnosis, treatment and care for 
people with DR-TB, which requires higher coverage of accurate DST and prompt feedback of results, 
alongside the overall reduction of under-diagnosis of all forms of TB (19).  
 
1.2 TB and MDR-TB burden in Tanzania  
In Tanzania, TB closely follows HIV and Malaria in the major causes of morbidity and mortality from 
an infectious disease, especially among adults (20). According to the WHO report, Tanzania is among 
the 30 countries with the highest TB burden (6). The national Prevalence Survey of TB (PST) 
completed in November 2012 revealed a higher TB burden than previous estimates had predicted. 
The survey showed a TB prevalence of 295 per 100,000 population among adults ≥ 15 years and a 
case detection rate of 42% – 54% (21). The WHO estimated that TB incidence was 269/100,000 in 
2017, which implies 154,000 people became infected with TB in Tanzania whereas only a total of 
69,623 TB cases were notified, equivalent to a 45.2% case detection rate. Overall this implies that 
approximately 84,000 TB cases were missed (19).  
In addition, TB cases notified in Tanzania had only increased from 62,100 in 2006 to 65,902 cases in 
2016 (22,23). The National TB and Leprosy Programme (NTLP) annual report of 2016 further reveals 
the distribution of notified cases of TB (all forms). This showed that Dar es Salaam city is the largest 








Figure 1 Distribution of TB cases notified by region 
 
Source NTLP annual report 2016  
 
 
The total previously treated TB cases notified in Tanzania from 2006 to 2016 were 38,200 with 3,051 
cases in 2016 representing 4.6 % of all cases notified in the country in that year. Previously-treated 
TB cases are made up of relapse, failures, lost to follow-up and other. Figure 2 shows the trend of 
recorded previously-treated cases, which may be impacted by changes in definitions effecting how 





























Figure 2  Trend Previously-treated TB cases notified 
Source NTLP annual report 2016 
 
Figure 3 shows the trend of new TB case notified compared to the contributions from previously- 
treated TB cases. This shows the level of Previously-treated TB cases as a proportion of all forms of 
TB has remained constant between 2011 and 2016 at around (4 to 5%). 
Figure 3: Trend of All TB notification and Previously-treated TB cases 2006 - 2016 
 





































































MDR-TB: MDR-TB in Tanzania is characterised by low detection and poor treatment outcomes. To 
avoid the spread of the resistant strains, it is essential that anti-TB drug resistant levels are better 
understood and that there is early detection and appropriate treatment of patients with drug 
resistant TB (DR-TB). Prevalence studies have shown that in Africa, including Tanzania, there are 
significant gaps in DR-TB detection and reporting (8). Based on the 2006/2007 National DRS in 
Tanzania the proportion of MDR-TB among new and previously-treated TB cases is estimated to be 
1.1% and 3.1% respectively in Tanzania (25).  
As shown in Figure 4, based on the NTLP and global data from 2009 – 2017, detected cases of MDR-
TB have risen from 15 in 2009 to 200 in 2017. This led to 15 and 167 cases respectively, being enrolled 
on treatment. This signifies that there is also a challenge of missing cases with DR-TB (8). This could 
be due to poor data recording, or delay in diagnosis, the reason behind it could not be established. 
More effort is needed to find the missing cases with TB and MDR-TB to prevent further transmission, 
enhance treatment outcomes and, ultimately to achieve the End TB 2030 targets (26).  
 
Figure 4 MDR-TB detected and enrolled 2009-2017 
 






1.3 Background of Tanzania and National TB and Leprosy Programme 
The United Republic of Tanzania is the largest country in East Africa, occupying an area of about 
945,082 square kilometres (approximately 365,800 square miles) with a population of 57.3 million, 
according to the 2017 World Bank update.1 Despite Tanzania being a low income country, there has 
been sustained, and relatively high, economic growth over the last decade, averaging 6–7% per year. 
The poverty rate has decreased slowly from 28.2% in 2012 to 26.9% in 2016. This decline has been 
accompanied by improvements in human development outcomes and living conditions. Gross 
Domestic Product (GDP) grew by 7.1% in 2017.  
The country borders with Kenya and Uganda to the north; Rwanda, Burundi and the Democratic 
Republic of Congo to the west; and Zambia, Malawi and Mozambique to the south. The Indian Ocean 
forms the eastern border. Administratively, Tanzania has thirty-five regions, of which, thirty are in 
mainland Tanzania and five in Zanzibar. Dar es Salaam, with a population of 4.36 million accounts 
for 10% of the total Tanzania mainland population (27).  
The Ministry of Health set up the TB Programme in 1977 to facilitate early diagnosis, treatment and 
cure of all TB and leprosy patients with the aim that the two diseases would no longer be a major 
public health problem in the country. The mission of the programme is to provide high quality, 
effective interventions for TB and leprosy care and control in Tanzania (28). 
 
1.4 Management of TB and MDR-TB in Tanzania  
At the ministerial level, National TB and Leprosy Programme (NTLP) coordinates all activities 
pertaining to TB and leprosy care and control in the country. It operates at the national, regional, 









Figure 5 National TB Programme Organisation  
 
                    Key: TB-tuberculosis   
 
Management of TB at the National level 
The management at the national level is responsible for overseeing all activities at the regional, 
district and community levels. In addition, the national TB Programme works closely with 
developmental partners to implement TB and leprosy control, prevention and care measures across 
the country (27).  
Management of TB and leprosy control activities at regional Level 
The NTLP splits the Tanzania Mainland into 30 regions. The Regional Tuberculosis and Leprosy 






activities and reports to the NTLP. The coordinator liaises with the local TB implementing partners 
to ensure that TB, TB/HIV and leprosy activities are prioritised by the communities in their respective 
region. He or she works closely with the Regional Health Management Team (RHMT) in planning and 
implementing all activities. The RTLC is administratively answerable to the Regional Medical Officer 
(RMO). 
Management of TB and leprosy control activities at district Level 
There are 165 districts across the country and the District Tuberculosis and Leprosy Coordinator 
(DTLC) is one of the co-opted members in the Council Health Management Team (CHMT) and 
collaborates with the team in addressing and implementing the NTLP agenda into a Comprehensive 
Council Health Plan (CCHP). Administratively, the DTLC reports to the District Medical Officer (DMO). 
However, for all issues pertaining to TB, TB/HIV and leprosy they report to the RTLC who as stated 
above then reports to the NTLP.  
Management of TB and leprosy control activities at community Level 
The Ministry of Health realized the importance of strengthening a linkage between health facilities 
and the community in the provision of health services at community level. The community is aware 
about TB and seek more services in TB and HIV. The NTLP adapted the ENGAGE TB approach so as 
to sensitize and encourage a wider range of stakeholders to involve themselves in community-based 
activities (29). It helped to increase case notification and reduced the workload on the health facility 
side (30). At the community level, TB, TB/HIV and leprosy care and control are implemented as part 
and parcel of routine NTLP activities to expand Directly Observed Treatment (DOT) activities beyond 
health facilities and to involve communities. The health care workers at the health facility level are 
responsible for providing and sustaining the quality of TB, TB/HIV and leprosy services. Health care 
workers at the facility level report to the DTLC (27).  
1.4.1 Donor support 
The TB Programme works closely with developmental partners to implement TB and leprosy control, 
prevention and care measures in the country. The NTLP receives financial support through Global 






majority of the key interventions promoted by the NTLP are donor-funded such as the introduction 
of new TB diagnostic technologies, innovative transport systems for sputum samples, and the 
strengthening of programme data quality - including transitioning to electronic-based platforms (31). 
Figure 6 shows which regions of the country are supported by which partners. 
Figure 6  The TB Implementing Partners Mapping by Region 
  
Key: KNCV-Koninklijke Nederlandse Centrale Vereniging tot bestrijding der Tuberculose (Dutch Tuberculosis Foundation). CDC- Centres for Disease 
Control and Prevention; GF- Global Fund; AMREF- African Medical and Research Foundation.  
Note: Under NTLP region Dar es Salaam has four regions (Ilala I, Ilala II, Temeke and Kinondoni).  
 
1.5 TB Laboratory Diagnosis in Tanzania 
The Tanzanian government continues to provide both TB diagnostic services and treatment free of 
charge in all public and private health facilities. The core activities of the TB Programme are based 






delivery of effective therapy to patients. Currently there is good network coverage of laboratories, 
and sputum smear microscopy services are fully integrated into the general health care delivery 
system, including private and public health institutions. At the time of conducting this study there 
were 788 Acid Fast Bacilli (AFB) diagnostic centres scattered across the country. Ziehl Neelsen (ZN) 
method has been the traditional diagnostic tool and performed at all diagnostic centres.  
In 2011 Light-Emitting Diode (LED) fluorescence microscopy was successfully piloted at two regions 
in Dar es Salaam. Capacity is being developed in laboratories with high workload particularly to 
improve the diagnostic efficiency of microscopy in TB suspects with HIV and Acquired 
Immunodeficiency Syndrome (AIDS) for which the sensitivity of ZN microscopy is known to be much 
lower, due to low bacterial load in their sputum samples (27).  
Out of the 788 diagnostic centres, two act as zonal TB culture laboratories. There is also one 
standalone TB laboratory (Central TB Reference Laboratory – CTRL) at the national level with a 
capacity for DST for the whole country.  In all other diagnostic centres (except at the CTRL and in a 
small number of new Xpert sites) AFB microscopy remains the initial test for detection of TB. For 
these two sputum specimens are collected. The first sample is collected on presentation of the 
presumptive TB case (SPOT) and the second an early morning sample the following day (MORNING). 
Zonal TB culture laboratories (Kibong’oto and Bugando) perform routine culture on solid LJ media. 
The CTRL has available both solid culture and liquid culture methods. The liquid culture approach 
uses the Mycobacterium Growth Indicator Tube (MGIT) method. DST is also performed at the CTRL 
for first- and second-line anti TB drugs.  
In 2010 the molecular test using Line Probe Assay (LPA) for FLD INH and RIF was introduced at the 
CTRL. LPA is used to confirm MDR-TB strains found by phenotypic testing. Xpert MTB/RIF was 
introduced in the country in 2012 at two regional hospitals (Temeke and Iringa) for evaluation of the 
technique. In 2013, 4- module Xpert MTB/RIF machines were installed in 13 health facilities. These 
were split as follows - 4 of these were in the Dar es Salaam region, 1 in Iringa, 1 in Mwanza, 6 in 
Mbeya (provided by the London School of Hygiene and Tropical Medicine), plus 1 at CTRL (provided 






The NTLP through Centres for Disease Control and Prevention (CDC) with World Bank support plan 
to install several more Xpert systems – this includes 4 more machines in Mwanza including one in 
the Bugando Zonal laboratory (more of this will be described in chapter 5). Although the Xpert 
machine at the CTRL was installed for research purposes, the laboratory uses it for diagnostic 
purposes when required by supplementing the cartridge supply (27).  
In summary, the TB laboratory network in Tanzania is organised into five main levels according to 
the type of services provided: -  
a) National: Central Tuberculosis Reference Laboratory (CTRL) (x1) 
b) Intermediate: Zonal Tuberculosis Reference Laboratories (x5) 
c) Regional: Referral hospital laboratories (x31)  
d) District: Hospital laboratories (x169) 
e) Peripheral: Health centres and dispensaries (x735) 
 
1.5.1 Responsibilities of the TB laboratory network levels 
a). National: Central Tuberculosis Reference Laboratory 
The CTRL is the principal national laboratory of the TB Programme in Tanzania situated in Dar es 
Salaam. Although part of the laboratory network led by the Assistant Director of Diagnostic Services 
of the Ministry of Health, the CTRL falls directly under the authority of the NTLP Programme 
Manager. Its principal responsibilities include conducting TB diagnostics for the Muhimbili National 
Hospital, where it is housed; performing diagnostics of samples submitted for analysis by 
intermediate and peripheral laboratories in the country, particularly for MDR-TB as part of the 
Routine Surveillance System (RSS); coordinating and implementing training of TB laboratory 
personnel throughout the country; and conducting supportive supervision and external quality 
assurance (EQA) within the laboratory network. In addition, personnel at the CTRL develop policies, 






diagnostic technologies to advise the Programme Manager. They also ensure availability of 
laboratory equipment, reagents, supplies at all levels in line with the NTLP guidelines. Operational 
research of relevant TB and leprosy control activities is initiated and coordinated at the CTRL.   
The author of this thesis is the current Head of the CTRL. The CTRL is directed by the Head of CTRL 
who also acts as the Laboratory Director. Head of CTRL responsibilities include professional, 
scientific, consultative, organizational, administrative, and educational matters relevant to the 
services offered by the laboratory.  
The Head of CTRL also delegates some of their responsibilities to the Laboratory Manager. At the 
time of conducting this study the CTRL had 15 staff members, of which 2 led management activities; 
9 were primarily responsible for diagnostics, supervision, training and EQA activities; 2 were 
laboratory attendants; and two data staff. Staff members are provided to the laboratory by a number 
of institutions including 3 from the Ministry of Health, 3 from partners Program for Appropriate 
Technology in Health (PATH), and 9 from the National Institute of Medical Research (NIMR) (28). 
b). Intermediate: Zonal Tuberculosis Reference Laboratories 
The Zonal TB Reference Laboratories conduct TB bacteriology testing using culture of samples 
referred by facilities in the relevant zone.  
All positive culture slopes are sent to the CTRL for additional testing. Personnel at the zonal 
laboratories participate in supervision of AFB microscopy in the zone and training of laboratory 
workers involved in AFB microscopy, in collaboration with the RTLC. In addition, operational research 
of relevant TB and leprosy control activities may sometimes be initiated and coordinated from the 
zonal laboratory. 
c). Regional: Referral Hospital Laboratories 
Personnel at the regional hospital laboratories plan and supervise AFB smear microscopy and 
molecular testing in the region and organize training of laboratory workers involved in AFB 






laboratory reagents and other supplies, in collaboration with the RTLC and the regional pharmacist. 
They participate in EQA of AFB smear microscopy.  
d). District: Hospital Laboratories 
Personnel at the district hospital laboratories are responsible to supervise AFB microscopy in the 
district and ensure the quality is maintained by adherence to NTLP policies and guidelines. They 
undertake smear microscopy testing for TB and the recording of results in the NTLP laboratory 
request form and register. They ensure that sufficient, quality-controlled stains and reagents are 
supplied to health facilities. They also assist in AFB microscopy training programs and participate in 
the EQA of AFB smear microscopy. Sputum specimens for culture and sensitivity testing (e.g. as part 
of the RSS) at the reference laboratory are collected, stored, and transported from the district 
hospital laboratories, in collaboration with the DTLC. 
e). Peripheral: Health Centres and Dispensaries 
Health centres and dispensaries are responsible to facilitate proper sputum specimen collection 
(SPOT, MORNING) and registration. They undertake smear microscopy testing for TB and the 
recording of results in the NTLP laboratory request form and register. They ensure that sufficient 
laboratory reagents are available, in collaboration with the District Laboratory Technician (DLT) and 
the DTLC. They ensure the safe disposal of infected materials (e.g., sputum containers, microscopic 
slides) whilst retaining all examined slides for EQA in line with the NTLP guidelines. They ensure the 
proper care, use, and safety of the microscope. They implement recommended corrective action for 
improvement of services.  
The levels of the network are linked through a two-way system: the lower level reports to the next 
higher level and higher levels supervise the lower levels, with the exception that the zonal level is 
not systematically involved in supervision. 
1.5.2 Infrastructure of the TB laboratory network 
There is a general national guidance for laboratory infrastructure within the Ministry of Health 






the laboratories in the country. The Infrastructure of TB zonal culture laboratories is of good quality, 
although negative air pressure is not available and is only available at the CTRL. All culture 
laboratories have biological safety cabinets (BSC). Infrastructure of most of the district and 
peripheral laboratories buildings are old and are not well maintained. 
1.5.3 Maintenance and validation of TB laboratory equipment 
According to the National policy on medical laboratory equipment, introduction of technologically 
new equipment should be approved by the Private Health Laboratory Board (PHLB) which is 
authorized to verify suitability of new equipment. Each laboratory is responsible for verification of 
any new equipment before routine use. Laboratory staff are trained in routine maintenance of 
equipment during technical training. The Negative pressure room and BSCs are serviced once a year 
by Air Filters cleaner from South Africa.  
1.5.4 Management of laboratory commodities and supplies 
The CTRL guides procurement of equipment based on the international standard specifications. 
Procurement of equipment is by two operational procurement channels: a). Procurement done by 
the Medical Stores Department (MSD) (supplies for microscopy), and b). Procurement done by the 
NTLP in collaboration with partners (supplies for culture, DST and molecular tests). The MSD 
procures supplies centrally and distributes to the zonal branches of the MSD. The zonal MSDs 
distribute supplies to the district level and large hospitals.  
1.5.5 Laboratory information and data management 
The laboratory information system is currently predominantly paper based using forms and 







1.6 Quality Assessment (QA) 
1.6.1 Overview 
Quality assurance (QA) covers processes and procedures that systematically monitor activities and 
processes done within the TB laboratory to ensure that testing activities generate consistently 
reliable results and are of the anticipated quality standard. The QA involves two major sets of 
activities i.e. Internal quality control (IQC) and EQA.  
1.6.2 Internal Quality Control (IQC) 
Internal quality control includes the means by which test procedures and instrument operations are 
regularly checked  (32).  
In Tanzania, as part of the routine IQC of AFB smear microscopy laboratories, known (1+) or scanty 
positive slides and known negative slides are used as controls to monitor the quality of AFB smear 
microscopy in the laboratory (33). For culture sterile distilled water is inoculated in both slope 
(pyruvate and glycerol media) as a negative control and known positive strains in used as a positive 
control.  The IQC for DST H37RV as a positive control, this is more virulent strain for TB, with R 
standing for rough morphology and v standing for virulent (34). while sterile distilled water is as a 
negative control. The performance of internal Proficiency Testing (PT) provides an additional means 
to assure the quality of laboratory testing results and in addition measures personnel 
competency/proficiency in testing during the daily performance of the laboratory. Details of these 
processes are shown in section 1.6.4. 
1.6.3 External Quality Assessment (EQA) 
The is a system for objectively checking the laboratory’s performance using an external facility. It is 
an indispensable part of a laboratory quality management system as it ensures that users of the 
laboratory can have confidence that it produces accurate and reliable results. An independent EQA 






ISO 15189: 20122, which states that “The laboratory shall participate in an internal laboratory 
comparison such as an EQA or proficiency programme appropriate to the examination and 
interpretations of examination results” (35). The EQA for AFB smear microscopy is a process which 
allows participating laboratories to access their capabilities and performances by comparing their 
results with those in other laboratories in the network. The EQA focuses on the identification of 
laboratories where there may be serious problems resulting in poor performance. The EQA for AFB 
smear microscopy consists of three methods (panel testing, onsite evaluation and blind rechecking) 
that can be combined to evaluate laboratory performance (32). 
In Tanzania, EQA for sputum smear microscopy is done by using an approach known as “blind 
rechecking system”. It was introduced in 2008 in collaboration with a technical consultant from 
Institute of Tropical Medicine (ITM), Antwerp, Belgium. This system covers both ZN and LED 
fluorescent dye techniques based on samples of smears examined in routine work. In this system, 
all routine slides used for TB diagnosis and follow-up are stored on a quarterly basis, ten slides are 
randomly sampled from each diagnostic centre and rechecked blindly by the first controller at the 
district level. In case of discordant results, slides are rechecked by the second controller (at the 
regional level), who serves as second controller (gold standard) as shown in Figure 7.  
Figure 7: Organization of EQA by Blinded rechecking in Tanzania NTLP 
 
Keys: CTRL- Central TB Reference Laboratory; ZTCL-Zonal Culture TB laboratory; lab-laboratory; DTLC- District TB and Leprosy Coordinator 
 






The rechecking data are compiled, and reports prepared and submitted to the regional and national 
levels. Analysis is done to identify centres performing below standard, and where corrective 
measures may be needed. The Zonal TB culture laboratory supervise the checking of the re-checker 
(second controller) at regional level (32,33). 
In addition, on-site evaluation of laboratories is performed during supportive supervision. Feedback 
of the results to the diagnostic centres is done within a month and corrective action is taken for any 
problem noted. External Proficiency Testing helps identify and verify that the performance of each 
test in-house is comparable with peers that perform the same analysis elsewhere – see section 1.6.4. 
1.6.4 Proficiency testing (PT) 
The CTRL participates in PT programs as necessary covering all the types of tests done at the CTRL. 
This includes Smear microscopy, Culture, DST, LPA and Xpert MTB/RIF.  
Smear microscopy 
The CTRL receives five unstained smeared slides for AFB smear microscopy once per year from the 
Supranational Reference Laboratory (SRL) in Uganda for PT of sputum smear microscopy. The CTRL 
also completes PT from the United Kingdom National External Quality Assurance System (EQAS) (UK 
NEQAS) once per quarter. The EQAS results report should be submitted within one month. The 
threshold for quality assurance is 80% matched results.  
Culture 
The IQC for MTB culture by solid media LJ H37RV is used as positive control and sterile distilled water 
inoculated on a solid media as negative control after every 32 tests. During culture reading the 
controls are read to check if it has passed, if it fails specimen testing should be repeated.  
The EQA procedure for culture at the CTRL involves receiving 12 lyophilised sputum for solid culture 
once per year, from UK NEQAS. The CTRL is required to culture and report on the presence or 
absence of ‘MTB’. The EQA results report should be sent back within two months. The date when a 






Drug susceptibility testing (DST) 
The IQC use a standard strain of MTB with known resistance pattern to different drugs. This is used 
in every batch of medium as a check on drug concentration. The IQC helps to check the on 
procedures and the individual performance. In addition, H37RV is included as positive control 
whenever DST is performed.  
EQA for DST: The CTRL is linked to the SRL at the ITM in Antwerp, Belgium. The SRL send 20 killed 
strains once per year for DST PT for FLD (INH, RIF, streptomycin (SM) and ethambutol (EMB). The 
CTRL is tested on the ability to detect true resistance strains (sensitivity), true susceptibility strains 
(specificity) and provide true results (efficiency) (resistant or susceptible). The Indication of overall 
laboratory efficiency in producing correct results, i.e. a combination of sensitivity and specificity 
should not score less than 85% score. 
Line Probe Assay (LPA)  
The IQC is performed using H37RV as positive control and molecular grade water as negative control 
whenever LPA test is done. 
For EQA, the CTRL receives panel package containing 10 PT tubes each containing at least 0.1 ml of 
inactivated strains from SRL Uganda once per year. The PT are labelled P1 to P10. Samples are 
processed according to internal Standard Operating Procedures (SOP) for staining. These PT can be 
tested on Xpert and LPA. The pass mark of a laboratory for any tested drug is based on efficiency 
(accuracy of performance) which is 95% and above for INH and RIF drugs while 90% for second line 
drugs. Performance of less than 80% is considered a fail. Results must be submitted on forms 
provided by the PT provider (PT 013 F17) within one month of receiving tubes. 
 
Xpert MTB/RIF 
Xpert is a system that has some automatic internal Quality Control (QC) for each sample. During each 






- Sample-processing control (SPC) is included in the cartridge and ensures a sample was 
correctly processed.  
- IQC—Verifies the performance of the Polymerase Chain Reaction (PCR) reagents and helps 
prevent a false negative result. The internal control PCR assay assesses if there is any 
inhibition, possibly by components, in the test sample. The internal control is provided in the 
cartridge and should be positive in a negative sample. 
- Endogenous control (EC)—Normalizes targets and ensures sufficient sample is used in the 
test. Because of its low variability, the endogenous control can also be used to indicate 
sample-inhibitor contamination. The endogenous control is taken from the specimen sample.  
 
In addition to these controls, the Xpert instrument performs a probe check during the first stage of 
the test. A probe check verifies the presence and the integrity of the labelled probes. A probe-check 
status of Pass indicates that the probe check results meet the acceptance criteria (36).  
1.6.5 Total Quality Management System (TQMS) 
In 2014, the CTRL became involved in the East African Public Health Laboratory Networking 
Programme (EAPHLNP), to implement a Total Quality Management System (TQMS). The Programme 
anticipated that if CTRL would be engaged in the TQMS it would be able to follow Good Laboratory 
Practice (GLP) and adhere to the international standards. On this basis, the CTRL was evaluated 
against the quality assessment obtained zero star. Second assessment was carried out in 2015 and 
the CTRL moved from zero to two stars (Figure 8).  
Additionally, in 2015 the CTRL was among the National TB Reference laboratories (NTRLs) in 18 
countries (Kenya, Lesotho, Malawi, Mauritius, Seychelles, Swaziland, Tanzania, Uganda, Zambia and 
Zimbabwe), to take part in a regional peer valuation on quality assessment which was supported by 








Figure 8 Road map towards routine quality improvement at the CTRL 
 






1.7 Drug Resistance TB Surveillance  
The DR-TB Surveillance (DRS) is a systematic process of detection and monitoring the 
epidemiological profile of TB medicine resistance with the aim of improving its prevention and 
control (37). The DRS also helps determine the disease burden and monitor trends over time and 
plan for new treatment regimens (8). Surveillance of anti-TB drug resistant is therefore an essential 
tool for monitoring the effectiveness of the TB control programs and improving national and global 
TB control efforts (8). Initial drug resistant detected in cultures from patients who have not been 
treated before or have received treatment for less than one month provides an indicator of the 
effectiveness of diagnostics and treatment regimens. Drug resistant in patients with a history of 
previous treatment “acquired resistance” points to failures in the management of the disease (3,38). 






the current diagnostic structure of Tanzania the RSS is a key element in the detection of drug 
resistant in individual patients, particularly for previously-treated TB patients. 
 
1.8 Routine Surveillance System (RSS) in Tanzania 
1.8.1 Importance of RSS 
Information on TB DR prevalence is an important management tool for evaluating the performance 
of a National TB Programmes (NTP)(3). The RSS in Tanzania is intended to monitor treatment 
outcomes by assessing patient response to individual TB drugs, monitoring the trend of MDR-TB and, 
importantly, to identify individuals with drug resistant and inform the relevant districts so patients 
can start appropriate treatment as early as possible.  
1.8.2 Description of the RSS 
The NTLP strategy for the RSS was designed based on the limited TB culture and DST capacities in 
the country, the geographical distribution of TB facilities, and the DR-TB burden. The current RSS 
policy specifies that 25% of new and 100% of previously-treated TB cases that are smear-positive for 
TB should be referred to the CTRL for culture and DST. A single -morning sputum specimens should 
be collected from all previously-treated TB cases for culture and DST. The DST is done primarily for 
routine surveillance of DR-TB using the Proportion Method on solid LJ media, and the CTRL is the 
only standalone TB reference laboratory with a capacity to perform both FLD and second line DST 
(27).  
The CTRL then feedbacks to the RTLC using standard expedited mail services (EMS) provided by the 
Tanzania Post Office after obtaining all test results. The RTLC should then distribute them to the DTLC 
who would communicate to the test requesters (peripheral level) see Figure 9 (27,39). The EMS 
system was chosen to ease specimen transportation and minimise delay in sending results back from 








Figure 9  Specimens flow for the existing Routine Surveillance System 






1.8.3 Weaknesses of the existing RSS in Tanzania  
There are a number of known weaknesses in the current RSS for TB in Tanzania as it is documented 
in the NTLP Manual (2013) (27,40).  
1. The current RSS refers only to DST using solid media at the CTRL which is particularly slow in 
delivering diagnostic results. Recently three other technologies have been adopted by the country 
for TB case detection and DST (MGIT, LPA and Xpert) (27) 
2. At district level Xpert is now becoming available in some centres which would allow 
resistance to rifampicin to be detected and an MDR-TB diagnosis to be made. The availability of Xpert 
is also gradually expanding across the country. The current RSS does not take account of this 
availability and expansion (40,41).  
3. Communication and transport between the CTRL and the laboratory network area are known 
weakness that contribute to delays in samples being tested and results feeding back to the periphery 
where appropriate action can be taken. This is not uncommon in sub-Saharan Africa (42).  
4. There is no National TB laboratory standard guideline for culture and DST which would 
provide a common understanding to laboratory staff, thus there could be a lack of consistency in 
approach between the CTRL and Zonal reference laboratories. In addition, guidelines for the smooth 
integration of new staff into their job and team and to provide existing staff with a quick reference 
to key policies and procedures is lacking. 
5. Despite all the NTLP efforts to control the country's MDR-TB over the years, the WHO 
estimated number of cases is still much higher than the cases identified by the programme year after 
year  (43). Clearly the current RSS is missing many cases and improvements could potentially help to 
close this gap. 
6. The specimen transportation system is not reliable, leading to poor access to laboratory 






7. In a study conducted by a partner organization contamination levels in samples received from 
the periphery and tested at the CTRL were found to be high. This at best means testing is delayed 
and at worst means no DST is conducted at all (44).  
8. Although 25% of all new cases and 100% of previously-treated cases are meant to be referred 
to the CTRL as part of the RSS, it is known volumes received fall well below these numbers overall 
(45,46). 
In summary the current RSS is complex as evidenced by the schematic flow shown in Figure 9; It is 
slow to provide results as evidenced by the methods used; It is not meeting current volume or speed 
of response targets or even close to them. All these issues call into question its effectiveness. To date 
this has not been accurately assessed. New technologies such as Xpert MTB/RIF offer opportunities 
for change that also have not yet been included in the context of the RSS.  
 
1.9  The Need for Research into the RSS 
Given all the known limitations described above it is vitally important that the RSS for TB is reviewed 
and improved. This is particularly crucial at a time of potentially changing resistance patterns in the 
country. An area of major concern must be where patients have already received TB treatment that 
has failed or not been completed (failure, relapse, return-after-default) (43). It is therefore not 
surprising that the WHO advises countries to invest in an RSS for drug resistance in previously-
treated cases where the majority of MDR-TB is found (50). 
Many of the issues described above in section 1.8.3 are common in other countries particularly in 
sub-Saharan Africa (47,48). Therefore, lessons from a review in Tanzania are likely to have many 
implications elsewhere. In addition, failure to detect and track MDR-TB cases appropriately would 
probably lead to emergence of XDR-TB in the country. Understanding whether (and if not – why 
not?) DST took place for all previously-treated TB cases is considered critical. It would be hoped that 






for DST at the CTRL and therefore improve result credibility, feedback and consequently better 
patient management and programme documentation.  
The focus of the research should initially be on previously-treated TB cases as this is where most of 
the MDR-TB cases are found. The RSS for previously-treated TB cases is the most established by the 
NTLP in Tanzania. The NTLP target for the RSS is 100% of previously-treated cases, so there is no 
ambiguity about which samples should be referred. For new cases the target is 25%, primarily as 
there has historically been low levels of MDR-TB in new cases, and the volumes that would be 
required to be referred if the target were 100% is way beyond the capacity of the referral 
laboratories. With an initial focus on previously-treated TB cases it would still be possible to learn 
lessons that could also be applied to the RSS for new TB cases. 
1.9.1 The Aims  
This study aims to investigate the current RSS and then identify and test interventions that enhance 
the effectiveness of the RSS for previously-treated TB cases in Tanzania, so that more patients with 
DR-TB could be identified and started on appropriate treatment earlier. 
1.9.2 Study specific objectives 
a) To measure the under performance of the current routine surveillance system for 
previously-treated TB cases in Tanzania 
b) To determine what factors, lead to the inadequate performance of the current 
routine surveillance system for previously-treated TB cases in Tanzania.  
c) To design and pilot a revised routine surveillance system for previously-treated TB 
cases in Tanzania. 
d) To evaluate the effectiveness of the revised routine surveillance system for 






1.9.3 Study research questions 
What is the scale of the inadequate performance of the current routine surveillance system for 
previously-treated TB cases in Tanzania? (Quantitative). 
What is the stakeholder perception of the current RSS for previously-treated TB cases in Tanzania? 
(Qualitative).  
What new design of routine surveillance system for previously-treated TB cases might overcome 
many of the weaknesses in the current system 
Does the newly designed and revised RSS improve the performance of the system, in particular by 
reducing the time from sputum collection at the district health facility to communication of the 
DST result by the CTRL back to the district? (Quantitative) 
Does the revised routine surveillance system reduce barriers to the effective performance of the 
system? (Qualitative). 
 
1.9.4 Study hypothesis 
The study hypothesizes that inadequate performance of the RSS for previously-treated TB cases is 
associated with poor and delayed diagnosis of MDR-TB. A revised RSS for previously-treated TB cases 
would identify more drug resistance cases and identify them earlier contributing to better outcomes 
for patients, particularly those with MDR-TB.  
1.9.5 Methodologies to be used for Research  
A combination of quantitative and qualitative data collection methods to determine the level of 
performance of the current RSS were deemed appropriate. Quantitative analysis was required to 
understand the level of testing taking place, the level of specimen contamination, the number of 
MDR-TB cases detected, and to calculate the time delays in getting results back to health facilities 
where appropriate treatment could be initiated. All this information is important and should be 
available from routine databases. Such quantitative analysis, however, would give little insight into 






required at peripheral and central TB facilities to seek to identify the issues causing the 
unsatisfactory performance. In this respect it would be important to get views from many different 
perspectives.   
Having identified the level of under-performance, and potential reasons for this, it would then be 
possible to redesign the RSS in a way that could address the issues found in the quantitative and 
qualitative data collection. This revised RSS could then be piloted, and quantitative impacts 
measured on things like number of specimens referred, MDR-TB volumes detected and delays in 
results feedback. In addition, qualitative data collective from the key stakeholders in the revised 
process would help identify if the issues with the previous RSS had been resolved, as well as any 
other measures it could be necessary to undertake. 
 
1.10 Ethical clearance    
Ethical clearance was granted by the Liverpool School of Tropical Medicine (LSTM) Research Ethical 
Committee in the United Kingdom and, in Tanzania, by the National Health Research Ethical Review 
Committee of the National Institute for Medical Research (NIMR). Application for the ethical 
clearance was submitted to the LSTM on 15th April 2014 and got approval on 3rd July 2014 see 
Appendix 1. Then a request for ethical review was sent to NIMR review committee on 2nd June 2014 
and approval was granted on the 26th June 2014 in Appendix 2.  During the study as details were 
firmed up, a further application for ethical clearance was submitted to the LSTM on 1st May 2016 
and approval obtained on 20th Sept 2016 shown in Appendix 3. In addition, an application to NIMR 
Tanzania on 20th Oct 2015 and approval granted on the 15th Nov 2016, see Appendix 4 and Appendix 
5 is the extension approval from NIMR 2017.  
The Principal investigator (PI) sought permission from the NTLP and Regional Administrative 
Authorities to conduct the study. Permission was granted by both establishments. Each participant 






free to withdraw from the study at any time, without prejudice. Confidentiality was maintained 
throughout the study. 
 
1.11 Structure of the thesis 
This thesis contains seven chapters, as follows: 
Chapter 1: Details the background to the research and identifies the problems in respect to TB, 
TB/HIV and MDR-TB globally. It also highlights TB laboratory diagnosis in Tanzania and outlines how 
the RSS is implemented in the country, along with an initial assessment of issues and weaknesses of 
that system.  
Chapter 2: Reviews the literature relevant to the study, including articulation of the method used 
for searching for relevant publications, key findings of previous studies and a summary of the 
reviewed publications.  
Chapter 3: Describes a quantitative evaluation of how the RSS is currently performing in the country, 
identifying both strengths and gaps.  
Chapter 4: Following on from the quantitative analysis of chapter 3 this chapter explores the reason 
for the weaknesses in the RSS identified. It does this by exploring stakeholders’ perceptions on the 
RSS implementation using qualitative methods and ultimately suggests possible opportunities for 
improvement.  
Chapter 5: identifies possible interventions to fill the identified gaps in the RSS and through a pilot 
study of a revised RSS in Mwanza region and the CTRL in Dar es Salaam, evaluates this using a 
quantitative ‘before and after’ approach. 
Chapter 6: Describes an evaluation study using qualitative methods to compare the two systems of 
the RSS (before and after implementation) in Mwanza and at the CTRL. This is designed to assist in 






Chapter 7: Brings the whole thesis together with a critical discussion of the findings in the light of 
existing literature and in the context in which the study was undertaken. It includes a critical 
reflection of the study design and methods used. It also includes a reflection on what the findings 







Chapter 2 Literature review  
2.1 Introduction 
This chapter presents a review of the published literature on surveillance systems for TB diagnosis 
and case detection in low resource settings. The study objectives, outlined in section 1.9.2, guide the 
literature search, evaluation, and presentation. This chapter is divided into two main parts; part one 
describes the literature search process and part two presents the narrative synthesis.   
 
2.2 The Literature Search Method 
2.2.1 Overview 
The search was aimed at identifying and reviewing peer-reviewed articles focusing on surveillance 
systems for TB; DR-TB; and diagnosis and case detection in resource-limited settings. The search 
period was between 2000 and 2019 in order to focus on the most recent and relevant studies. The 
literature review aimed to establish what peer-reviewed published literature already exists relating 
to the themes and research questions studied and described in this thesis. It sought to understand 
and explore the relevant literature in order to learn lessons that might usefully contribute to this 
study.  
The process involved identifying search terms; choosing which search engines to use; defining 
inclusion and exclusion criteria; performing the search; selecting relevant articles and appraising the 
studies (49). Also, a summary table of reviewed articles is presented for swift referencing. It should 
be emphasised the literature review was not a full and exhaustive systematic review of all papers 
that might potentially be relevant to the key areas under consideration in this study. Although 
systematic reviews are often used in health-related research, they require a tightly defined 
intervention with outcomes reported in similar ways. Since the aim of this review was to understand 
a range of study outcomes on TB surveillance systems in low resource settings, the studies reviewed 






Instead as the objective of the review was to help identify new ideas and lessons learnt from previous 
published research that might assist in the design and execution of the data gathering and 
implementation of a revised routine surveillance system in Tanzania, a narrative approach was 
chosen.  
2.2.2 Search terms  
In order to establish search terms, the study objectives and research questions (see sections 1.9.2 
and 1.9.3) were considered. This led to four high level search terms - Surveillance systems,  
Tuberculosis, Diagnosis, and Low- and Middle-Income countries (LMIC). 
A list of synonyms and related terms for each search term were created and are listed below. 
Group 1: Search terms related to Surveillance systems. These included: Routine surveillance, 
specimen transport and TB surveillance 
Group 2: Search terms related to tuberculosis. The terms used included: tuberculosis, drug resistant 
tuberculosis, multidrug resistant tuberculosis, MDR-TB.  
Group 3: Search terms related to Diagnosis. The search terms included: TB laboratory Diagnosis, 
Rapid Test, Xpert MTB/RIF, Line Probe Assay, drug sensitivity testing. 
Group 4: Search terms related to LMIC included: Tanzania, Sub-Saharan Africa, resource limited 
settings and Developing countries.  
The searching was performed by using some keywords to search for literature articles either as an 
independent group or by combining search term in group 1 AND group 2 AND group 3 AND group 4. 
Or by single group 1 OR group 3 etc. This was repeated until it appeared that the saturation point 
had been reached (in other words where new combinations of search terms did not appear to be 
retrieving new articles). 
In addition to literature sources from scholarly theses, published journals, and conference 






programme documents, Ministry of Health policy documents and through government websites 
including Government Bureau of Statistics, Ministry and NTLP websites. 
The reference lists of the selected relevant articles were also manually reviewed to see if there were 
any articles that may have been missed during the electronic search. This involved reading abstracts 
and considering what the problem was that the authors were addressing, the methods used and 
how the publication related to this study.  
The documenting process was started by taking notes as I read through the literature and the cited 
sources. I made an annotated bibliography, where I compiled full reference information and wrote 
a paragraph of summary and analysis for each source. I kept track of the sources with references 
to avoid plagiarism.  
2.2.3 Search engines 
The following search engines were used to search for articles: The LSTM library catalogue, The 
Cochrane Library, Web of science, MEDLINE, Science Direct and Social Sciences Citation Index, and 
Google Scholar.  
2.2.4 Inclusion and exclusion criteria 
Inclusion criteria: The search was limited to articles published in English between January 2000 to 
December 2019. The cut-off years were chosen in order to ensure articles were most relevant to the 
current situation. Starting in 2000 and ending in 2019 ensured the articles covered a period of 10 
years before, and 10 years after, the WHO’s endorsement of Xpert MTB/RIF for diagnosis of TB and 
detection of RR as an initial diagnostic test in individuals living with HIV and/or suspected of having 
DR-TB.  
Exclusion criteria: Any articles published in a language other than English were excluded and those 






2.2.5 Identification of applicable publications relevant to study 
The search was conducted by the author using different combinations of the search terms presented 
above, until no new combinations of search terms appeared to be retrieving new articles. A total of 
524 apparently unique peer-reviewed articles were retrieved.  
Mendeley® referencing software was then used to double check no duplicates had been included. 
30 duplicates saved with slightly different names were identified and these were removed leaving a 
total of 494 articles. 11 more key articles were added from the Ministry of Health in Tanzania making 
a total of 505 articles.  
After performing the initial screening through titles and abstracts a total of 302 articles were 
removed. The main reason for exclusion was the articles were concerned with National DRS rather 
than RSS. This left 203 articles.  
A total of 203 text articles assessed as being relevant to this study whereas 140 articles were 
excluded with reasons.  
Therefore, full manuscripts for these were retrieved and thoroughly scrutinized, following which, a 
total of 62 articles applicable to this study were identified.  
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Table 1: Papers included in the final analysis 
SN First Author or 
Organization 
Year Setting Title 
1 WHO 2015 Global Global Tuberculosis Report (43) 
2 WHO 2016 Global Global Tuberculosis Report (9) 
3 Nkengasong JN 2009 Ethiopia Critical role of developing national strategic 
plans as a guide to strengthen laboratory 
health systems in resource-poor settings  (51) 
4 Liu Z 2017 China Feasibility of a new model for early detection 
of patients with multidrug-resistant 
tuberculosis in a developed setting of eastern 
China (52) 
5 Hofmann-T S 2017 Germany How should discordance between molecular 
and growth-based assays for rifampicin 
resistance be investigated? (53) 
6 WHO 2017 Global Global Tuberculosis Report (54) 
7 Rabia J 2007 South Africa Understanding the mechanisms of drug 
resistance in enhancing rapid molecular 
detection of drug resistance in Mycobacterium 
tuberculosis (55) 
8 Acosta C 2014 Eastern 
Europe 
Drug-resistant tuberculosis in Eastern Europe: 
challenges and ways forward (56) 
9 Zumla A 2012 Global Drug-Resistant tuberculosis-current dilemmas, 
unanswered questions, challenges, and 
priority needs (57) 
10 Solomon SL 2009 CDC Plan to Combat Extensively Drug-Resistant 
Tuberculosis (58) 
11 Park P 2012 Kenya Increasing access to the MDR-TB surveillance 
programme through a collaborative model in 
western Kenya (47) 
12 Omar S 2016 Malaysia Treatment Outcomes of Patients with 







13 Paul D 2012 India Factors Associated with Delays in Treatment 
Initiation after Tuberculosis Diagnosis in Two 
Districts of India (60) 
14 Sagbakken M. 2010 Global Tuberculosis as a global challenge A qualitative 
study of patients’ and health (61) 
15 Johnson R 2010 South Africa Drug-resistant tuberculosis epidemic in the 
Western Cape driven by a virulent Beijing 
genotype strain (62) 
16 Castro K 2007 Global Tuberculosis Surveillance: Data for Decision-
Making (63) 
17 Bazira J 2011 Uganda Mycobacterium tuberculosis spoligotype and 
drug susceptibility pattern of isolates from 
tuberculosis patients in South-Western 
Uganda (64) 
18 Hoza AS 2015 Tanzania A cross sectional facility-base prevalence 
among pulmonary TB patients (65) 
19 Chonde TM 2010 Tanzania National anti-tuberculosis drug resistance 
study in Tanzania (25) 
20 NTLP 2013 Tanzania NTLP Manual for management of TB (28) 
21 NTLP 2014 Tanzania Report M. for new tuberculosis diagnostics: 
report of a consensus meeting (66) 
22 García-Basteiro 
A 
2016 Mozambique Poor tuberculosis treatment outcomes in 
Southern Mozambique (2011-2012) (67) 
23 Weyer K 2011 Global Viewpoint TB diagnostics: What does the 
world really need? (68) 
24 Kumar A 2013 State of 
Karnataka 
Efficient, quality-assured data capture in 
operational research through innovative use 
of open-access technology (69) 
25 Kilale A 2013 Tanzania Are sputum samples of retreatment 
tuberculosis reaching the reference 
laboratories? A 9-year audit in Tanzania (46) 
26 Kebede 2016 Ethiopia Improved Specimen-Referral System and 







27 MOHSW 2012 Tanzania Service Availability and Readiness Assessment 
(SARA) 2012 July 2013. 2013;(July) (71) 
28 Olson S 2012 India Facing the Reality of Drug- Resistant 
Tuberculosis in India (72) 
29 Guio H 2006 Japan Method for efficient storage and 
transportation of sputum specimens for 
molecular testing of tuberculosis (73) 
30 Harries A 2004 Malawi Using a bus service for transporting sputum 
specimens to the Central Reference 
Laboratory: effect on the routine TB culture 
service in Malawi (74) 
31 Timire C 2018 Zimbabwe Has TB CARE I sputum transport improved 
access to culture Services for retreatment 
tuberculosis patients in Zimbabwe? (75) 
32 Bhat J 2011 Africa Yield of culture of Mycobacterium tuberculosis 
complex in sputum samples transported from 
tribal areas (76) 
33 Daum L 2015 South Africa Yield of culture of MTB complex in sputum 
samples transported from tribal areas. (77) 
34 UNION I 2007 Low-Income 
countries 
Priorities for Tuberculosis Bacteriology 
Services in Low-Income Countries. 2007 (78) 
35 Ridderhof JC 2007 Global Roles of laboratories and laboratory systems 
in effective tuberculosis programmes (79) 
36 Royce S 2014 Cambodia Identification of multidrug resistance in 
previously treated tuberculosis patients: a 
mixed methods study in Cambodia (80) 
37 Nagu T 2017 Tanzania Tuberculosis associated mortality in a 
prospective cohort in Sub Saharan Africa: 
Association with HIV and antiretroviral 
therapy (81) 
 
38 WHO 2010 Global TB Diagnostics and Laboratory Services 
Information (82) 
 
39 Birx D 2009 Thailand Laboratory challenges in the scaling up of HIV, 






health and laboratory systems, clinical 
research, and service delivery (83) 
40 Cowan J 2014 Mozambique Implementing rapid testing for tuberculosis in 
Mozambique (84) 
41 WHO 2008 Global Policy guidance on drug-susceptibility testing 
(DST) of second line antituberculosis drugs 
(85) 
42 Agrawal M 2016 India Comparative Study of GeneXpert with ZN Stain 
and Culture in Samples of Suspected 
Pulmonary Tuberculosis (86) 
43 WHO 2017 Global GLI Practical Guide to TB Laboratory 
Strengthening 2017 (87) 
44 Fox GJ 2017 Australia Preventing the spread of multidrug-resistant 
tuberculosis and protecting contacts of 
infectious cases (88) 
45 Albert H 2016 South Africa Development, roll-out and impact of Xpert 
MTB/RIF for tuberculosis: What lessons have 
we learnt and how can we do better? (89) 
46 Global Fund 
Long R 
2018 Global Drug-resistant tuberculosis.  Global Fund  (90) 
47 Tenover F 1993 Global The resurgence of tuberculosis: Is your 
laboratory ready? (91) 
48 Yon Ju Ryu 2015 Global Diagnosis of pulmonary tuberculosis: recent 
advances and diagnostic algorithms (14) 
49 Li Y 2013 China Factors associated with patient, and diagnostic 
delays in Chinese TB patients: A systematic 
review and meta-analysis (92)  
50 Ramsay A 2009 Global Front-Loading Sputum Microscopy Services 
(93) 
51 Said K 2017 Tanzania Diagnostic delay and associated factors among 
patients with pulmonary tuberculosis in Dar es 
Salaam, Tanzania (12) 
52 UNITAID 2017 Global UNitaid. Diagnostics Technology Landscape 







53 Omar S 2016 South Africa Field evaluation of a novel preservation 
medium to transport sputum specimens for 
molecular detection of Mycobacterium 
tuberculosis in a rural African setting (95) 
54 Lienhardt C 2017 Global Global Observatory on Health Research and 
Development (R & D) Background paper on 
Tuberculosis Specific R & D Research Priorities 
and Funding Gaps (96) 
55 McNerney R 2011 Resource 
Limited 
Settings 
Towards a point-of-care test for active 
tuberculosis: obstacles and opportunities (10) 
56 Davis J 2011 San Francisco The Clinical and Public Health Impact Of 
Automated Nucleic Acid Testing For TB 
Evaluation In San Francisco (97) 
57 Trébucq A 2011 Low Income 
countries 
Xpert ® MTB/RIF for national tuberculosis 
programmes in low-income countries: when, 
where and how? (98) 
58 Mnyambwa PN 2017 Tanzania Assessment of sputum smear-positive but 
culture-negative results among newly 
diagnosed pulmonary tuberculosis patients 
(99) 
59 Hoza A 2016 Tanzania Increased isolation of nontuberculous 
mycobacteria among TB suspects in North-
eastern, Tanzania: public health and diagnostic 
implications for control programmes (100) 
60 Kilale A 2016 Tanzania Who Has Mycobacterial Disease? A Cross 
Sectional Study in Agropastoral Communities 
in Tanzania (101)  
61 Shahraki A 2015 Indonesia “Multidrug-resistant tuberculosis” may be 
nontuberculous mycobacteria (102) 
62 Ani A 2009 Nigeria Comparison of a DNA based PCR method with 
conventional methods for the detection of M. 






2.3 Narrative synthesis of literature 
2.3.1 Introduction  
The included studies were all read carefully, taking detailed notes of the design of the 
study, the main findings, and any interesting subjects. An annotated bibliography was 
produced which compiled full reference information and a paragraph of summary and 
analysis for each source.   
A narrative approach was taken to presenting the findings of the review because the 
studies were too disparate to allow a meaningful systematic presentation of the results. 
Furthermore, a narrative review allows the researcher to reflect critically on the 
knowledge, which is an essential element in establishing gaps in understanding and 
identifying areas in which the proposed study can contribute (49). The table of the 
reviewed papers is described in Table 1 showing author’s name, year of publication and 
title. Six important linked themes were identified in the reviewed literature and these 
are described in the following sections. The final section outlines the gaps in knowledge 
identified and draws conclusions. 
 
2.3.2 Key themes from the literature review  
1. The surveillance system for TB   
Globally, the TB surveillance system is one of the oldest and largest surveillance systems 
to monitor anti-microbial resistance across the globe, reaching a milestone of 20 years 
of operation in 2014 (9). It commenced  in the 1990s in recognition that the emergence 
of strains of MTB that are resistant to anti-mycobacterial agents was a worldwide 
problem whose global magnitude needed to be better understood (50).  
In this context, it was recognised that early diagnosis, including universal access  to DST, 
and immediate initiation of treatment are essential for an effective TB control 






timely diagnostic tests are essential to providing critical information for the right medical 
decisions and management of a particular health condition. In particular, the rapid and 
accurate laboratory diagnosis of MDR-TB is crucial to ensure early initiation of 
appropriate treatment, to adequately manage the disease and to control further 
transmission (53). For all these reasons, a successful continuous RSS is reckoned to be 
the best way to detect and monitor DR-TB (9). As Rabia et al. highlighted in 2007, 
accurate routine surveillance is of particular importance to prevent future transmission 
of DR-TB (55).  
Uncertainty continues to characterise the understanding of DR-TB. According to the 
WHO, TB transmission and the occurrence of MDR-TB has increased (9). And although 
the numbers of MDR-TB patients enrolled each year has also increased, MDR-TB case 
detection rates are still very low (9). Acosta et al., provide evidence that there has been 
an increase in MDR-TB and XDR-TB cases in high-burden countries (56). In 2012, Zignol 
et al. revealed that the burden of DR-TB is not uniform across the globe and in many 
countries the prevalence is increasing (54). In the same year, the global TB report showed 
that strains of MTB are becoming increasingly resistant to anti-TB treatments, especially 
in areas where TB control programmes have been less effective (54). This was assumed 
to be linked to the improper use and substandard quality of anti-TB drugs in certain 
settings. It is agreed that this represents a major threat to TB control (54,57)  and leads 
to emergence of XDR-TB which is much more expensive to treat (58). Park et al. 
suggested that these challenges need to be properly evaluated and addressed (47) 
because treating patients with MDR-TB strains is much more complex and expensive 
than treating patients with susceptible TB strains (59).  
In this perspective, continuous surveillance of drug resistant based on the routine testing 
of TB patients allows for the systematic, ongoing collection of data and analysis for 
prompt and appropriate public health responses. In particular, there is a need to reduce 
TB transmission between initial diagnosis and the beginning of TB treatment (60). The TB 






reduce some of the physical, psychosocial and economic costs patients face while 
undergoing treatment (61). Routine surveillance therefore plays a number of vital roles 
(62). As a long-standing and large-scale multinational monitoring process it helps to 
improve researchers’ understanding of the epidemiology and trends in MDR-TB which 
can assist in identifying interventions to address the needs within TB programmes. It is 
also central to the early diagnosis of MDR-TB and thus to the long-term goal of limiting 
the spread of such drug resistant forms. 
The question that arises from this is, why if surveillance has been in place globally for 
such a long time, the prevalence of MDR-TB is still uncertain and, in so far as trends are 
understood, why it appears to be increasing? This would suggest that surveillance 
programmes have thus far not been entirely successful in the roles identified in the 
previous paragraph. The remaining sections of this review will therefore explore what 
the current knowledge has to say about the challenges in implementing an effective RSS 
and the potential approaches to improving such systems (9).  
2. Challenges affecting the surveillance system for drug resistant TB 
As discussed in the preceding section, surveillance data are crucial to measuring the 
burden of disease and, thus, serve as the basis for informed decisions about the planning 
and targeting of health care interventions (63). There is a particular need for such data 
in respect to TB and MDR-TB. However, the realisation of this ambition is hampered by 
significant practical challenges. The widespread emergence of DR-TB has complicated 
the management of TB disease (64), and has made the WHO’s Global TB Programme’s 
requirement for periodic DRS based on random, representative, DST among previously 
untreated smear-positive cases, all the more important. In resource-poor settings like 
Tanzania, such testing is seldom performed (65), with reliance placed mainly on 
phenotypic DST and with significant logistical and operational challenges (25,47). Lack of 
resources makes an accurate diagnosis of TB cases more difficult, and in many countries, 
TB control programmes rely almost exclusively on sputum microscopy for the diagnosis 






Globally, one-third of all TB cases are not notified, and many patients’ samples do not 
undergo DST (66). In addition, there is limited data regarding the monitoring of TB 
treatment results and determinants of adverse outcomes under routine surveillance 
conditions (67). Furthermore, clinical data management is mainly paper-based which is 
characterized by inadequacy and insufficient quality control and surveillance (68). 
3. Specimen transportation and storage 
In regard to specimen transportation and storage, it has been noted that difficulties 
involved in the collection, transport and prompt processing of samples in clinical practice 
could be contributing factors for DST not being done or leading to false culture positive 
(69). Transport of sputum samples from peripheral facilities to central laboratories is a 
major bottleneck in identifying MDR-TB cases particularly among previously-treated TB 
patients in low resource countries, hampering efforts towards eradication of MDR-TB 
and XDR-TB (46). In addition, effective specimen delivery arrangements can affect 
specimen viability hence speed of results feedback (70), since samples that arrive at 
testing facilities in a poor condition cannot be properly tested, and a new sample must 
be obtained from the patient. This wastes time and resources, resulting in further spread 
of TB and MDR-TB to the community and, as a result, an increased burden on the health 
system and the patient (47,71). Indeed, as a study conducted in India has pointed out, 
longer transportation times increase the risk of contamination and false negatives (72). 
A study in Kenya has also pointed out the effect of unreliable means of transportation on 
the effectiveness of a surveillance system (47,73).  
In Tanzania, a study has shown that only 10% of sputum samples from notified 
previously-treated TB cases received culture and were subject to DST. This study, 
however, could not identify the underlying causes of the shortfall in transported samples 
(46). Equally, a study conducted in a neighbouring country, Malawi, showed that despite 
implementation of a new bus transport system for specimens from previously-treated 
TB patients, only 40% of cases resulted in a sample being received by the central 






diagnostic delivery barriers by using the existing transport system and a result tracking 
system. The study revealed that, a number of specimens could not undergo DST as some 
sputum specimens were never collected or reached the National Reference Laboratory 
(NRL), although they were unable to establish the reason(s) for this (75). Specimen 
viability can be improved by use of more reliable modes of transport and good storage 
conditions, especially in hard to reach areas (74,76,77).  
Different approaches have been suggested, taking into consideration individual settings 
and the availability of resources. Findings from a study conducted  in Zimbabwe in 2018 
on using motorbikes to transport sputum samples (75) came to a similar conclusion as a 
study from Malawi which used public bus service for specimen transportation (74). Both 
studies point out that the new means of transportation did not lead to a higher 
proportion of samples reaching the lab nor did they significantly reduce the time taken 
for samples to be analysed. Both also concluded that there is a need for improvement in 
the entire system, including the increase in the number of competent and trained 
personnel  (74,75), as well as the involvement of multiple stakeholders (47).   
4. The role of the laboratory in the TB Control Programme 
Another theme in the literature links shortages of staff and laboratory supplies to failures 
in RSS implementation and hence the identification of DR-TB. Although notable progress 
has been made regarding TB identification and treatment of MDR-TB cases, gaps remain 
in the availability and good access to effective DST, particularly at the peripheral 
laboratories. Adequate staffing, equipment and other provisions at all levels, including 
peripheral laboratories, is key to effective identification, treatment and follow-up of all 
categories of TB patients (78). Most peripheral laboratories in low resource settings 
experience serious challenges with competent staffing levels, lack of resources and lack 
of/or outdated standardised laboratory protocols (79). Likewise, lack of data and 
improper categorisation of cases led to some re-treatment patients being recorded as 
new patients, posing a challenge in MDR-TB case finding and monitoring for previously-






samples were collected by general nurses who had not received any specific training on 
the collection of MTB specimens (74). 
Another study revealed high contamination rates of 9% versus the expected maximum 
of 5%, which also indicates poor laboratory quality assurance mechanisms. The study 
suggested that on-site training and regular supportive supervision is needed if the quality 
of TB services at peripheral laboratories is to be optimised (74). While a study conducted 
in Kenya showed that lack of awareness of a TB-programme intervention by healthcare 
workers affected TB surveillance (47).  
Royce et al. explored healthcare workers’ perspectives on enablers and barriers to 
effective TB intervention programmes. Their study participants identified the following 
as enablers: (1) training on sputum sample collection; (2) streamlining sputum sample 
transportation; (3) prompt reporting of cases. Barriers included: (1) patient reluctance to 
disclose information; (2) stigma; (3) difficulty with eliciting previous treatment history, 
and (4) inadequate mechanisms to diagnose and report DST results. The study pointed 
out that correct diagnosis and classification, reviewing treatment history and making 
sure samples reach the central reference laboratory would increase the detection rate 
of MDR-TB (80). 
Inefficient functioning of peripheral laboratories and an inability to perform smear 
microscopy can also cause a delay in both diagnosis and treatment initiation (47). 
According to Ridder et al., the laboratory plays a critical role in TB diagnosis and 
treatment monitoring, and the strength of the laboratory network is often a direct 
reflection of the success of TB Control Programmes (79). In order for peripheral 
laboratories to function well and contribute to enhancing the TB surveillance system, 
they need to be connected to central laboratories (79). Central laboratories play a key 
role in the quality assurance of peripheral laboratories, apart from their primary 
diagnostic role. Hence the robustness of the surveillance system is a reflection of the 
proper functioning of central laboratories (79). Park et al. showed that effective and 






concern is that tests taking place in the private sector are not being reported centrally 
and a complete picture is not established (81), therefore greater engagement with the 
private sector is required. Overall, the WHO believes that strengthening TB laboratory 
services offers one of the best avenues for overall laboratory improvement as an 
essential health systems activity (82). Now is the time to build sustainable laboratory 
capacity in resource-poor settings that can be used to manage existing epidemics, fight 
multiple emerging and remerging diseases, and provide local facilities for scientific 
investigators of all levels (83). 
5.      Diagnostic methods for drug resistant TB 
Newer molecular diagnostic methods have been developed aimed at improving case 
detection and identification of DR-TB (16,89,103). Case detection can be particularly 
challenging for TB patients who are co-infected with HIV, since smear microscopy has 
low sensitivity among these people (84). In 2008, several tests for rapid detection of RR 
were validated in laboratory-based studies and evaluated for feasibility and cost-
effectiveness (85). The method has a dual advantage of detecting cases of MTB and 
proving the DR status for RIF in one go. Xpert has a high sensitivity of 88% for MTB and 
94% for RR. This is an ideal approach for TB surveillance, however financial and logistic 
constraints determine its universal rollout (84). 
On the other hand, in 2016, Agrawal showed that the culture method is more sensitive 
and specific than microscopy and Xpert and hence continues to serve as the gold 
standard (86). However, to perform cultures properly requires highly qualified personnel 
and infrastructure (87). Improved case finding is required to bridge the substantial MDR-
TB case detection gap (88). Albert et al., shed light on how Xpert MTB/RIF can be used as 
a point of care technology and can reduce the time from specimen collection to testing 
results, although the high costs of the Xpert machine and tests are likely to be a barrier 
in the developing world (89). The Xpert technology has transformed the way the world 
diagnoses DR-TB. It has allowed screening of thousands of TB cases around the world, 






The study conducted in Mozambique by Cowan J et al., revealed that the cost of installing 
one Xpert machine and the accompanying laptop was about 17,000 USD and one 
cartridge, per sample, costs an additional 10 USD (84). Rolling out new diagnostic 
technologies is not without multiple challenges, therefore, not least high maintenance 
costs (91). These need to be considered when devising TB surveillance intervention 
programmes. Current research in the field clearly shows the need for more empirical 
evidence to integrate bacteriological and molecular methods of detecting TB and drug 
resistant that have high diagnostic accuracy (sensitivity and specificity), are cost-
effective, temperature stable and simple to use. Such methods do have the potential to 
improve surveillance systems in resource-limited settings (84,91). 
6. The need for improved RSS in Tanzania 
As in many sub-Saharan Africa countries, the true burden of MDR-TB in Tanzania remains 
unknown due to inadequate laboratory infrastructures and lack of resources to diagnose 
and report MDR-TB (14). The inadequate surveillance system that is hindered by lack of 
resources such as staff, insufficient laboratory set-up, unreliable transport and specimen 
tracking methods contributes to the poor presentation of national TB programmes 
(14,45). The delay in the diagnosis and management of MDR-TB poses a threat to the 
success of the TB control programme and potentially creates an enormous financial 
burden and disease control issues for both individuals and the community (12,60,92). In 
order to minimise the economic burden and multiple patient visits to the health facilities. 
Andy Ramsay et al. suggested that, smear microscopy services should be front loaded in 
the interests of fairness and improved TB control. This approach could be improved if 
most specimens were collected the first day of consultation (93).   
Despite the efforts made by the WHO on the use of rapid and sensitive diagnostic 
techniques that provide information on DR-TB in a timely way, such as Xpert MTB/RIF 
and LPA (94), researchers continue to note the poor uptake of new diagnostic tools and 
continued logistical delays in sub-Saharan Africa (52), which increases the threats from 






TB (28). Like in many other LMIC, diagnosis of active TB in Tanzania is achieved by 
detection of bacilli through smear examination, mycobacterial culture (10) and more 
recently Xpert in a small number of district laboratories (97,98) as well as molecular 
MTBDRplus tests for DST at the CTRL (9). Smear microscopy is done in all diagnostic units 
while one standalone laboratory has the capacity to perform susceptibility testing for 
both first and second line anti-TB drugs (45). It is well-known, however, that smear 
microscopy suffers from low sensitivity and does not distinguish between live and 
nonviable organisms, or between Non-tuberculous Mycobacteria (NTM) and MTB 
complex (10,99). In recent years, there has been an increasing trend of NTM in Tanzania, 
which are easily misdiagnosed as TB (99,100), (101) and sometimes as MDR-TB (102), 
which may result in the unnecessary rendering of toxic second-line anti-TB drugs. Xpert 
has higher sensitivity than smear microscopy, however, the rollout of the assay 
throughout the country has been slow (61) and is characterised by an insufficient supply 
of cartridges (99). The culture method is more sensitive and specific than microscopy and 
Xpert, hence serving as the gold standard test (86). Unfortunately, most routine 
laboratories do not culture mycobacteria due to limited infrastructure and the slow 
generation time (3-8 weeks) in the LJ media (65). In addition, in a recent study conducted 
in Tanzania, it was reported that only one-third of MDR-TB patients diagnosed by Xpert 
between 2013 and 2016 were placed on MDR-TB treatment due in part to seriously 
inadequate data recording (61). Scaling up the coverage of rapid diagnostic techniques 
across the country could increase case detection, early treatment and help reduce 
further transmission, but this needs to be supported by accurate reporting and effective 
RSS (37). Strengthening decentralisation of laboratories for culture and DST with 
improving peripheral specimen collection as well as referral mechanisms for both 
specimens and patients are also recent recommendations (47). 
2.3.3 Gaps in knowledge and conclusions  
The review has revealed the importance and role of TB surveillance systems, but also 
identifies especially in low-resource countries such as Tanzania, there are many issues 






These include sample handling, accurate case and drug resistant detection, proper and 
timely records at the peripheral laboratories, timely diagnostic and confirmatory tests at 
the central laboratory, as well as the lack of a robust means of transportation that 
provides a reliable link between the CTRL and peripheral laboratories. 
There remains a lack of clarity in the literature about how such issues may be tackled, 
especially in low-resource settings. Nor is it clear if all the challenges have been properly 
identified, evaluated, and addressed. Where solutions have been proposed, they have 
not necessarily been successful. For example, the use of public bus service to transport 
sputum samples in Malawi and use of motorbikes in Zimbabwe did not result in an 
increased proportion of samples from previously treated TB case patients being put 
forward for DST, nor was duration from sample collection to processing shortened 
(74,75). Furthermore, although there is increased interest in the potential of molecular 
diagnostic techniques, how feasible is it to fully roll these out in low resource countries 
is unclear. 
This study takes note of these current gaps in understanding and seeks to contribute to 
the literature by (a) developing a fuller appreciation of the factors limiting the success of 
TB surveillance, and (b) proposing and piloting an integrated set of interventions in a 
specific low-resource country with a high burden of TB (Tanzania). This is in order to 
assess the feasibility of options for tackling the common challenges facing RSS in such 











This chapter addresses research question (a) as referred to in the Introduction section in 
1.9.3., i.e. What is the scale of the inadequate performance of the current RSS for 
previously-treated TB cases in Tanzania? (Quantitative). The chapter describes an 
investigation conducted of the existing RSS designed to understand the performance of 
that system and whether the NTLP policy of submitting 100% of all previously-treated TB 
cases to the CTRL has been fulfilled. The analysis was conducted using the previous three 
years’ routine data held at the CTRL. It was anticipated that the study would identify 
strengths to be sustained, weaknesses to be rectified and importantly highlight areas for 
improvement.  
Before this part of the study commenced there was only anecdotal evidence and a 
mission report carried out in 2013,3 which suggested that the RSS was underperforming, 
with high levels of contaminated samples and long delays in patients being started on 
appropriate MDR-TB treatment.  
The study used the quantitative data extracted from the routine databases to look at the 
efficiency of the existing system. The study focused on previously-treated TB cases only 
because this is where most of the MDR-TB cases are found. The RSS for previously-
 








treated TB cases is the most established by the NTLP in Tanzania. The NTLP target for the 
RSS is 100% of previously-treated cases, so there is no ambiguity about which samples 
were required to be referred. For new cases the target is 25%, primarily as there has 
historically been low levels of MDR-TB in new cases, and the volumes that would be 
required to be referred if the target were 100% is way beyond the capacity of the referral 
laboratories. Despite only focusing on previously-treated TB cases in this study, it is 
believed many of the lessons learnt from this study could also be applied to the RSS for 
new TB cases. This chapter covers the methods used in the investigation, the findings, 
and a discussion of the results. 
The research covered in this chapter has now been published (45).  
3.2 Quantitative study 
3.2.1 Study research questions 
What is the scale of the inadequate performance of the current routine surveillance 
system for previously-treated TB cases in Tanzania? (Quantitative). 
3.2.2 Study aims 
This study aims to measure the effectiveness of the RSS for previously-treated TB cases 
in Tanzania with a view to providing evidence that will help identify interventions to 
improve and accelerate positive patient outcomes.  
3.2.3 Study hypothesis 
The study hypothesizes that the inadequate performance of routine surveillance systems 
for previously-treated TB cases is associated with poor TB diagnosis, particularly of MDR-






3.3  Quantitative method 
3.3.1 Study sites  
This quantitative study reviewed the routine TB laboratory data collected electronically 
from TB laboratory registers at the CTRL from January 2011 to December 2013. This 
period was chosen in 2014 when this part of the study was conducted, as it represented 
the most recent 3 years where electronic data was available. The dataset contained 
information on all the specimens received at the CTRL from across the country (27). The 
information from the quantitative part of the study fed into the design of the qualitative 
part of the study which is covered in chapter 4.  
3.3.2 Study design and population 
A cross-sectional study that employed a quantitative approach was used to analysed 
routine data collected from January 2011 to December 2013. This included information 
on completion of request forms, transit times, turnaround times, culture positivity and 
contamination rates.  
The transit time was defined as the time from specimen collection in the peripheral 
health facilities to the time the specimen is received at a site where DST can take place 
(i.e. the CTRL and/or Mwanza sites with Xpert MTB/RIF). 
The turnaround time was defined as the time from specimen receipt at the CTRL to the 
time the DST results are sent back to the requesting clinician, as in Figure 11. Ideally it 
would have been preferable if the date the result was received by the peripheral facility 
were the end time for the turnaround time. Unfortunately, this date is not available on 
the electronic database and therefore the date the CTRL reported back to the region had 








 Figure 11 Specimens referral showing Transit and turnaround times from peripherals to CTRL 
 




According to the NTLP, the anticipated transit time should be a maximum of 7 days (27).  
Culture at the CTRL is performed using direct sputum specimens. Culture growth can be 
seen from 3 weeks of incubation, but complete culture incubation is 8 weeks (56days), if 
there is no growth by 8 weeks it is considered culture negative. All positive isolates from 
zonal TB culture laboratory are sent for DST with a maximum of 6 weeks (42 days) 
incubation. The results are sent back after obtaining the DST results.  
3.4 Sample size estimations 
The study encompassed all specimen records from all previously-treated TB cases 
collected and processed at the CTRL for the three-year period 2011-2013.  
3.4.1 Inclusion Criteria 
a) Previously-treated TB case specimens. 
b) Specimens collected and processed between 2011 and 2013. 






3.4.2 Exclusion Criteria 
a) Specimens collected before the year 2011 or after the year 2013 
b) Presumptive new case specimens. 
c) Specimens collected for research purposes.   
 
3.5 Justification of the Methodology Used  
3.5.1 Quantitative Design 
Quantitative studies provide answers or insights for many important questions or issues 
in health care and clinical research (105). In this study, quantitative data collection was 
selected because it provides a measurement of the scale of any performance issues in 
the current RSS in respect to the management of specimens associated with previously-
treated TB cases. It reveals any disparity between the specimens collected at the 
peripheries and those processed at the CTRL. It can give a measure of the efficiency of 
the system by calculating the time from specimen reception to the time results are 
reported. It also shows the proportions of positive cultures and contamination rates for 
the solid medium mycobacterium cultures processed and the proportion of previously-
treated TB case specimens received that had DST performed. The quantitative approach 
would also reveal trends related to the detection of MDR-TB.  
3.5.2 Preparation and study set up 
The first step was reviewing the dataset to exclude all specimens associated with studies, 
projects and presumptive new cases. The next step was to understand the parameters 
collected and their availability. The third step was data cleaning to check for missing 






3.5.3 Data collection and analysis  
Quantitative data were extracted from the routine database at the CTRL and TB 
laboratory registers covering the three-year period. The collected data were cleaned and 
analysed using Statistical Package for Social Science (SPSS) version 23. Frequency tables 
were generated to explore outliers and abnormal values which were then rectified using 
the available source documents. The transit time and the turnaround time for TB tests 
performed at the laboratory were calculated. The proportion of the specimens tested 
within the recommended time (106,107) was also calculated and coded as 1, and those 
outside this time coded 0. Descriptive analysis compared the proportion of specimens 
recorded as out of the recommended time.  
 
3.6 Quantitative findings 
a). The distribution pattern of Specimens  
The study analysed routine specimens received at the CTRL during the time under review 
(2011-2013). There were 16,423 specimens in total including both new and previously-
treated TB cases. Of these 2,750 (16.7%) were from previously-treated TB cases which 
were the focus of this study. The majority of these specimens (61.7%) were received in 
2013 and most were from males (60.2%). A total of 1,495 (54.4%) were from the young 
adult population aged between 25 and 44 years. HIV status was known in 1,962 (71.4%) 
and of these 1,293 (65.9%) were HIV negative. A high proportion of specimens 1,118 
(40.7%) were from the Eastern Zone (Mtwara, Lindi, Dar es Salaam). A total of 98 (3.6%) 














% Total % 
Zone 
Northern 37 46.3 186 19.1 630 37 853 31.0 
Southern 3 3.8 115 11.8 94 5.5 212 7.7 
Eastern 23 28.8 459 47.2 636 38 1,118 40.7 
Lake/Central 17 21.3 210 21.6 315 19 542 19.7 
Zone unknown 0 0 3 0.3 22 1.3 25 0.9 
Gender 
Male 51 63.8 468 48.1 1,137 67 1,656 60.2 
Female 29 36.3 319 32.8 550 32 898 32.7 
Gender unknown 0 0 186 19.1 10 0.6 196 7.1 
Age group 
<15 2 2.5 10 1 29 1.7 41 1.5 
15-24 8 10 137 14.1 262 15 407 14.8 
25-34 21 26.3 294 30.2 444 26 759 27.6 
35-44 21 26.3 255 26.2 460 27 736 26.8 
45-54 24 30 277 28.5 502 30 803 29.2 
Age unknown 4 5 0 0 0 0 4 0.1 
HIV status 
Positive 14 17.5 206 21.2 449 27 669 24.3 
Negative 13 16.3 443 45.5 837 49 1,293 47.0 
HIV Unknown 53 66.3 324 33.3 411 24 788 28.7 
TB type 
Pulmonary -ve  0 0 4 0.4 1 0.1 5 0.2 
Pulmonary +ve  67 83.8 957 98.4 1,685 99 2,709 98.5 
Extra pulmonary 2 2.5 3 0.3 1 0.1 6 0.2 
Not specified 11 13.8 9 0.9 10 0.6 30 1.1% 
Smear result 
Positive 36 45 645 66.3 993 59 1,674 60.9 
Negative 44 55 328 33.7 704 42 1,076 39.1 
Culture result 
Positive 34 42.5 392 40.3 755 45 1,181 42.9 
Negative 45 56.3 532 54.7 879 52 1,451 52.8 
Contamination 1 1.3 44 4.5 53 3.1 98 3.6 
Undocumented 0 0 5 0.5 10 0.6 20 0.7 
Keys: HIV- Human Immunodeficiency Virus; N- Number; TB- Tuberculosis; Zones are Eastern (Mtwara, Lindi, Dar es Salaam);  
Northern (Arusha, Kilimanjaro, Tanga, Manyara); Southern (Iringa, Mbeya, Ruvuma, Katavi) Central (Dodoma, Morogoro,  






b). The relation between cases notified versus specimens received 
Analysis of the data showed that, out of 8,482 previously-treated TB cases notified across 
the country for the three years, only 2,750 (32.4%) were received at the CTRL. A 
significant variation was recorded across the years. In 2011 2,936 cases were notified 
and only 80 (2.7%) were received at the CTRL. The trend improved in 2013 whereby 2,780 
cases were notified and 1,697 (61.0%) specimens were received at the CTRL in Figure 12.  
Figure 12 Previously-treated Cases Notified Versus Specimen Received at the CTRL (2011-2013) 
 
Key: Retreatment- Previously-treated cases 
 
c). Transit Time (Time between sputum collection and arrival at a site where DST can 
take place (i.e. the CTRL and/or Mwanza sites with Xpert MTB/RIF)) 
 The study findings showed that 2,608 (94.8%) of previously-treated TB case specimens 
had documented transit times. The mean and median transit time was 7.7 and 6, 
respectively, with a full range of 0 to 100 days. The mean and median transit time was 
lower 6.1 and 3 (IQR; 1-6.5) in 2011 compared to 2012 and 2013, although the difference 






Table 3: Transit time for previously-treated TB cases from 2011 to 2013 






p25 p75 F-value p-value 
2011 76 6.1 6.9 3 1 6.5 1.3 0.271  
2012 911 8.4 12.2 6 4 9  
  
2013 1,621 8.1 11.7 5 3 9 
  
Total  2,608 7.7 8.4 6 3 9  
  




d). Turnaround Time (Time between specimen arrival at CTRL and results sent back) 
Of the 2,750 previously-treated TB case specimens received, 1,244 were subject to 
microscopy, 2,703 to culture and 392 to DST. Of these, for microscopy, 1,024 (82.3%) 
specimens were documented and processed within the recommended turnaround time; 
while for culture and DST the parallel figures were 1,146 (42.4%) and 11 (2.8%), 
respectively Table 4). In respect to cultures performed outside the recommended time, 
77.6% (1,208 out of 1557) were culture negative.  
Table 4: Turnaround time for previously-treated cases from 2011 to 2013 
S/N Status Microscopy Culture DST 
1 Within recommended time 1,024(82.3%) 1,146(42.4%) 11(2.8%) 
2 Out of recommended time 220(17.7%) 1,557(57.6%) 381(97.2%) 
 
Total 1,244 2,703 392 




The study findings showed specimens that took longer than the recommended 
turnaround time for microscopy, culture and DST by descriptive variables were not 






Table 5: Specimens turned around in longer than the recommended time by descriptive variable 
Variable Outside 
recommend
-ed time  
Microscopy 
N=220 
(%) p  Outside  
recommend-
ed time  
Culture 
N=1,557 
(%) P  Outside 
recommend-
ed time;  
DST 
N=381 
(%) p  
Zone                   
Northern 48 21.8 0.5 479 30.8 0.9 91 23.9 0.5 
Southern 19 8.6   119 7.6   86 22.6   
Eastern 98 44.5   633 40.7   142 37.3   
Lake/central 55 25   326 20.9   57 15.0 0.5 
Unknown 0 0   0 0   5 1.3   
Gender                   
Male 152 69.1 0.4 1017 65.3 0 225 59.1 0.7 
Female 68 30.9   533 34.2   71 18.6   
Unknown 0 0   7 0.4   85 22.3   
Age group               
<15 2 0.9 0.4 21 1.3 0.1 4 1.1 
0.8 
* 
15-24 35 15.9   229 14.7   41 10.8   
25-34 59 26.8   430 27.6   119 32.3   
35-44 69 31.4   397 25.5   104 27.3   
45+ 55 25   480 30.8   112 29.4   
Unknown 0 0  0 0  1 0.3  
HIV status                   
Positive 51 23.2 0.1 378 24.3 0.7 117 30.7 0.4 
Negative 106 48.2   733 47.1   138 36.2   
Unknown 63 28.6   446 28.6   126 33.1   
Years                   
2011 0 0 
0.0
* 17 1.1 0 25 6.7 0.1 
2012 0 0   677 43.5   155 40.6   
2013 220 100   863 55.4   201 52.8   
Test Result                   
 Positive 150 68.2 0.9  307 19.7 0 -     
Negative 70 31.8   1,208 77.6   -     
Culture CT 0 0   42 2.7         
Keys: rec- recommended; DST- Drug susceptibility testing; N- Number; HIV- Human Immunodeficiency Virus; Eastern Zone (Mtwara, 
Lindi, Dar es Salaam); Northern (Arusha, Kilimanjaro, Tanga, Manyara); Southern (Iringa, Mbeya, Ruvuma, Katavi) Central (Dodoma, 








In Table 5 we used routine data from 2011–2013 specimens showing time specimen 
processed to time results issued and contamination rate. These are data on what 
happened within the laboratory but did not include the results took to reach the 
clinicians, as historically the date the clinician received the result was not recorded. 
Table 6: Drug Susceptibility Testing Results Profile from 2011- 2013 
Year 2011 2012 2013 Total % of Total 
Positive Culture 34 392 755 1,181 100 
DST not done  6 235 548 789 66.8 
Total number set up for DST 28 157 207 392 33.2 
Total number with DST results 28 151 194.0 373 31.6 
Total number DST contaminated 0 6 13 19 1.6 
DST Patterns          % of Results 
Total Susceptible to all 16 123 130 269 72.1 
Total MDR-TB 9 16 47 72 19.3 
Total Mono resistant 3 12 12 27 7.2 
Total other resistant 0 0 5 5 1.3 
MDR-TB           
HRSE 5 8 18 31 8.3 
HRS 4 1 14 19 5.1 
HR  1 7 14 22 5.9 
Mono resistant           
H 1 5 2 8 2.1 
S 1 1 3 5 1.3 
R 1 6 7 14 3.8 
Other resistant           
HS 0 0 4 4 1.1 
ES 0 0 1 1 0.3 
Key: DST- drug susceptibility testing; MDR- multidrug-resistant tuberculosis; TB- tuberculosis; HRSE. H-Isoniazid; R- Rifampicin; S-
Streptomycin, E-Ethambutol 
 
The study findings showed that, from the previously-treated TB case specimens 
analysed (2,750), only 1,181 (42.9%) were culture positive. From the positive cultures, 
only 392 (33.2%) were set up for DST. This proportion fell during the 3 years from 






results and 19 (4.8%) were contaminated. 269 (68.6%) of the specimen’s subject to DST 
were susceptible to all FLD whereas 31 (8.3%) were resistant to all FLD as in Table 6. 
3.7 Summary discussion 
The quantitative results of this study show the target of 100% of previously-treated TB 
case specimens being routinely investigated for DR at the CTRL was far from being met. 
The proportion being sent showed a significant improvement over the 3 years, however 
only 61% of cases were sent for testing even in the last year (2013) of the three-year 
period investigated. This implies that full surveillance of the TB programme was not 
undertaken and thus that cases of drug resistant are likely to have been missed.  
In addition, when samples were sent for surveillance the median transit time from 
sputum collection to arrival at the CTRL was over 7 days, which may have affected 
specimen culture viability, and consequently the results. The policy that all positive 
culture slopes should undergo DST at the CTRL was adhered to on less than 50% of 
occasions (falling during the 3 years from 82.4% in 2011 to 27.4% by 2013). This means 
drug resistant could be missed even when samples are sent for testing.  
Part of the reason for the reduction in the DST% can be put down to the huge increase 
in volumes between 2013 and 2011 (755 vs. 34 i.e. over 20 times larger) and capacity 
constraints in staffing and equipment at the CTRL to process this increased volume. This 
is a significant weakness at the CTRL.  
On the positive side culture contamination was recorded as being within the 
recommended level (0-5%) (108) in this study. However, a Supra-National & GLI Mission 
Visit Report in 2013 showed higher contamination rates (~30%).4 The reason for this 
difference is unclear but may relate to how contamination rates are calculated and 
historically poor recording of contamination at the CTRL.  
 








The study was not without limitations. Poor record keeping made it difficult to attain 
more meaningful and conclusive results on the effect of delayed submission of sputum 
specimens. Routine data were captured electronically, but incomplete form filling led to 
difficulties in analysing some information. It seems that the RSS policy was not well 
understood by TB health care workers as it was evident in the TB laboratory request 
forms that the patient’s category was not usually indicated. This all made analysis difficult 
because of a lot of missing information. 
In relation to understanding the turnaround time it would have been preferable if the 
date the result was received by the clinician at the peripheral facility were the end time. 
Unfortunately, this date was not available on the electronic database and therefore the 
date the CTRL reported back to the region had to be used instead. This means the true 
time for results to be received so they can be acted on will in reality be longer and 
possibly more variable than that which could be calculated. 
 
3.8 Conclusion  
The outcome from this quantitative study provides baseline data from which to focus the 
subsequent exploration of mechanism of transferring specimens from peripheries to the 
CTRL and performance within the CTRL itself. Further research to explore the reasons for 
this performance and stakeholder’s perceptions of the RSS would potentially allow the 
development of measures to reduce turnaround times, increase the level of valid DSTs 
being completed overall, and to reduce delays in clinicians receiving results and therefore 













According to Natasha Mark, qualitative approaches to operational research are targeted 
to generate knowledge and information that reflects the perceptions, understandings 
and practices of different groups (109).   
This chapter addresses research question (b) as referred to in the Introduction, section 
1.9.3. - What is the stakeholder perception of the current routine surveillance system for 
previously-treated TB cases in Tanzania? (Qualitative).   
A study using a qualitative design was undertaken to understand the process and 
performance of the existing RSS operation. The focus was to provide explanations for the 
inefficiencies described by the 2011 to 2013 routine data as shown in Chapter 3. It 
explored the perceptions of health care workers through group discussions and in-depth 
interviews; seeking to understand their views, knowledge and awareness of the existing 
RSS policy implementation, and importantly, then to link these qualitative perceptions 
to the quantitative findings of chapter 3. It was anticipated that the knowledge and 
understanding attained would generate ideas of suitable interventions to improve 
performance.   






4.2 Study Overview 
4.2.1 Study objectives 
To determine what factors, lead to the inadequate performance of the current routine 
surveillance system for previously-treated TB cases in Tanzania.  
4.2.2 Study research question 
What is the stakeholder perception of the current routine surveillance system for 
previously-treated TB in Tanzania?  
4.2.3 Study aim 
The aim was to explore the stakeholder perception of the current routine surveillance 
system for previously-treated TB cases in Tanzania with a view to identifying 
interventions to improve and accelerate positive patient outcomes in particular with 
relation to DR-TB.  
4.2.4 Study hypothesis 
The study hypothesizes that the inadequate performance of the current RSS is associated 
with poor TB diagnosis for DR-TB in Tanzania.  
4.2.5 Study approach 
This study involved a range of different stakeholders (including health care providers and 
implementing partners) within the TB Programme. They were selected to investigative 
and understand the context and practice of the current RSS implementation from the 
perspective of individuals in their own place of work within the healthcare system. These 
observations would be based on stakeholders own reported experiences and 
perceptions. This qualitative research would address the policies and operation that 
relate to the RSS and would look at issues that patients may never see. These problems 
are likely to have repercussions on efficiency as well as patient outcomes. The research 






carried out, what its strength and weaknesses are, and to suggest ways for improvement. 
This would lay the foundation for subsequent stages of the study (117). 
4.2.6 Study sites and population 
4.2.6.1 Introduction 
The study was conducted in four regions of Tanzania, representing regions with high 
demand for TB services and spread across the country. These four regions were among 
the ten regions that individually represented more than 4% of the total TB notifications 
in the country  (110), see Figure 13. The regions were Arusha (4.9%), Dar es Salaam 
(21.9%), Morogoro (5.1%) and Shinyanga (6.4%). Dar es Salaam was purposefully 
selected as it is by far the largest region and contains the CTRL. The other 3 regions were 
selected using a simple random sampling technique from the remaining 9 high volume 
regions (111). These health regions reflected Tanzania’s decentralized public health 
service system, in which each region is led by a Medical Officer (MO) and where all TB 
activities are overseen by an RTLC.  
The study also involved participants from members of the health system staff at the NTLP 
and CTRL based in Dar es Salaam. Health care workers at TB clinics at regional and district 
level were also included. Also, implementing partners supporting the NTLP, Ministry of 












4.2.6.2 Overview of study sites 
The study was conducted in four regions in Tanzania each study site is described below.  









Table 7: Summary of the study sites by 2015 
Region No. of 
diagnostic 
centers 
TB Cases notified TB/HIV 
New cases Previous 
treated TB 
cases 
Total  Positive Rate 
Dar es Salaam 64 11,052 525 11,577 4,738 40.9% 
Arusha 43 2,320 132 2,452 773 31.5% 
Morogoro 34 2,668 72 2,740 995 36.3% 
Mwanza 37 2,743 79 2,822 1,381 48.9% 
Shinyanga 24 1,535 84 1,619 966 59.7% 
Grand Total 165 20,318 892 21,210 8,853 41.7% 





Arusha  is in north eastern Tanzania and is one of Tanzania's 31 administrative regions in 
Tanzanian Mainland. Figure 14 shows a map of the region split into districts. The city of 
Arusha is the capital of the Arusha region. The region has a population of 1.7 
million (2012 census) (112) and a total area of 82,428 square kilometres. Around 4.3% of 
the region is covered by the water bodies of Lakes Eyasi, Manyara, Babati and Natron. 
The region has a common border with Kenya to the north, Kilimanjaro and Tanga regions 
to the east, it shares a border with Dodoma region to the south, and west with Singida, 
Shinyanga and Mara regions. The average economic growth rate for the region is 
relatively high, it stands at 3.8% against the national rate of 2.8%. The main economic 
activity of Arusha region is agriculture, tourism and mining. Arusha economically is very 
important to the nation, ranking second to Dar es Salaam in this respect (112). It is a 
multicultural city with a majority Tanzanian population of mixed backgrounds: 
indigenous African, Arab-Tanzanian and Indian-Tanzanian population. There is a small 
European and American minority population.  
The main ethnic groups are Iraqw, Arusha, Maasai and Meru. Religions of the Arusha 






major international diplomatic hub and hosted the East African Community from 1994 
to 2015. 
Figure 14: Map of Arusha Region Showing Diagnostic sites 
 
 
Dar es Salaam 
The Dar es Salaam region is in Eastern Tanzania and is one of  31 administrative regions 
in Tanzanian Mainland. Figure 15 shows a map of the region split into districts.  
Dar es Salaam city is the largest city in East Africa and the seventh-largest in Africa, with 
a population of 6.7 million (114). The city’s land area is 1,393 square kilometres, making 
the population density 4,800 per square kilometer. The city was formerly known as 
Mzizima. It was the capital city until 1974, when Dodoma was named as the capital. 
However, today, Dar es Salaam remains the largest city in Tanzania in terms of population 
and is the financial and business capital of the country. Dar es Salaam is also where the 










Morogoro region is in the south centre of the country and is one of 31 
administrative regions in Tanzanian Mainland. Figure 16 shows a map of the region split 
into districts.  The region has a population of 1.2 million and occupies a total of 72,939 
square kilometres which is approximately 8.2% of the total area of Tanzania mainland 
(114).  It is the third largest region in the country after Arusha and Tabora regions. The 
region is bordered by seven other regions. Arusha and Tanga regions to the North, the 
Coast region to the East, Dodoma and Iringa to the West, and Ruvuma and Lindi to the 
South. The ethnic groups in Morogoro region are Waluguru, Wakaguru, Wandamba and 
Wapogoro. The economy of the region is dominated by agriculture and other allied 











Shinyanga region is in the North Western part of the country and is one of Tanzania's 31 
administrative regions. The regional capital is the municipality of Shinyanga. Figure 17 
shows a map of the region split into districts. It has a population of 1.5 million with a size 
of 50,781 square kilometres (116).  The region is bordered to the north by the Mwanza, 
Mara, and Kagera regions and to the south by the Tabora region. Kigoma region borders 
to the west, and the Simiyu region to the east. The predominant tribes of the Shinyanga 
region are the Sukuma, Nyamwezi, and Sumbwanga tribes. The region economy depends 










4.3 Study Method 
4.3.1 Methodology used and justification 
A qualitative research method was selected because it is appropriate for understanding 
views, perceptions and to discover new thoughts that can identify problems and provide 
solutions to them. The method is specifically designed to uncover a target audience’s 
thoughts and behaviour in connection to a particular topic or issue (117). A qualitative 
study method can obtain detailed and nuanced information. It would help in 
understanding fully the weaknesses in the RSS identified in the quantitative data, and to 






There are four main methods of collecting qualitative research data, these are: 
interviews, focus groups, observations and action research (118). In this study we chose 
to use in-depth interviews (IDIs) and focus group discussions (FGDs) with a range of 
health care service providers which are described in detail later in this chapter. These 
approaches are particularly appropriate to this study because they both allow for open-
ended questions so that in-depth information can be collected (127).  
IDIs involve a one-to-one session with key informants which allow an extended time to 
discuss topics privately and confidentially in detail with each person. Quality IDIs depend 
largely on the quality of interactive dialogue between the interviewer and the participant 
(122). They were chosen as a method appropriate for discussions with senior individuals 
within the health care programme and implementing partners supporting the NTLP. IDIs 
can be time consuming and resource intensive (128).  
FGDs are a good way to gather together a group of participants from similar backgrounds 
to discuss a specific topic of interest.  They allow participant interaction to agree and 
disagree thus stimulating discussion which aids in revealing respondents’ real 
perceptions on the subject of interest (113). Gathering thoughts and traditional views on 
the RSS was possible through this method of data collection at both regional and national 
levels.  The facilitators were also, where appropriate, able to use lessons and information 
from earlier IDIs and FGDs to improve questioning in subsequent IDIs and FGDs (118).  
4.3.2 Sampling procedure for FGDs and IDIs 
In this study we used both convenient and purposive sampling approaches in participant 
selection. The selection was done purposively targeting the RTLC and Regional 
Laboratory Technologist (RLT)  (one per region) (117). They were chosen on the basis of 
their unique detailed understanding of the issues concerning the existing RSS 
implementation (117). Based on their experience this would enable all concerns relevant 
to the study to be raised (117). Health care providers at all study sites were conveniently 






Programme at the selected study sites (119) were selected based on availability and 
willingness to participate.  
The CTRL had few staff, and therefore the sampling strategy of selecting study 
participants for a small population (i.e. less than fifty) was adopted (120). In other words, 
if the population is less than 50, researchers can involve the entire population in the 
study, and there was no need to sample. For that reason, the study targeted all 20 CTRL 
staff who were willing to participate in the FGDs.   
Implementing Partners supporting the TB Programme, managers and administrative 
personnel at the regional level were all chosen for IDIs to provide information about the 
existing RSS. It was thought their awareness and opinions could play a large role in 
influencing considerations related to system improvement and policy change.   
 
4.3.3 Sample size  
The sample size for the FGD’s was 45 participants (25 males and 20 females). At each 
selected study site, there were at least six to eight participants (mix of people) in each 
FGD per region as shown in (Table 2). The FGDs were guided by two trained research 
assistants, one leading the discussion and the other observing and writing down the main 
points for each theme.  The total sample size for IDI’s was 10 participants (6 males and 4 
females). They took part in interviews as shown in (Table 3). Confidentiality was 









4.3.4 Inclusion Criteria 
A range of health professionals working in TB clinics, including regional administrative 
authority staff, TB programme staff, and laboratory staff at both the regional and 
national levels.  
Implementing partners were included based on those present during the study period 
and those who agreed to participate. 
4.3.5 Exclusion Criteria 
a) Non-health care service staff  
b) Non-TB health care professionals 
  
4.3.6 Participants and sample size  
At each selected regional study site there was a mix of people selected as shown in Table 
8. Before participant recruitment, the Principal Investigator (PI) sought permission to 
conduct the study with all the study sites. The official request letter was signed by the 
NTLP Programme Manager and sent to all the study sites. All sites gave their 
authorisation to proceed.  
The sample size for the FGD’s was 45 participants (25 males and 20 females). At each 
selected study site, there were at least six to eight participants (mix of people) in each 
FGD per region as shown in Table 8. The FGDs were guided by two trained research 
assistants, one leading the discussion and the other observing and writing down the main 
points for each theme.  The total sample size for IDI’s was 10 participants (6 males and 4 
females). They took part in interviews as shown in Table 9. Confidentiality was 








Table 8: List of Participants, study sites and FGD coding 
Region & study site  Participants role No. of participants  Group Level 




Lab TB focal person, 
Courier boy, 





Dar es Salaam, Ilala 
- Amana 
RLT, DOT nurse 
Lab TB focal person, 
Courier boy, 





Dar es Salaam, 
CTRL 









GR3 (1) National 
Dar es Salaam, 
CTRL 
Lab personnel (3), 
Data manager, 





GR3 (2) National 
Dar es Salaam, 
CTRL 






GR3 (3) National 
Shinyanga RLT, DOT nurse,  
Lab TB focal person,  







Morogoro RLT, DOT nurse,  
Lab TB focal person,  







Arusha RTLC, DOT nurse,  
Lab TB focal person, 















The total number of FGD participants was 45 (25 males and 20 females). The FGDs were 
guided by two trained research assistants (RA), one leading the discussion and the other 
observing and writing down the main points for each theme.   
The total sample size for IDIs was 10 participants (6 males and 4 females). They took part 
in interviews as shown in Table 9.  
Table 9: List of Participants, study sites and IDI coding 
Study sites Participant job role Group no Gender Level 
Morogoro RTLC GR7 M Regional 
Shinyanga RTLC GR7 M Regional 
Arusha Ag. MO in charge GR7 F Regional 
Kinondoni RTLC GR7 F Regional 
Ilala RTLC GR7 M Regional 
MoHSW Ag. DPS GR8 M National 
NTLP PM GR8 F National 
NTLP MDR coordinator GR8 M National 
Partners MSH GR9 M National  
Partners PATH GR9 F National 
Keys: Ag. MO- acting medical officer; GR- group; MSH- management science for health; M- male; F- female; RTLC- regional TB  
and leprosy coordinator; NTLP – national TB and leprosy Programme; PM – Programme Manager 
 
Confidentiality was maintaining throughout all the FGDs and IDIs. Refreshments were 
provided during each FGD (109). 
4.4 Study preparation  
4.4.1 Pilot Study  
Before the interviews, a pilot study was conducted in three regions which were not 
among the selected study sites: Iringa, Lindi and Manyara. The aim was to test out the 
qualitative research tools (topic guides). It was observed that not all the health care 
workers at the TB clinics had knowledge of the RSS. It was also evident that there were 
variations in levels of knowledge and commitment to its implementation. One region 
could not be interviewed as the administrative authorities refused to participate in the 
study. This was because of staff shortages and felt it would cause problems for their jobs. 






Due to these difficulties I engaged the NTLP Manager with study sites to emphasise the 
benefit of the study and provide assurance on adherence to confidentiality. They were 
informed that their participation would improve the outcomes of the Programme.  
4.4.2 Research team responsibilities  
As the head of the CTRL, the research team leader, and a laboratory scientist with several 
years’ experience I was responsible for the overall study. In particular, I was responsible 
for the design of the study; support to and quality assurance of data collection; training 
and management of the research team; and writing up of the research in this thesis. I 
have experience in assisting research projects on TB under the NTLP in Tanzania, 
including a master’s degree in Medical Microbiology and Virology. I have undergone a 
one-week training in conducting qualitative research as part of my PhD course.  Analysis 
of the data collected was supported by a statistician. 
The study research team consisted of a senior research assistant (social scientists) with 
experience of qualitative research and a research assistance (RA). Both were responsible 
for conducting interviews and focus group discussions. The senior research assistant 
ensured the careful translation of documents such as the consent sheets, topic guides 
and transcripts of interviews and FGDs. The second RA also undertook some transcription 
and translation of the recorded interviews and focus group discussions. Both the 
research assistants collated the data with my close supervision.  
A senior laboratory person with experience of carrying out laboratory field work and 
some qualitative research, undertook additional qualitative research training provided 
by NIMR Muhimbili. He acted as my immediate assistant and was able to accompany the 
social scientist while conducting interviews and FGD’s.  In order to facilitate openness, I 
did not take direct part in most of the interviews and discussions. Instead, the senior 
laboratory person helped provide participants with an opportunity to speak out and give 
their ideas openly in order to accomplish the objectives of this study.  






-  PhD supervisor Professor Bertie Squire (LSTM) provided technical input and 
guidance on the layout of the study thesis.  
- PhD supervisor Dr Ivor Langley (LSTM) has extensive experience in designing and 
supervising research particularly quantitative methods. He worked very closely 
with me and provided technical input and proof-reading support of the thesis. 
- PhD supervisor Dr Eleanor MacPherson (LSTM) has extensive experience in 
qualitative methods. She provided technical input on qualitative design and layout. 
She trained me on the qualitative methods and how to conduct the qualitative 
study. 
- PhD supervisor Dr Esther Ngadaya (NIMR) has experience doing research and 
supported me in Tanzania throughout the whole study as it went forward. 
 
4.4.3 Training  
The PI provided extensive training and support to the research assistants and the 
laboratory personnel assistant. The core skills required to establish positive interviewer 
and participant dynamics are rapport-building and accommodating different 
personalities and emotional states. Effective use of these skills affects the kinds of 
information that participants disclose in a research setting and depend in part on the 
nature and quality of the relationship participants have with the researcher (109,121).  
The training provided - background to the study; how the current RSS is undertaken; 
selection criteria and procedures; qualitative research methods; how to ask questions; 
how to translate; how to record information; data analysis; ethics and confidentiality; 
and data collection tools with emphasis on the terms used and how to translate them. 
Emphasis was also given on the importance of probing; informed consent process and 






RAs went through the topic guide that would be used during the interviews and FGD’s, 
until all felt confident with it and the whole exercise of participant’s confidentiality. 
4.4.4  Development of tools  
The data collection tools were developed using knowledge gained from the qualitative 
training. Alongside this, inputs were received from research supervisors, especially Dr 
Eleanor MacPherson of LSTM who is a Qualitative research expert. In addition, I also read 
about similar studies conducted in different countries in the published literature.  
Topic guides were designed for FGD and IDI and are shown in tabular form in Tables 10 
and 11 respectively. A topic guide is a practical framework that indicates what is to be 
included and reassures all involved that the researcher will cover all the important areas 
of the research (127). In this study it was used to guide interviewers and participants 
through the principal themes and issues to be covered according to the study objectives. 
Questions asked to participants could be modified and followed up in more detail as 
appropriate. In the interviews and focus groups the questions focused on specifics and 
getting examples of how the area under discussion supports and impacts on participants 
work (109).  
The interview guides for FGDs and IDIs were available in Swahili and English Appendices 
6 to 8). The consent form for FGDs was conducted in Swahili in Appendix 6 or in English 
and Appendix 7 as appropriate. The translation was done by a bilingual speaker (Ms. 
Marijani) at the Community department, Muhimbili University. It was then translated 
back to English by another bilingual speaker (Ms. Tunu) at Ifakara Health Institute (IHI) 
who did the verifications (Appendix 8). They were both based in Dar es Salaam, Tanzania 
and were not involved with other aspects of the study. The independent translations had 
no major differences when compared to the originals. The translators followed the 
principles published by Jootun, who recommend that researchers need to engage with 







Table 10: Topic Guide for Focus Group Discussion 





CTRL  Relationship to the 
workload 
 




1 How are TB health care workers 
involved in the RSS?  





What is the 
perception of the 
health care 
workers on the TB 
reference 
laboratory?  
Where do your 
patients come from?  
 
How do health care 
workers become aware of 
new TB diagnostic 
strategies?   
Is there anything 
else you think 




2 Probe; what is their roles in RSS, 
what do they think of the current 
method, what is their perception 
on the TB Programme and the 
reference laboratory?). 
 
Who does the 
specimen 
transportation? 
(Probe; how is it 
transported?) 
What do they 
think could be 
done better or 
could be 
sustained? 
probe ;( how many 
patients per day per 
clinic, if heavy clinic, 
why, issues around 
health education and 
who does the TB 
screening)  
(Probe; from the 
programme, training, 
internet, collaboration with 
the TB programme, how is 
it disseminated) 
Do you have any 
questions about 
any aspect of this 
interview? 
3 Describe how RSS is implemented 
in your health facility?  







times and the 
performance). 
What perceptions do 
the health workers 
have towards patient 
management?  
What do health care 
workers know about TB 
transmission?  
 
4 Probe: if health care workers 
know about the RSS and what 
type of specimens need to be 
sent, algorithm and safety)  
  (Probe; compared to 
the number of staff, 
skills, motivation) 
 
Probing on ways it is 
transmitted, ways it is 
prevented, explore 
questions relating to TB 
diagnosis) 
 
5 What do health care workers think 
are the challenges in 
implementing the routine 
surveillance system?  
   What knowledge do the 
health care workers have 
on RSS? 
 
6 Probe issues related to causes that 
contribute to TB diagnosis delays, 
is it the patients or the 
programme, feedback of the 
   Probe; how it works, 
collaboration with the 
reference lab, specimen to 







results, specimen handling and 
support from the TB Programme). 
7 What could be done differently to 
make it better, what could be 
beneficial to the community?  
     






Table 11: Topic Guide for In-depth Interview 
S/N Heath workers Views and Roles Health workers perception Knowledge on RSS Perceptron on the 
Network 
Closing 
1 What are your views about the TB 
control Programme performance?  
 
Ask for their perspective; is 
there anything, which 
would prevent them from 
changing the current 
services provided or the 
system?  
What do you know 
about TB routine 
surveillance system?  
 
Probe what is their 
perception of the TB 
networking? 
 
Is there anything else you think 
would be useful for programme 
to know? Do you have any 
questions about any aspect of 
this interview?  
2 What do you regard as the successes 
of routine surveillance system?  
 
What have been some of 





would you make on 
RSS? 




3 How do you view your own role in 
the TB programme? (Probe)  
    
4 How do you see your role in 
supporting TB programme policies 
implementation? 
    







4.4.5 Confidentiality and Consent 
The RA was trained on how to carry out the interviews and FGD’s, and how to maintain 
confidentiality. Issues of confidentiality would also be addressed at the time of data 
collection. At this point, assurances of confidentiality, via consent form statements such 
as, “All identifying characteristics, such as occupation, city, and ethnic background, will 
be changed” (124). In this study codes were used in place of participant or site names to 
ensure anonymity and participants job security. Consent forms were provided a day 
before the interview to provide sufficient time for the participants to understand the 
information relating to the study.  
The RA explained the purpose of the interviews and FGDs, confidentiality issues and the 
informed consent process. The RA informed potential participants both at the national 
and regional levels of the methods of obtaining data and the expected benefit arising 
from the study; this was before consent. They were then given an opportunity to go 
through the document before filling in the translated consent form as shown in 
(Appendix 6). They were also given an opportunity to ask questions and responses were 
provided accordingly. They were granted freedom to withdraw from the study at any 
point without prejudice. The RA informed them that the information collected would be 
treated confidentially and that the research assistant would keep the signed consent 
forms in a locked cabinet. The RA emphasised that no name or site name would be used 
throughout the study, instead codes would be used to maintain confidentiality.  
 
4.5 IDIs and FGDs Conducted 
4.5.1 Overview 
There were two types of qualitative data collection used in this study. i) IDI with key 
informants, and ii) FGD with health care workers. Topic guides were used to guide 






to the gathering of information, 6 FGDs and 10 IDIs were conducted with a total of 55 
participants. The IDIs and FGDs were audio-recorded to not only capture all valuable and 
detailed discussions, but also to help the research team to be attentive to the 
conversation with study participants.   
1. In-depth interviews (IDIs) 
The IDIs were conducted by one of two RAs. Firstly, a senior Research Scientist from 
NIMR with experience in qualitative methods. She conducted interviews at health 
facilities in Dar es Salaam- Ilala, Kinondoni and at the CTRL in Dar es Salaam. Whilst a 
second RA from NIMR was hired to conduct the interviews in Arusha, Morogoro and 
Shinyanga. The IDIs were conducted in English on the recommendation of the 
participants. The IDIs involved TB programme staff, managers, policy makers at the 
Ministry of Health (preventive unit), regional administrative authorities and 
implementing partners Management Sciences for Health (MSH) and PATH who were 
supporting the NTLP. The venues were selected depending on the location of the 
participants. The sessions lasted for an hour up to 2 hours. All interviews were conducted 
in a quiet environment that provided privacy. The location was that preferred by the 
individual, but most often was their office or in the CTRL conference room. The 
interviews with Implementing Partners were conducted in their offices. Most of the IDI 
were conducted early in the morning before they started their daily routine work. 
2.  Focus group discussions (FGDs) 
Participants for the FGDs were recruited from the selected study sites. Purposeful 
sampling technique was implemented at the national and regional level by intentionally 
selecting study participants in order to ensure that a variety of perspectives on the 
research topic were represented (119,127). This ensured a diverse range of views with 
respect to roles, seniority and experience. So as to avoid tension among participants, the 
higher-level staff were not included in the FGDs, instead they were recruited to the IDIs 






answering questions. So, each FGD involved participants of similar seniority so that they 
would feel able to respond freely and openly to the questions (109).  
The FGDs were conducted at regional and national levels depending on the participants’ 
availability and workplace.  
3. Regional level 
Six participants from each selected study site were recruited for each FGD. See 
participant’s distribution in Table 9. In each selected region one member from DTLC, a 
DOT nurse, a courier person, a TB laboratory focal person and a TB/HIV coordinator were 
selected based on their willingness to participate in the FGD. By default the RTLC and 
Regional Laboratory Technologist (RLT) were purposefully selected because each region 
has one RTLC, while other health staff were conveniently selected (125). The district level 
DTLC and TB/HIV coordinators also took part in the study.  
The FGDs were guided by the two RAs with the senior RA leading the discussion, and the 
other observing and writing down the main points for each theme. The concept of 
theoretical saturation was used to halt discussion when no new conceptual information 
was emerging from discussions (126). Data saturation was reached at six FGDs. The 
selection of the venue was done with the help of the RTLC. Each participant was given a 
consent form prior to taking part in the study. Additionally, participants were made 
aware that interviews were being tape recorded, and informed that the recording will be 
kept for up to seven years. This permitted re-analysis if need be using the tape 
recordings. The FGDs were conducted in Swahili and each session lasted for an hour up 
to 1.5 hours. Refreshments were provided during the FGD session. The FGDs conducted 
at the regional level used venues agreed with the participants and were undertaken late 
afternoon when the staff had finished attending to all patients. A typical room layout is 










4. National level 
FGDs were planned to be conducted involving 20 CTRL staff to explore the perception of 
the programme staff about RSS implementation. In the end only 15 participants took part 
in the FGDs at the CTRL, as some were out of the office or on annual leave.  The CTRL 
participants for FGDs were divided into three groups; two groups each contained 6 
participants and one group had three participants. The CTRL FGDs were conducted once 








4.5.2 Study data handling  
During fieldwork, two digital audio-recorders were used to record interviews and field 
notes. The senior RA and the PI kept the recorders securely and the PI transferred audio 
files at the end of each day to their laptop which is password protected, deleting the 
original file from the digital device. The protected laptop was accessible only to the PI. 
The PI carried with her or stored it in a locked cabinet in her office at the CTRL in Dar es 
Salaam. A duplicate copy of electronic files was stored on a password-protected external 
hard drive to ensure full back-up of collected data. The hard drive, along with hard copy 
documents related to the study, such as handwritten field notes and signed participant 
consent forms, were stored in a locked cabinet at the CTRL accessible only to the PI. 
Audio-recordings and corresponding transcripts and notes were marked with unique 
identifiers to protect participants’ identities. The participants unique identifier was based 
on the type of data collection used (e.g. Focus Group); the group number (GR1 – GR6 
depending on location); whether regional or national; gender; and participant number 
(between 1 and 15). For example: 
1. FG-GR1-REG-F1  
FG- focus group discussion  
GR1- sites name 
REG- region level 
F1- F – female 1- participants number 1 
 
2. FG-GR3-NL-M15 
FG- focus group discussion  
GR3- sites name 
NL- national level 
M1- M - male, 15- participants number 15 
 
 
The participant identifiers for in depth interview participants included a group number 
between 7 and 9, implementing partner or national level; gender; and the participants’ 







IDI- In-depth Interview 
GR9- site name 
IP- Implementing partners 
F2- female participants number 2 
 
4.  IDI-GR7-RG-M7  
IDI- In-depth Interview 
GR7- site name 
RG- regional level 
M7- Male, participants number 7 
 
5. IDI-GR8-NL-M8 
IDI- In-depth Interview 
GR8- site name 
NL- national level 
M8- Male, participants number 8 
 
 
Seven years post data collection all identifying markers will be removed (de-linked) from 
all electronic and hard copies of transcripts and field notes. Consent forms (original and 
scanned versions) and digital recordings will also be destroyed.  
 
4.5.3 Qualitative analysis 
Qualitative research usually produces large amounts of textual data in the form of 
transcripts and field notes. The systematic and rigorous preparation and analysis of 
qualitative data is usually labour intensive. To lessen this burden, it is important that 
health researchers become aware of the possibilities of using Computer Assisted 
Qualitative Data Analysis Software such as ATLAS.ti, MAXqda and NVivo  (129,130).  
In this study the qualitative data analysis for the 10 IDIs and 6 FGDs was done using 
NVIVO 10™. NVivo is a qualitative data analysis computer software package. NVivo is 
short for Navigating Viewpoints, Images and Value Observed by informants/interviewee, 
FGD and observation. It has been designed for qualitative researchers working with very 






large volumes of data are required (131). The software program can also be used in a 
mixed-methods research such as quantitative and qualitative approach. Specifically, it is 
intended to help users organize and analyse non-numerical or unstructured data (132). 
Data analysis from the IDIs and FGDs were carried out using the framework approach 
which provides researchers with a systematic and flexible structure to manage and 
analyse data (133).  
The steps taken to analyse the qualitative data is summarized in (Figure 19).  




First the recorded IDIs and FGDs were transcribed in Swahili and then translated into 
English. Transcription and translation were conducted concurrently with data collection 
and continued after the interviews were completed. Manual analysis began by preparing 






notes were taken and transformed into electronic format. The FGDs and IDIs were 
individually transcribed in its original language, Swahili. This allowed both the precise as 
well as the symbolic meanings of statements to be understood. The tape-recordings 
were transcribed verbatim in Swahili by a transcriber and then translated in English by 
an independent person who was not involved in this study.  Each transcribed IDI and FGD 
was reviewed for accuracy by replaying each recorded interview whilst reading and 
translating the transcripts. The PI and RA had frequent meetings to evaluate transcripts 
and notes from the interviews and update topic guides.  
Three transcripts were randomly selected and translated by a bilingual speaker who was 
not involved with other aspects of the study. The independent translations had no major 
changes when compared to the originals. NVIVO 10™ was used to facilitate the coding 
process, the codebook was established where key themes and sub-themes were 
developed from research questions and broader study objectives. The coding was used 
to organize data and identify different themes and the relationships between them. To 
refine the codebook, a few interviews were read and re-read to find out the key 
messages considering the frequency of responses. More frequently occurring statements 
were underlined, whilst keeping a record of lesser views. Quotations were used to 
illustrate these themes. Nodes (themes) were developed into qualitative data analysis 
using NVIVO 10™(131). This coding process was finalized with support from Senior RA 
and the PhD supervisors.  The PI together with the senior RA went through the assembled 
table and quotes to make sure the results were grounded in the data. This was shared 
with the supervisors who provided advice on the quotes and assisted in drawing up a 
structured and simplified flow diagram of linked key themes and sub themes.  
Additional emerging themes were added if their inclusion was considered important for 
improving the TB programme services. Common thematic explanatory categories were 
constructed to help shed light by identifying key bottlenecks that were limiting the 
usefulness of the existing RSS implementation for previously-treated TB cases. The 






participants in the interviews and discussions. The analysis came to an end once the 
theoretical saturation point had been reached (127).  
 
4.6 Qualitative findings   
4.6.1 Summary of key themes 
Data were coded by themes and sub-themes through content analysis. A table of 
matched themes with subthemes showing strengths and weakness emerging from 
participants comments. These are summarized in Table 12.   
The three main health system areas were the District Diagnostic Centres (DDC), 
transportation between the DDC and the CTRL, and the CTRL itself. In each of these areas, 
key themes from the IDIs and FGDs were identified and then sometimes further divided 
into subthemes. Key themes identified at the DDC were staff demotivation, failure to 
follow good practice, delays sending samples, and lack of appropriate technology. In 
relation to transportation between the districts and the CTRL, the key themes were the 
lack of reliable transportation, lack of funding for transportation, and the distance 
between the districts and the CTRL. At the CTRL, the key themes were unreliable 
diagnostic technology, contaminated samples and poor communication with districts. 








Table 12: Codebook for Qualitative Study of RSS using NVIVO 10™ 
Theme/Main Code Observed weaknesses in RSS Other observations 
A. District Diagnostic Centres (DDC) 
Staff motivation Lack of incentives 
Poor safety implementation 
Missing and poor supervision  
Some feel well supported by 
supervisions 
Follow good practice Lack of training 
Poor packaging 
Incomplete forms  
Lack of lab supplies at DDC 
Some feel training better in 
urban areas  
Delays sending samples Specimen batching Urban sites do better 
Technology No Xpert 
Unreliable diagnostics 
No biosafety cabinets 
Xpert now in place in Iringa, 
Temeke and being slowly rolled 
out.   
B. Transport between DDC and CTRL 
Transportation from/to 
remote sites 
Poor expedited mail service (EMS) 
No EMS available at periphery 
Centres close to the CTRL have 
less of a problem.  
Funding for 
transportation 
Districts required to pay  
Distance between CTRL 
and some sites 
No Zonal reference laboratory 
Poor communication 
CTRL does receive samples from 
every region 
C. Central Reference Laboratory (CTRL) 
Technology Xpert technology not used 
Lack of guidelines for new 
technology incl LPA 
LPA now available, but not used 
Contamination High contamination at CTRL (30%) 
Not all regions using recommended 
transport medium 
The NTLP recommend use of a 
transport medium to avoid 
contamination 
Communications Lack of reliable internet and phone. 
Verbal messages head wrongly 
Toll free number available 
Delays in results Poor communications 
DST just not done 
Consequence of all the 
weaknesses 








4.6.2 IDI and FGD quotations and the key themes 
4.6.2.1 District diagnostic centres 
Staff Motivation 
Participants considered poor staff motivation at the DDC was impacting the effectiveness 
of the RSS. In particular this focused on poor supervision, lack of incentives and poor 
health and safety. For example: - 
“There is a need to strengthen supervision, make it more fruitful not just a 
vehicle visiting. It needs to be supportive, get there, stay with the staff, for 
them to recognise and listen to their problems, and establish the hidden 
problems too; then provide a solution.” (IDI-GR9-IP-M1, 2015) 
“If the supervision is done properly it will discover many things and resolve 
problems.” (FG-GR4-REG-M4,2014) 
“There is a need to strengthen supervision, make it more fruitful not just a 
vehicle visiting. It needs to be supportive, get there, stay with the staff, for 
them to recognise and listen to their problems, and establish the hidden 
problems too; then provide a solution.” (IDI-GR9-IP-M1, 2015) 
“Supervision must be supportive, and we have had training often taught 
supportive techniques. In the district, the DLTC works in cooperation with the 
CHMT, goes to the facilities with help from CHMT…” (IDI-GR7-M7, 2014) 
“I think supervision and training is not bad but in the supervision issue it is still 
not done very well, mainly because there are too many sites.”  (IDI-GR9-IP-F2, 
2015). 
“Supervision is done more frequent in urban areas we have seen this TB 
program work well because, we find that this service in the city is in frequent 
and even in the nearby districts. But in some remote areas is a problem 
because of rains and difficulties to go to there.” (FGD-GR2-REG-F6,2014)  
“The TB program would have some incentives to employees as the CTC. The 






are loose, then take them to the post office are all our activities, but no one 
remembers you when seminars come. Seminar on sputum collection so and 
so will go, but they do not come to do the work that we are doing, some other 
things we do is by experience, not that we understand them.” (FGD-GR4-REG-
M3,2015)  
“As my colleagues said, incentives are very helpful, giving workers heart 
because you look at the context of the work done is difficult, so if there is 
incentive at least gives one heart to work; maybe after a year you say the best 
worker is so and so, even if you do not give him anything only a certificate 
helps; even applauds someone gets motivated; it is not necessarily motivated 
in terms of money or anything else.” (FGD-GR5-REG-F4,2015)   
“Here I see no safety, for what reason, you are so close to the patient, when 
weighing the patient, asks you where should the sputum taken, by the 
window is given the first dose; that is no, now I do not know what the 
government is thinking about for us” (FGD-GR1-REG-M6,2015) 
On the positive some feel well supported by supervisions. For example: -  
 “I think to be very sincere; the support they are giving us at peripheral level 
is tremendous. They are supportive and as far as the National TB and Leprosy 
Programme is concerned and very well organised when we have a problem 
they will sort it out.” (IDI-GR7-REG-F5,2014). 
Follow good practice 
There were many comments which indicated a failure to follow good practice. In 
particular, relating to training, packaging of samples, form completion and supplies. For 
example: - 
“Education is not only done once, but it also is a continuous process, and 
people need to be taught regularly, whether to provide people with new 
techniques or to refresh them.” (IDI-GR9-IP-F2, 2015)  
“As my colleagues have said, to check what is not there, what has broken 
down, more trainings to educate the coordinators and nurses about form 







“Another challenge is sometimes that there is a lack or shortage of packaging 
materials and supplies. We used to receive these items from the donor but 
their contract finished and this is now a problem. We need to know how to 
package specimens in layers to avoid leakages and specimen rejections at the 
Central TB Reference Laboratory.” (IDI-GR7-M4, 2014) 
“In different areas it can be difficult to get specimens to reach the central level 
quickly enough, and the methods used to examine the specimens, like the 
Lowenstein Jensen medium, take too long to get results and request forms 
are not filled in properly.”(FGD-GR2-REG-F6,2014) 
“This is a long-standing problem – laboratory request forms are not filled in 
well; a lot of information is missing. We see forms coming with either one 
name or just initials and the rest of the information not filled in.” (IDI- GR7-
F5, 2015) 
“Our programme is vertical, so when there is a shortage of slides we grieve. 
They should integrate so that some of these things could also be budgeted for 
by the councils at the district level.” (IDI-GR7-M4, 2014) 
There were some positive comments about training in urban areas and central supplies 
procurement: - 
I think TB control program works better in urban areas, as we have said, 
because, firstly has invested more in urban areas such as training done for 
people in towns and cities, support based more in urban areas. (FGD-GR5-
REG-M5, 2014). 
Delays sending samples 
Participants were concerned about delays in samples leaving the DDC. – E.g.: - 
“In a parcel of specimens, you could find one specimen 15 days old and 
another 3 days old, something impossible. I think they get a specimen, but 
they don’t send it on time. Instead, they wait for them to be many before 






“First of all, coordinators need to know the time specimens are to be sent to 
Dar es Salaam for culture. The awareness of the importance of those 
specimens should be there so that they would have enough containers and be 
able to truck the specimens as they are sent by expedited mail services.” (FGD-
GR3-F12-NL, 2014) 
Some felt things were better in Urban areas e.g.: - 
A female participant felt that TB surveillance is doing well in urban areas it 
was also agreed with another male participant; (FGD-GR4-REG-F6, 2014). 
Technology 
Participants raised concerns about how well functioning the DDC network was in reality. 
Part of this related to equipment which as new technologies such as Xpert MTB/RIF begin 
to become available will need to be rolled out and included in the RSS. For example: - 
“Of course we know there 900, but they might not know how many of these 
are functional and how many are not functioning; and for those not 
functioning to look at the problem/why; is this human resource, equipment 
or infrastructure; as i said, supervision will tell all these.” (IDI- GR7-F5, 2015)  
“Yes, I do but now because of HIV patients, I think a different approach should 
also be used to help these patients because most of them are not able to 
produce conducive specimen, so most of them are smear negative, nothing 
seen but they are ill. Therefore, because of HIV a different machine should be 
used like the GeneXpert that would help these people with lowered immunity 
and are unable to produce sputum.” (IDI – GR7-M5, 2015)  
“So if it would possible for the program to get some money then I am making 
a request even though I will be retired, when our kids come to work here 
should find a biosafety cabinet there, even if it is a small one; as small as it 
might be if they will be able to use it, it is O.K. There we have a bigger one 
but, because it is there and microbiology is done there too, they want us to 
get out, GeneXpert done there too. But if another biosafety cabinet was here 
then he processes his specimens then puts them in the gene Xpert and that is 






“With a new technology GeneXpert and we are trying to get to the district 
level, and it helps us in identifying resistance to one of the particularly 
important drug RF. Therefore, gene Xpert gives you two results at once. You 
take the specimen and start examining it, after two hours it gives you two 
results, you are infected with TB or not and if you are infected what type of 
TB, resistant to RIF or not. Therefore, straight away you know what type of 
TB you are dealing with, responds to the first line drugs or not. From there 
treatment regime may change, may be given first line drugs or second line 
drugs but at the same time take more specimens to check the susceptibility of 
the other drugs.” (IDI-GR1-REG-M7, 2015) 
4.6.2.2 Transport between DDC and CTRL 
Transportation from/to remote sites 
Transportation from and to many sites was seen as a major problem by some. E.g.: - 
“Another challenge I have seen so far is that transportation is also quite a big 
challenge. In different areas it can be difficult to get specimens to reach the 
central level quickly enough,.” (FGD-GR2-REG-F6,2014) 
“Actually, the biggest problem is referring samples from the peripheral 
laboratory to district laboratory where post services are not available.” (IDI- 
GR7-F5, 2015) 
“First of all, coordinators need to know the time specimens are to be sent to 
Dar es Salaam for culture. The awareness of the importance of those 
specimens should be there so that they would have enough containers and be 
able to truck the specimens as they are sent by expedited mail services.” (FGD-
GR3-F12-NL, 2014) 
Some felt there was less of a problem with centres in Dar es Salaam close to the CTRL. 
E.g. 
“The transportation from Dar es Salaam Laboratory to the Central TB 







Funding for transportation 
Finding the funds to transport samples to the CTRL was identified as a problem for 
some. E.g: - 
“I said, there used to be some assistance like some amount of fuel from the 
district budget”. (IDI-GR7-M7, 2014) 
“We have a challenge in how to send those specimens. Who will take the 
specimens to the stations and who will pick the specimens up in Dar es Salaam 
and who will pay the costs for sending specimens? We had a partner, but their 
contract ended. So, that is still hanging in the air waiting for someone else to 
kick in.” (IDI-GR7-M4,2014). 
Distance between CTRL and some sites 
Some participants saw a real difficulty with the lack of a nearer facility to do drug 
susceptibility testing and to take pressure off the distant CTRL. For example: -  
“Central TB Reference Laboratory staff have been trying to perform their 
work, but they are overloaded with many specimens from each side of the 
country. One reference laboratory for culture and drug susceptibility testing 
in Tanzania, I would suggest that, to identify another branch to reduce 
congestions which causes delays in results.” (IDI-GR7-F6, 2014) 
“In different areas it can be difficult to get specimens to reach the central level 
quickly enough.” (FGD-GR2-REG-F6,2014) 
4.6.2.3Central TB Reference Laboratory (CTRL) 
Technology 
Technology at the CTRL was seen by some to be not quick enough and caused delays. 
E.g.: - 
the methods used to examine the specimens, like the LJ medium, take too long 







“In general, I would say, the system needs to probably encourage a lot more 
other techniques I would say the methods used to examine the specimens like 
the LJ medium method for culture and the drug susceptibility testing both take 
too long. I think it is a big challenge because we need to be able to get these 
results quicker. For instance, they could be examined by liquid culture and 
drug susceptibility testing is done using molecular methods these could give 
results quicker.” (IDI-GR9-IP-F2, 2015). 
Contamination 
Some participants mentioned the problems associated with samples that are found to 
be contaminated. E.g.: - 
“I think sometimes they are late. As mentioned, there are many challenges, 
some examinations, whose specimen has spoilt (contaminated) that needs to 
be re-tested and that is when they are delayed, although not intentionally.” 
(FGD-GR3-NL, 2014) 
Communications 
Communications between the CTRL and the DDC can sometimes be difficult as is 
evidenced by theses quotes: - 
“My perception is the networking is not that strong: one reference laboratory 
for the whole country without internet and telephone services for sharing 
information.” (IDI-GR9-F2, 2015)  
“These challenges could be solved if first communication; there should be 
rapid communication between the CTRL and the facilities sending specimens; 
as they are saying, these laboratory people who are responsible for collection 
at least a tiny allowance; for them it is harder than even us who only prescribe 
and who give medicines, the laboratory people are not remembered they are 
forgotten.” (FGD-GR1-REG-F2,2015)  
“Let me add, if communication were there, with MDR patients you would get 
a call a certain person with the number so and so should be prepared, we are 
come to pick the person up. You call the person if lives in the village and is 
easily picked up when the vehicle arrives. At the moment no communication, 






“It is the turnaround time, it is supposed to be 48hrs to 72hrs, but looking at 
the reference laboratory, the feedback from central laboratory takes about 
two weeks. However, if the system is improved they can attain the period that 
is required about 48hrs to 72hrs. This is only in microscopy, but the culture is 
a bit longer but as far as results are obtained, they should not be delayed. So 
with time this is going to be improved because of the introduction of new 
laboratory information system, candidates can be instituted in central lab and 
communication through internet and everything.” (IDI-GR7-F3, 2015) 
“We would like it to be better, that everyone has a mobile phone for example, 
you could just send a message, and we are not at that level yet.” (IDI-GR8-NL-
F9, 2014)  
“So, I think we have a problem, the system of feedback has to be improved in 
both, from central level to the peripheral level because communication has to 
be improved.” (IDI-GR7-F3, 2015) 
Some other individuals in the DDC obviously had fewer problems and welcomed toll free 
access: - 
“With us when we have a problem, we don’t keep it, we look for a way to 
solve it, if we fail, we communicate to the central laboratory. All the time they 
are supportive and communicate, tell us what to do as an alternative to the 
problem we have, and obviously sometime is a big problem, they usually 
come, they very well organized, when we have a problem they will sort it out.”  
(FGD-GR6-REG-M3, 2014)  
“With the telephone free system, the DTLCs are supposed to communicate 
with the CTRL without paying anything so that will improve, because the 
payment is not the interest anymore because has been paid by reference 
laboratory, the web system you can just log in the computer and get the 
results.” (IDI-GR3-F3,2015) 
Delays in results 







“Another challenge is the delay in results; I think the patients and the 
clinicians are not getting the right message. They think culture and drug 
susceptibility testing would only be a day’s work, which is not right –culture 
on its own takes up to eight weeks.” (FGD-GR3-NL-F9, 2014) 
4.6.2.4  Some comments about the RSS overall 
In addition, there were some overall comments by participants about the RSS that were 
worth noting. Not everything was perceived as week, but many identified improvements 
were needed. E.g.: - 
“routine surveillance system is a good programme; they also work smartly, 
but the programme needs some improvement…” (FGD-GR2-REG-M2,2014) 
“Although Routine Surveillance is working well, the way I see it, most of its 
targets have not been reached. I suggest that it is better if the number of 
people responsible should circulate the information to all health care 
providers on how to do it for better understanding.” (FGD-GR2-REG-
M2,2014). 
4.6.2.5 Summary of key themes 
The results from the qualitative research were reviewed and presented according to the 
key themes in Table 12. These key themes and related sub-themes were simplified and 
links between them identified following discussions with the PhD supervisors. This 








Figure 20:  Key themes and subthemes observed from the FGDs and IDIs. 
 
 
       
OBJECTIVE: To determine what factors lead to the inadequate 
performance of the current routine surveillance system for 






4.7 Summary discussion   
This qualitative study involved using FGD’s and IDI’s to review every element of the routine 
surveillance system for previously-treated TB in Tanzania. It was designed to try and 
understand why some of the shortfalls in performance of the current system for 
previously-treated TB cases were occurring, and potentially to help identify initiatives to 
address these weaknesses.  
The qualitative study results showed many associations between the quantitative results 
(Chapter 3) and qualitative findings (chapter 4). The key shortfalls identified in the 
quantitative study described in chapter 3 were low volumes of samples being referred for 
DST to the CTRL; long time delays in transit of samples when they were referred; when 
they did arrive at the CTRL few samples were receiving a valid DST test; and those that did 
had long turnaround times. The findings from this qualitative study go some way to 
explaining these results. For example, poor staff motivation at the DDCs resulting from 
poor supervision and training would probably contribute to low volumes being transferred 
to the CTRL. Failure to follow good practice at the DDC in areas such as sample packaging, 
supplies management and form completion were likely to contribute to difficulties at the 
CTRL when samples arrive including contamination and the ability to link the sample with 
a district and patient. The batching of samples and unreliability of transport between the 
DDC and the CTRL would contribute to long delays before and in transit. Similarly, the use 
of techniques such as Lowenstein Jensen for drug susceptibility testing rather than Xpert 
MTB/RIF and LPA would contribute to long turnaround times at the CTRL. This would be 
further compounded by poor communications between the CTRL and DDC’s. Most of these 
issues including making greater use of new diagnostic techniques like Xpert MTB/RIF need 
to be addressed if the RSS in Tanzania is to be fit for purpose.  
A potential way forward would be to redesign the RSS based on addressing many of the 
issues identified above. In particular, making use of new and much rapid diagnostic and 
DST approaches such as Xpert MTB/RIF and LPA, alongside addressing the transport and 






hoped this would also lead to an increase in the detection, and speed of detection, of 
MDR-TB. A way forward to test this could be by a regional pilot in the first instance 
This qualitative study to gather the perceptions of stakeholders concerning the RSS was 
not without limitations. First, many of the experienced laboratory and districts staff were 
not available for IDI as a result of high staff turnover, however it was still felt a reasonable 
cross section of views were gathered. Secondly, it had initially been hoped that additional 
districts could be added to the study. Unfortunately, due to other pressures on staff time 
in the districts it was not possible to get a sufficiently large group together to run further 
FGD’s. 
The author of this study is unaware of any similar qualitative studies published that review 
this critical part of TB control in high burden TB countries. With the growth in drug 
resistant TB, strengthening of the RSS for TB is of particular importance. The findings and 
methodology used in this study would be of particular relevance for others working in 
similar settings. 
 
4.8 Conclusions  
The study findings provide a basis for identifying potential methods of improving the RSS 
and thereby providing more timely and appropriate management particularly for patients 
with MDR-TB. Based on these findings there is a need to address the identified shortfalls 
of the current system.  The next step would be to design and pilot a revised a RSS that 
addresses some of these constraints and takes on board the use of Xpert MTB/RIF at some 
district diagnostic centres and LPA at the Central TB reference Laboratory with the focus 














This chapter addresses research questions c) and d) as referred to in the introduction 
section - 1.9.3. The chapter describes a revised TB RSS for previously-treated TB cases that 
seeks to address many of the issues identified in the earlier quantitative and qualitative 
studies described in chapters 3 and 4 respectively (45). 
The revised RSS for previously-treated TB cases was designed and then piloted in Mwanza 
region, Tanzania. The design took into account the recent introduction of molecular 
diagnostic techniques (i.e. Xpert at some peripheral diagnostic laboratories and LPA at the 
CTRL). The analysis looked at the effects of the revised RSS on the number of specimens 
received and tested, the duration for specimen transportation and result feedback, and 
the number of MDR-TB cases detected. It was hoped the revised system would have 
quantitative impacts on reducing the time from specimen collection at the peripheral sites 
to the communication of DST results by the CTRL back to the requesters; increasing the 
number of specimens received and tested at the CTRL; reducing contamination rates at 
the CTRL; and ultimately increasing the number of cases starting appropriate MDR-TB 
treatment. The analysis would also enable a qualitative assessment to take place 
(described in chapter 6) on the benefits of the revised RSS at addressing many of the key 
themes and sub themes from the qualitative study described in chapter 4, Figure 20.  






5.2 Study objectives 
To design and pilot a revised routine surveillance system for previously-treated TB cases 
in Tanzania. 
5.2.1 Study research questions   
This part of the overall study was designed to address research questions c) and d) as 
shown in section 1.9.3 and below: - 
c) What new design of routine surveillance system for previously-treated TB 
cases might overcome many of the weaknesses in the current system? 
d) Does the newly designed and revised routine surveillance system improve 
the performance of the system, in particular by reducing the time from 
sputum collection at the district health facility to communication of the 
drug susceptibility test result by the Central Tuberculosis Reference 
Laboratory back to the district? (Quantitative) 
5.2.2 Study aims 
Identify and pilot a revised and improved RSS in Tanzania for previously-treated TB cases 
that overcomes many of the barriers to performance in the current RSS.  
5.2.3 Study hypothesis 
A revised RSS for previous treated TB cases would accelerate and increase the number of 
DR-TB cases identified and provide timely information for patients, clinicians and 







5.3 Methods  
5.3.1 Study site 
Four districts of Mwanza region (population of 2.77 million (114) were chosen for the 
study. Mwanza was chosen because it was not among the four regions selected in the 
qualitative study in chapter 4 and is a remote area with a high TB caseload and therefore 
an area where transportation of specimen could be particularly problematic. The region is 
1,142 km by road from Dar es Salaam where the CTRL is located and where drug 
susceptibility testing currently takes place. There is also a high burden of HIV/AIDS in the 
region (23,24).  
At the time this study was conducted, there were 80 smear microscopy diagnostic centres 
in Mwanza region, with 5 centres recently installed with Xpert MTB/RIF for routine 
diagnosis (4 diagnostic centres plus the Bugando Medical Centre Zonal Lab) – see Figure 
21. 
Mwanza is one of eight regions under the ‘Challenge TB’ umbrella supported through 
USAID. This made it easier to set specimen referral arrangements as all the components 
necessary to setup and run a logistics system that moves specimens from collection sites 
to the testing laboratories and return results were in place. In addition, this would provide 
facilities to monitor and track specimens; to document the level of inappropriately filled 
in request forms; and to improve overall communications.  
Therefore, for the above reasons and due to its size and location, Mwanza was considered 
an effective location for evaluating the impact of a revised RSS. If a revised RSS can deliver 












5.3.2 Study design and population 
A revised RSS was designed and a prospective pilot study of the revised RSS for previously-
treated TB cases was implemented. Before and after quantitative analysis of the impact of 
the revised RSS was completed. Following the completion of the quantitative study a 
qualitative study with key stakeholders in Mwanza and the CTRL was carried out, and this 
is reported in chapter 6. 
5.3.3 Sample Size Calculation 
The primary outcomes of the study were to assess the impact of the revised RSS on 
specimen transit time (the time from specimen collection in the peripheral health facilities 
to the time the specimen is received at a site where DST can take place time) and 
turnaround time (the time from specimen receipt at the CTRL to the time the DST results 
are sent back to the requesting clinician). Outline NTLP data from 2015 were used to 






time outcome. A total of 315 specimens were required to show a significant reduction in 
this time using a 95% confidence interval, 80% power, and hypothesised average 
difference of 10 days with a population standard deviation of 44.85 as shown in Tables 13 
and 15. 
Table 13: Population standard deviation of 44.84 
Turnaround time (TAT) for Mwanza Region for the year 2015 
Year Number (TAT) Mean (TAT) Standard Deviation (TAT) Minimum (TAT) Maximum (TAT) 
2015 69 88.9 44.8 12 304  
Key: N- Number; TAT- turnaround time; CTRL- Central Tuberculosis Reference Laboratory; SD- standard deviation 
 
 
Formula: n = (Zα/2+Zβ)2 *2*σ2 / d2 
Where: Zα/2 is the critical value of the Normal distribution at α/2 (at 95% confidence 
levels) =1.96 
a). Zβ is the critical value of the Normal distribution at β (at power 80%) =0.84  
b). σ2 is the population variance 
c). d is the difference you would like to detect. 
d). n is the sample size required 
Table 14: Sample size titration (66) 
Zα/2=1.96 Zβ=0.84 SD (σ) d n 
1.96 0.84 44.8 5 1259 
1.96 0.84 44.8 10 315 
1.96 0.84 44.8 15 140 
1.96 0.84 44.8 20 79 
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5.3.4 Inclusion Criteria 
The study included all routine specimens tested at the study sites in Mwanza region from 
April 2017 to March 2018. 
Specimens from previously-treated TB cases only  
5.3.5 Exclusion criteria 
a) Specimens from follow up cases or known MDR-TB patients who were on 
treatment   monitoring were excluded from the study. 
b) Specimens from outside Mwanza region.  
c) Specimens from new cases 
 
5.3.6 The justification for eligibility criteria 
Mwanza was chosen for the reasons stated in section 5.3.1. 
The study focused on previously-treated TB cases only because this is where most of the 
MDR-TB cases are found. The RSS for previously-treated TB cases is the most established 
by the NTLP in Tanzania. The NTLP target for the RSS is 100% of previously-treated cases, 
so there is no ambiguity about which samples were required to be referred. For new cases 
the target is 25%, primarily as there has historically been low levels of MDR-TB in new 
cases, and the volumes that would be required to be referred if the target were 100% is 
way beyond the capacity of the referral laboratories. Despite only focusing on previously-
treated TB cases in this study, it is believed many of the lessons learnt from this study 
could also be applied to the RSS for new TB cases. A pilot of a revised RSS would be a great 
help in identifying an optimal means of specimen referral from remote areas to the CTRL, 
as well as provided the likely benefits of the revised RSS across the country as Xpert 






5.3.7 Procedure for the pilot study  
To complete the design and analysis of a revised  RSS for previously-treated TB cases that 
has the potential to overcome many of the current barriers to its effectiveness and also 
takes into account Xpert MTB/RIF use routinely in some district sites, three stages were 
followed.  
- STAGE 1 – Design of a revised RSS  
- STAGE 2 – Implementation of the revised RSS in Mwanza as a pilot 
- STAGE 3 – Quantitative performance evaluation of the revised RSS  
 
(Note: A qualitative evaluation was also conducted, and this is described in Chapter 6) 
Descriptions of each stage are detailed in the following sections 
5.3.8 Stage 1 - Design of a revised RSS  
5.3.8.1 Interventions to address key themes identified with current RSS 
The key themes and sub themes from the qualitative analysis (Chapter 4) that could 
potentially be addressed by the revised RSS are indicated in (Figure 22). Those that could 
not be included in the scope of this study are indicated by the red dotted lines around the 
blocks.  These were excluded as the PI had no direct authority to make changes to address 
these issues. For instance, where there were additional funding requirements with wider 
ramifications such as changes in the infrastructure effecting sustainability. The blocks with 
a solid green line around represented those that could partially or fully be addressed in 
this phase of the study.  
Visits to study sites took place to identify possible solutions to the individual issues raised 
in the qualitative study described in chapter 4. Interventions were designed and are 














Table 15: Interventions to addresses the weaknesses observed 
 










Poor Health and 
safety  
Introduced standard operating procedures on 
safe specimen packaging and transportation.  
Introduced ‘Triple packaging’ system for 
specimen. 
Poor supervision  
 
Reviewed, adopted and modified supervision 
tools to accommodate Xpert MTB/RIF 
technique. 
Trained health care workers and trained on the 
use of supervisory tools. 
Developed new national supervisory schedules.  






Lack of training  Improved and implemented new training 
materials for refresher and in-service training of 
TB lab staff. 




Created a tool for quantification of TB 
laboratory supplies.  
Created a procurement plan based on the 
consumption per laboratory. 
Training of health care workers for the adoption 
of the quantification tool and procurement 
plan. 
Introduced ‘Triple packaging’ system for 
specimen. 
Trained study health care workers on the 
specimen packaging and transportation 
guidelines. 
Monitored safe specimen packaging and 
transportation.   
Incomplete forms Reviewed and updated TB laboratory request 
forms to improve clarity and accommodate 
Xpert and new algorithm.  
Provided on the job training to health care 
workers on how to complete the new TB 
laboratory request form. 














Sample batching Created standard policy guideline for specimen 
referral including time limits (e.g. three days’ 
maximum). 
Trained health care workers on a revised 
specimen referral system. 
Lack of 
Technology  




Introduced and promoted the use of Xpert 
MTB/RIF technique in Mwanza region. 
Mapped all diagnostic facilities with Xpert 
MTB/RIF. 
Training in the use of Xpert MTB/RIF including 






is unavailable in 
remote sites 
Lack of reliable 
mail services 
Created service contracts for specimen 
transportation with local couriers – bodaboda 
drivers. 
Introduction of service levels in contracted EMS 
services with Tanzania Post Office.  
Monitoring of transit time against targets. 
Distance 
between CTRL 
& some sites 
No TB Zonal 
reference centres 
Included the Bugando Medical Centre as a Zonal 








No rapid test LPA technique was used to test all previously-
treated TB cases received from Mwanza as part 
of the revised RSS at the CTRL. 
New monitoring approach to reduce numbers 





rate at the CTRL  
Introduced culture performance guidelines 
including 
specimen to be processed as soon as it is 
received.  
Improved sterility by use of disposable pipettes 
or loops for culture inoculation.  
Processing specimen in batches of eight instead 
of batches of sixteen.  








CTRL and districts 
Facilitated CTRL internet connectivity for 
sharing of patient results.  
Introduced WhatsApp groups to facilitate rapid, 
free and effective communication. 







The form for specimen rejections and SOP for sputum specimen transportation that the 
PI introduced are available in Appendix 9 and Appendix 10 respectively. The PI also 
reviewed and developed a revised TB laboratory request form see Appendix 11 and 
modified the TB laboratory register to accommodate changes see Appendix 12.  
A revised RSS included the design of a modified algorithm. Firstly, for the sites with no 
testing facilities, secondly sites with microscopy testing available but no Xpert, thirdly 
sites with Xpert technology available for previously-treated TB case specimens, and 
fourthly the Bugando Medical Centre Zonal laboratory – see section 5.3.8.2. 
5.3.8.2 The Revised Routine Surveillance System Algorithm 
The existing (‘Before’) RSS is described in chapter 1 Figure 9.  
The revised RSS (‘After’) design that could be piloted, involved sputum specimens being 
collected from the study sites and examined using a revised algorithm is shown in Figure 
25 for the detection of DR-TB. The algorithm design was in four parts, plus a new 
algorithm for the CTRL: - 
Part A: Study sites with neither microscopy nor Xpert MTB/RIF capacity. 
The design involved non-diagnostic heath facilities in remote areas transporting sputum 
specimen using motorbikes commonly known as “bodabodas” (see Figure 23) to the 
nearest peripheral laboratory where smear microscopy could be conducted. The 
bodabodas were identified and registered in collaboration with the Koninklijke 






Figure 23: Sputum specimens transportation using motorbike (bodaboda) 
 
 
Part B: Study sites where only microscopy is available  
At microscopy sites where Xpert MTB/RIF for TB diagnosis is not available,  samples from 
all previously-treated TB cases that were found to be smear positive were then referred 
to a local site with Xpert MTB/RIF for testing (this could be either a conventional 
diagnostic site with Xpert available, or the Bugando Medical Centre where Xpert 
MTB/RIF and culture could be performed). This would enable RIF resistance to be 
detected at an early stage and the patient’s clinician informed. The bodaboda were used 
to transfer the samples and results.  
Part C: Study sites where both microscopy and Xpert MTB/RIF are available  
At sites where Xpert MTB/RIF was available and used as the primary diagnostic tool for 
TB, those with a positive MTB diagnosis wound require a sample to be sent to the CTRL 






25). This was irrespective of whether Xpert identified RIF resistance or not. The CTRL 
was informed of this by means of a WhatsApp group message for easier tracking and 
sharing of information in case of any problems. The WhatsApp group was initiated to 
ease communication between the CTRL and the study sites (‘Mwanza Family’). The 
bodaboda were available to be used to transfer the Xpert MTB/RIF result from sites with 
Xpert MTB/RIF, including RIF resistance status, back to patient’s clinicians if required. 
 Figure 24: Expedited mail service (EMS) documentation 
 
 
Part D: Bugando Medical Centre (Zonal TB laboratory Site)  
Bugando Medical Centre is a Zonal laboratory with capacity for both Xpert MTB/RIF and 
TB culture (LJ media). Samples received here were first tested using Xpert MTB/RIF and 
any specimens with a positive MTB result (whether RIF sensitive or resistant) would then 
be referred for culture within the Bugando Medical Centre. The laboratory does not 
have the LPA technique therefore positive culture slopes were then transferred to the 
CTRL using EMS for DST as shown in (Figure 25). Bodaboda were available to be used to 
transfer the Xpert MTB/RIF result, including RIF resistance status, back to patient’s 






CTRL: CTRL for drug susceptibility testing 
When specimens arrived at the CTRL their accompanying forms would be checked for 
completeness and accuracy against the specimen container. If any problems were found 
a message would immediately be sent through the WhatsApp groups back to the 
requesting clinician to rectify any problems.   
Specimen preparation at the CTRL was carried out in class II biosafety cabinets and 
details recorded in the TB laboratory register. LPA was performed for all samples with 
MTB detected results. This provided evidence of DR including INH mono-resistance, RIF 
mono resistance, and MDR-TB (resistant to both RIF and INH). Feedback of the LPA result 
was to be targeted to be within 7 days from the day of collection. A unique patient 
identification number was generated for easy tracking and dissemination of results. No 
personal details about the patient were to be kept with the results other than the 
identification number. 
Data were to be entered in an Epidata database and results put on the TB laboratory 
request forms, which were immediately sent back to the requesting facility through EMS 




Figure 25 Revised RSS Algorithm  
 




5.3.9 Stage 2 – Implementation of the revised RSS in Mwanza as a pilot 
5.3.9.1 Intervention summary  
The redesigned RSS was implemented in Mwanza region as shown in Figure 25 alongside 
interventions listed in Table 15 above. A summary of the key interventions is listed 
below: 
a) Change in the diagnostic approach to use Xpert MTB/ RIF at local sites in 
Mwanza and Bugando Medical Centre, and LPA at the CTRL for DST.  
b) Introduction of reliable specimen and results transportation between 
remote sites in Mwanza and Xpert MTB/RIF sites in Mwanza using 
motorbike couriers (bodabodas).    
c) Changes in results dissemination from CTRL to the requestor and copies 
to the Regional TB and Leprosy Coordinator (RTLC) using new contracted 
EMS and WhatsApp groups. 
d) The CTRL monitored specimen transportation time against a target of a 
maximum of 7 days 
e) The CTRL compared number of specimens received versus cases notified 
and communicated this to the RTLC using WhatsApp. 
f) Revised TB laboratory request form and TB laboratory register were 
used to improve clarity and accommodate other changes. 
g) A supportive supervision schedule was created and implemented with 
the Mwanza team.  
h) Improved general communication between the CTRL and the health 
facilities in Mwanza region through WhatsApp groups; the Mwanza 
family, RTLC, DTLCs and CTRL staff was introduced. 
The interventions are described in more detail in the following sections corresponding 




5.3.9.2 Staff Demotivation 
Poor health and safety 
Standard operating procedures on safe specimen packaging and transportation were 
introduced which are described in more detail in section 5.3.9.3 and in Appendix 10.  
Poor supervision 
Supervision and mentorship are among the core functions of the CTRL in respect to the 
lower level laboratory facilities. During the study period supervision was conducted as 
part of continuous training and corrective action. Modified supervision tools were 
introduced to accommodate use of Xpert MTB/RIF. Health workers were trained on 
these new tools and then monitored for a trial period. In addition, new supervisory 
schedules were agreed and implemented. A feedback tool was introduced to allow 
peripheral sites to engage more closely with the CTRL as part of supervision. As normal, 
the CTRL itself was supervised by the Supranational Reference Laboratories (SRL) of 
Uganda and Antwerp Belgium.  
 
5.3.9.3 Failure to follow good practice 
Lack of training 
Training was provided on the procedures for sputum specimen collection, transport, 
reception and accessioning to support the RSS (see Appendices 10, 13 and 14). A single 
morning sputum specimen should be collected from all previously-treated TB cases in all 
study sites using a modified algorithm depending on the test method used as shown in 
the revised algorithm (Figure 25). The training emphasised the importance of the 4 areas 






Figure 26: Sputum specimen collection (33) 
 
 
A: The PI emphasised to the DOT nurses to use the audio-video presentation on how to 
produce good sputum “Sampuli Bora ya Makohozi Kwa Kifua Kikuu”6 during the pilot for 
health education at the TB clinics. Patients were instructed on how to produce good 
quality sputum and not saliva for easy identification of Mycobacterium TB. Patients were 
informed their mouth should be free of any food substance and rinsed with water prior 
to sputum collection.  
B: Patients were instructed to produce sputum in an open area directed by the DOT 
nurse.  
C: Sputum specimens were labelled both at the top and on the side of the container. 
D: Specimens are transported to the nearby laboratory for testing using bodabodas.  
Emphasis was also provided during training on proper recording of patient’s information 








Figure 27: Record the specimen before processing (32) 
 
 
1. Label patient details on the container including: Health facility name, date, 
patients name, Age, gender and physical address  
2. Fill in the laboratory request form, patient’s details must match with those on the 
container. 
3. Record patient details from the Laboratory Request Form to the Laboratory 
Register 
4. Write the Laboratory Serial Number (LSN) on the side of the specimen container 
5. Write the Patient study number  
 
Training on the revised RSS using the modified TB laboratory algorithm and specimen 
transportation system was conducted for Mwanza TB health care workers involved in the 
study and at the CTRL. This included reviewing the SOPs and algorithm to maximise Xpert 
utilisation and smooth specimen flow and transportation within the region. In Mwanza 




coordinator, DOT nurse, laboratory personnel working at the TB section, sputum fixers 
and RLT. A review of the existing system of results dissemination was also conducted. 
Good Laboratory Practice (GLP0 was emphasised and staff trained on how to implement 
the pilot study. 
Supply shortages and poor packaging 
A new tool was created for the monitoring and quantification of TB laboratory supplies. 
A procurement plan based on the consumption per laboratory was initiated to avoid 
supply shortages. Health care workers were trained in the adoption of the quantification 
tool and procurement plan.  
For safety purposes, all specimens were securely packaged using triple pack as shown in 
Figure 28. A Triple pack is a system where a specimen is inserted in a clear zip bag and 
the zip bag is put in a small plastic container with a screw cap (known as a primary 
container together with absorbent material in case of leakages). Then the primary 
container is inserted in a plastic container (secondary container) together with the 
completed TB laboratory request form.  
The secondary container is then put in either a metal, plastic or cardboard box. At every 
step, labelling is done. The laboratory personnel on duty at each site cross-check all TB 
laboratory request forms for completeness and appropriate packaging. Study health care 
workers were trained in the specimen packaging and transportation guidelines. The PI 
monitored safe specimen packaging and transportation as samples were received at the 









Reviewed and updated the TB laboratory request forms to improve clarity and 
accommodate Xpert and the new algorithm – (see Appendix 11). Daily monitoring of the 
number of incomplete forms took place. Incomplete forms were identified, and the 
respective site was immediately informed using WhatsApp’s. Forms were also scanned 
and sent as an email attachment or through an agreed method so that the problems 





5.3.9.4 Delays sending samples 
Sample Batching 
Specimens were transported on the day of collection whenever possible, even if it was 
just a single specimen. This avoided unnecessary delays which would have occurred if 
samples were batched with samples from previous days.  
5.3.9.5 Lack of Technology at DDCs 
No Xpert  
Most specimens collected were analysed using either LED or ZN microscopy techniques 
depending on availability in the relevant laboratory (see PARTS A and B in Figure 25). 
If both sputum smears were negative, the laboratory personnel sent results to the 
clinician for clinical management. If one or both were positive, then a morning specimen 
was collected and sent to the nearest Xpert MTB/RIF site for examination (this could be 
Bugando Medical Centre or another Mwanza site). If the Xpert test detected MTB and 
was RIF resistant or RIF sensitive, another specimen was collected, packaged and sent to 
the CTRL to be tested with LPA (see Figure 25).  
All results obtained were recorded in the TB laboratory registers and on the TB laboratory 
request forms. Laboratory personnel submitted results to the requesting clinician who 
initiated treatment in accordance with the existing treatment guidelines (28). 
5.3.9.6 Reliable transportation is unavailable 
Lack of reliable mail services 
In conjunction with study site staff, the PI developed guidelines for specimen 
transportation from the periphery to the Xpert MTB/RIF sites, and from these sites to 
the CTRL for LPA analysis using new contracted EMS with the Tanzania Post Office.  
Contact details of a courier at the dispatching and destination sites were provided to the 




sent and the methods used.  Logbooks were used to record date and time specimen 
received as well as the specimen’s general condition (packing, documentation and 
problems if any). The courier at the dispatching site signed the dispatch book.  
Transportation by EMS was on Mondays to Thursdays. If specimens would be 
transported on Friday it would reach CTRL on Saturday and there would be no one in the 
laboratory to pick the samples, therefore there were no samples sent on a Friday. The 
EMS service was only available at the regional level. The peripheral laboratory was 
required to submit specimens to the nearest sites equipped with Xpert MTB/RIF machine 
by using the bodaboda.  
5.3.9.7 Distance between CTRL and some sites 
No TB Zonal reference centres 
The Zonal reference laboratory was integrated into the revised RSS. This enabled 
Mwanza sites to refer specimens for Xpert MTB/RIF and culture assessment to the Zonal 
laboratory at the Bugando Medical Centre. 
5.3.9.8 Unreliable diagnostic technology (CTRL) 
No rapid test 
LPA techniques at the CTRL were introduced for use with all previously-treated samples 
referred via the revised RSS. Using this technique, it was possible to complete drug 
sensitivity testing for all first line TB drugs. In addition, new daily monitoring processes 
of samples being received at the CTRL were introduced to increase the numbers actually 
receiving a DST and improve turnaround time. 
5.3.9.9 Contaminated samples 
High contamination rate at CTRL 
CTRL staff were re-trained on routine procedures to minimise contamination and to 
identify factors associated with specimen contamination. The PI presented SOPs on the 




5.3.9.10 Poor communications between CTRL and districts 
Poor communication between CTRL and districts  
All results obtained at the CTRL were sent back to the requesting clinicians using the EMS 
service, or by secured and protected emails. During dissemination of results, patient’s 
confidentiality was maintained throughout by using unique identifiers. Results were 
disseminated using sealed and stamped envelopes.  
Monthly reports were generated from each laboratory, the regional coordinator 
compiled the regional report and sent it to the CTRL. The EQA reports were produced on 
a quarterly basis. The PI was responsible for developing quarterly reports and for sharing 
information with the regional and national levels.  
WhatsApp groups such as the Mwanza Family group were created by the RTLC in Mwanza 
to include RTLC, DTLCs and CTRL staff. This facilitated rapid and easy communication 
between the CTRL and the study sites.  If any problems were found, they could 
immediately send a message through the WhatsApp group back to the requester to 
rectify the problem. Also, various other WhatsApp groups were created by the NTLP 
Manager for lab supplies to improve communication between the NTLP and Medical 
Store Department for easy tracking of the laboratory commodities. 
5.3.9.11 Quality control and quality assurance 
Quality Control (QC) and Quality Assurance (QA) were performed in accordance with the 
NTLP quality assurance system (blind rechecking). This helped to detect systemic errors 
and improve compliance with the revised RSS design. To ensure that results of Xpert 
MTB/RIF and LPA were reliable and comparable, the procedure followed manufacturers’ 
recommendations. Specifically, controls were run first to check the validity of the 
reagents and functionality of the equipment. Once the controls passed, tests were then 
performed. The quality assurance on smear microscopy was checked using blind 




Quarterly, ten slides from each laboratory were collected and checked for consistency 
and accuracy. Laboratory supplies, personnel and laboratory performances were also 
reviewed quarterly by the PI. The PI provided refresher training on smear microscopy 
EQA. Quarterly reports were generated and shared with the laboratories. 
5.3.10  Stage 3 - Quantitative performance evaluation of the revised RSS 
5.3.10.1 Overview 
The effects of the revised RSS using a modified algorithm as outlined in Figure 25 above 
were assessed at the end of the pilot (after 12 months) using a before and after design. 
There was a quantitative assessment described in this chapter and a qualitative 
evaluation which is described in chapter 6.  
5.3.10.2 Research Question and how it was addressed 
In the evaluation of the pilot study the research questions that was addressed was 
research question d) from section 1.9.3, i.e.:  
Does the newly designed and revised routine surveillance system improve the 
performance of the system, in particular by reducing the time from sputum collection 
at the district health facility to communication of the DST result by the CTRL back to 
the district? (Quantitative) 
This question was further split into the following five component questions for a 
quantitative evaluation of the revised RSS during the pilot in Mwanza. 
1) Did the revised RSS in Mwanza region increase the number of non-contaminated 
specimens received and tested at the CTRL? 
How was this to be achieved?  Reviewed TB laboratory registers to see how many 
specimens in total from previously-treated cases were received by the CTRL from 
Mwanza region in April 2017 to March 2018 compared to April 2016 to March 2017 and 





Number of previously-treated patients tested in the Mwanza region  
Number of patient’s specimens received at the CTRL from Mwanza region 
The contamination rates for previously-treated TB case specimens calculated as the total 
number of contaminated slopes/samples divided by the total number of specimens 
received at the CTRL for each period (the 12 months before and the 12months after the 
intervention).   
2) Does the revised RSS in Mwanza lead to better completion of TB laboratory 
request forms received at the CTRL?  
How was this to be achieved? The proportion of forms with missing data from Mwanza 
was compared before and after the intervention of the new RSS.   
Variables: 
Proportion of forms with missing data in the following key fields – date sample collected, 
case number, address, ward, age and TB district number. 
3)  Does the revised RSS in Mwanza region reduce the time from specimen collection 
at peripheral health facilities to the time the specimen is received at a site where DST 
can take place (i.e. the CTRL and/or Mwanza sites with Xpert MTB/RIF)? (transit 
time). 
How was this to be achieved?  Routine NTLP data was analysed. The difference between 
the date specimens were collected in the peripheral Mwanza districts and the date 
specimens were received by the CTRL or the Xpert MTB/RIF site in Mwanza was 
calculated. This required a review both of hard copies and the CTRL electronic datasets 
of TB laboratory registers. Data was collected during the pilot phase April 2017 and 





a) Date previously-treated specimen collected at the periphery in Mwanza 
b) Date and time specimen received at study site (i.e. either CTRL or Xpert 
MTB/RIF site in Mwanza)  
c) The difference in the above dates was calculated as the transit time  
 
4) Does the revised RSS in Mwanza region reduce the time from specimens received 
at the CTRL to the time results were sent back to the region? (turnaround time) 
How was this to be achieved? The difference between the date results were 
communicated back to Mwanza region by the CTRL and the date specimens were 
received at the CTRL was calculated. This required a review both of hard copies and the 
CTRL electronic datasets of TB laboratory registers. Data was collected during the pilot 
phase April 2017 and March 2018 and the analysis compared with the previous years’ 
data 2016/2017. Ideally it would have been preferable to have used the date the 
requesting clinician at the periphery received the result, but unfortunately this date was 
not available historically. 
Variables:  
a) Date Mwanza specimen from previously-treated cases were received 
at the CTRL  
b) Date and time results sent back to the region  
c) This was used to calculate the turnaround time from date specimen 
received at the CTRL to the date results were sent back to the region. 
5) Did the revised RSS in Mwanza region increase the number of cases starting MDR-
TB treatment? 
How was this to be achieved? Reviewed TB registers to identify the number previously-
treated TB cases starting MDR-TB treatment in Mwanza region in 2016/17 compared to 





a) Number of previously-treated TB cases on MDR-TB treatment in 2016/17 and 2017/18. 
b) Number of tests conducted through the RSS for previously-treated cases at the CTRL 
5.3.11 Data collection and analysis  
All data collected were double entered independently into the computer database in 
Epidata software version 3.1 by two independent data entrants located at the CTRL. 
Forms were sent to the CTRL throughout the data collection period. The data were 
validated, and consistency checks were done by a trained statistician using SPSS version 
17. The statistician providing feedback queries to the data entrants for verification and 
rectification as required. Errors were corrected before analysis.  
Data analysis used data collected from April 2017 to March 2018 in Mwanza TB centres 
and the CTRL. The analysis was mainly descriptive. Frequencies and proportions were 
used to describe characteristics of previously-treated TB cases who submitted their 
specimens to the respective laboratory. Transit time and turnaround time were reported 
although there was some missing data from 2016/2017.  Results were presented in 
tabular format, and in graphs and charts. Bar charts were used to compare the number 
of MDR-TB cases between the revised and current RSS, and demographic information 
and Z-test data were presented in tabular format. The dataset was stored on a password 
protected computer accessed only by those authorised. Meanwhile, the hard copies 







5.4 Study findings   
All results below are for specimens collected as part of the RSS for previously-treated TB 
cases only. 
1. Number of non-contaminated specimens received and tested at the CTRL? 
There were 75 Mwanza specimens sent to be processed at the CTRL from April 2016 to 
March 2017. Of these only 48 (64%) were processed, 27 (36%) had missing information 
and could not be fully analysed. Of the 75 specimens received, no contamination was 
found, and no positive isolate specimens were received from the Zonal TB culture 
laboratory in Mwanza (see Table 17).   
After the intervention and during the pilot, the total specimens received and analysed 
both at the CTRL and Mwanza study sites are shown in Figure 29. A total of 471 specimens 
were collected during the study period from April 2017 to March 2018. Over half of the 
specimens, 273 (58.0 %) were received in the Mwanza sites and 198 (42.0 %) were 
received at the CTRL.  13 of the 198 (6.6%) specimens received at the CTRL were rejected 
(primarily due to wrong treatment category or specimen leakage). The remaining 185 
(93.4 %) were sent for processing with LPA. Of these, 4 were contaminated, 1 had no 
MTB detected, 171 had MTB detected and were sensitive to both RIF and INH and 9 (5%) 
were found to be resistant to RIF or INH or both (Figure 29).  
Of the 273 specimens received in Mwanza study sites; 62 (23%) were not analysed due 
to various reasons including shortage of reagents and equipment breakdown. The 
remaining 211 specimens were processed, out of which 134 (63.5%) were submitted 
from study sites with microscopy but no Xpert MTB/RIF capacity. 77 (36.5%) were from 
the study sites with no diagnostic testing available.  In total out of the 211 specimens 
tested, 1 test was invalid, 31 had no MTB detected, 173 had MTB detected and were 





  Figure 29 Specimen analysis 2017/2018 – during the pilot study 
 
Keys: CTRL- Central Tuberculosis Reference Laboratory; LPA- line probe assay; MTB-Mycobacterium tuberculosis; labs- laboratory; 
INH- Isoniazid; RIF- Rifampicin. 
 
Table 16 shows the split of DR results at the CTRL. In particular, it shows of all samples 
tested and with MTB detected, 95.0% were sensitive to both INH and RIF, 2.8% resistant 




Table 16: Drug susceptibility testing results using Line Probe Assay at the CTRL in 2017/18 
Line Probe Assay CTRL Positive isolate- 





Total % of tests (excl. no MTB 
and contaminated 
samples 
RIF (R), INH (R) 5  0  5  2.8% 
RIF (R) 1 3  4  2.2% 
INH (R) 0  0  0  0% 
Sensitive to both RIF and 
INH 
115  56  171  95.0% 
Total 121  59  180  100.0% 
MTB Not Detected 0 1 1  
Contaminated 1  3  4  
Key: CTRL- Central Tuberculosis Reference Laboratory; RIF (R) - Rifampicin resistant; INH (R) - Isoniazid resistant  
 
Figure 30 shows the extent of the variation in the number of specimens received at the 
CTRL by month throughout the pilot study. This indicates the largest number of 
specimens were recorded in May 2017, January 2018 and March 2018. Fewer specimens 
were received in April and December 2018.   






In 2017/2018 the total number of specimens received and examined at the CTRL was 
185, of these 63 (34%) were sputum specimens from the periphery and 122 (66%) were 
positive TB culture isolates from Bugando Medical Centre (BMC). In comparison before 
the intervention from April 2016 to March 2017, of the 75 specimens received, 48 (64%) 
were analysed, 27 (36%) had missing information and could not be analysed. No positive 
isolate specimens were received. The total annual previously-treated TB cases in 
Tanzania were 3,072 in 2016/17 and 3,528 in 2017/18. Table 17 shows that in 2017/18 a 
significantly greater proportion of these came from Mwanza. 









treated TB cases in 
Tanzania 
3072 3528 +556 +14.8% 
Number referred from 
Mwanza to the CTRL 
via the RSS  
75 185 +110 +146.7% 
Proportion 
2.44% 5.24% +2.80% * +114.8% * 





2. Level of completion of TB laboratory request forms received at the CTRL 
The completeness of TB laboratory request forms received at the CTRL before and after 
the intervention from Mwanza was compared for a number of key fields. In 2016/17, 
32% had missing address information and 52% had missing district number. In 
comparison, in 2017/18, the proportion of missing address information dropped to 13% 
and missing district number fell to 3%. Figure 31 shows there was a significant 






Figure 31 Incomplete TB Laboratory Request Forms 2016/2017 and 2017/2018 
 
Keys: TB- tuberculosis 
 
During the pilot, 198 samples were sent for processing at the CTRL of which 185 were 
processed (93%). This compares to 75 sent for processing and 48 processed the year 
before (64%). This improvement in proportion processed was driven by a reduction in 
the level of missing information on laboratory request forms. 
 
3. The time from specimen collection at peripheral health facilities to the time 
the specimen is received at a site where DST can take place (transit time)   
The transit time recorded in 2016/2017 for sputum showed 44 % of specimens were 
received after 21 days. There were no isolates sent in 2016/2017. Overall, the median 
and interquartile range (IQR) was 12 (51) days in 2016/2017 as shown in Table 18.  
The transit time recorded in 2017/2018 for both sputum and isolates showed 21% of 
specimens were received after 21 days. Overall, the median and interquartile range (IQR) 




Table 18: Transit time: Number (%) of the specimen received at CTRL from Mwanza site 
Year Sample < 3 days ≥ 3 days 
& 
< 7 days 
≥7 days & 
<21 days 





















122 10 27 




















48 12 51 


















48 12 51 
Key: IQR – Interquartile range=Third Quartile – First Quartile 
 
There is a significant reduction at the 95% level in the proportion taking 21 days or over 
between 2017/18 and 2016/17, however there is no significant difference in the 
proportion taking less than 7 days (the target maximum) and the number taking less than 
3 days is in fact significantly lower in 2017/18 than in 2016/17 at the CTRL. However, the 
most notable change between the years is the big reduction in the IQR, reducing down 
to 9 days during the pilot compared to 51 days in the year before (i.e. transit times are 
much more consistent – fewer outliers). This was also associated with a slightly lower 
median transit time during the pilot, 10 days compared to 12 days in the year before.   
Out of 273 specimens referred to the Xpert MTB/RIF study sites in Mwanza, 62 (23%) and 
had no recorded transit time. This maybe for a variety of reasons, e.g. the Xpert test was 
never performed or the dates were not recorded. Of the 211 with a recorded transit time 
96% took less than 3 days (Table 19). In 2016/2017 the RSS did not have the opportunity 
to transfer samples to an Xpert MTB/RIF site in Mwanza as this was only introduced as 





Table 19: Transit time from Mwanza study sites without Xpert to Mwanza sites with Xpert in 
2017/2018 
 
4. Time from specimen receipt at the CTRL to the time the DST results are sent 
back to the requesting clinician (turnaround time) 
Turnaround time was calculated by subtracting the date results were sent back to the 
requester from the date the specimen was received at the CTRL. The overall median (IQR) 
turnaround time was 7 (8) days for 2017/2018 and 62 (10) days for the 2016/2017 (Table 
20).  
       Table 20: Turnaround time for specimen results at CTRL 
Year Sample < 3 days ≥ 3 days & 
< 7 days 
≥7 days & 
<21 days 




Sputum 11 (18%) 38 (63%) 8 (13%) 3 (5%) 60 3 2 
Isolate 14(12%) 21 (17%) 55 (45%) 31 (25%) 122 7 22 




Sputum 0(27%) 0 (8%) 0 (21%) 8 (100%) 8 62 10 
Isolate 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 
  
Total 0 (0%) 0 (0%) 0 (0%) 8 100%) 8 62 10 
 Key: CTRL- Central tuberculosis reference laboratory; IQR – Interquartile range 








< 3 days 
(%) 
≥ 3 &  
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In addition to the turnaround time at the CTRL, it was possible to look at the turnaround 
time for Xpert MTB/RIF sites in Mwanza which had been introduced as part of the revised 
RSS algorithm in 2017/18. Out of 211 specimens processed, turnaround times for 59 
(28%) could not be calculated due to missing dates, leaving 152 (72%). Results at the 
Mwanza Xpert sites (including Bugando) were sent back to the requestor in less than 
three days for 145 (95%). On 4 (3%) occasions the turnaround time was greater than 21 
days (Table 21). 
Table 21: Turnaround times for specimen results sent to an Xpert site in Mwanza from a Non Xpert 
sites in Mwanza Region 2017/2018 
Mwanza Site < 3 days ≥ 3 days &  
< 7 days 
≥ 7 days &  
< 21 days 
≥ 21 days Total 






























5. The number of cases starting MDR-TB treatment in Mwanza 
From the findings earlier we know only 48 previously-treated cases were processed via 
the RSS at the CTRL in 2016/17, whereas 185 were processed in 2017/18 in Figure 29. 
This would on its own, be expected to lead to a rise in MDR-TB diagnosis.  
In 2017/18 the proportion of samples received at the CTRL completing a valid DST was 
91% (181 – excluding those not processed and contaminated samples out of 198). 
Unfortunately, similar data has not been recorded for 2016/17. 
From the TB registers we know the number of previously-treated TB cases recorded as 
having started MDR-TB treatment from Mwanza in 2016/17 was 12 and in 2017/18 this 
rose to 20 (+67%). From Figure 29 there are 9 DR-TB cases identified in the CTRL with 




Xpert MTB/RIF that were never referred to the CTRL. Unfortunately, similar breakdown 
of data is unavailable for 2016/17. 
5.5 Summary discussion 
The study involved the design and piloting of a revised RSS for previously-treated TB 
cases in Mwanza region. The revised RSS aimed to address many of the issues raised in 
the earlier quantitative (Chapter 3) and qualitative (chapter 4) studies described in this 
thesis (45), as well as taking into account the wider availability of molecular testing. The 
primary outcomes of the study were to assess the impact of the revised RSS on specimen 
transit time to the CTRL and the time from specimen receipt at the CTRL to when drug 
susceptibility results were sent back to the requesting clinician (turnaround time).  
The pilot of the revised RSS showed some notable improvements compared to the 
current RSS. In particular, it resulted in a significant reduction in turnaround times for 
testing at the CTRL driven by the use of molecular techniques and closer monitoring 
(median of 7 days compared to 62 the year before); an increase in the number of 
specimens referred (198 compared to 75 the year before) and processed (185 verses 48 
the year before) at the CTRL; and a reduction in incomplete forms sent with samples (e.g. 
only 3% of forms had missing date information when this was 24% the year before). In 
addition, the introduction of using Xpert MTB/RIF at the periphery in 4 Mwanza centres 
and at the Bugando Zonal Laboratory meant resistance to rifampicin could be reported 
much more rapidly than was the case with the old RSS when any resistance result had to 
wait until DST was completed at the CTRL.  This enabled in these cases 96% of transit 
times to be less than 3 days and 95% of turnaround times for an Xpert MTB/RIF result, 
including testing for RIF resistance, in less than 3 days. The low transit time was 
supported by the use of motorbike couriers known as bodaboda. 
In relation to the transit times from the Mwanza periphery to the CTRL the results are 
less clear, although median transit time did reduce to 10 days during the pilot from 12 




However, it was noted that 27% of samples had a transit time of less than 3 days in 
2016/17 whilst only 3% achieved this during the pilot. This requires further investigation, 
but it should be noted there was also a reduction in the proportion of samples with 
transit times of over 21 days to reach the CTRL from the periphery during the pilot (21% 
compared to 44% the year before). This reduction in outliers, led to a much narrower 
inter-quartile range (9 during the pilot compared to 51 the year before). This more 
consistent result for transit time with a slightly reduced median is encouraging. 
There was no evidence of changes to the contamination rates between the new and 
revised RSS processes. This is a little surprising, but is mainly because from the 
documented evidence in 2016/17 there was nothing recorded as contaminated from 
Mwanza. Anecdotally, it is believed however there was contamination, and this is 
probably supported by the low level of samples that could be processed at the CTRL in 
2016/2017 (i.e. only 48 out of 75 – 64%). Some of the loss in samples processed maybe 
as a result of unrecorded contamination. The contamination level in 2017/18 was 5% 
which was around what was expected.   
The increased volume and proportion of samples being tested for drug sensitivity, and 
the more rapid availability of DST results, would be expected to increase the level of 
MDR-TB detected. MDR-TB is still at a relatively low level in Tanzania and in Mwanza, 
however during the pilot period, 20 new cases of MDR-TB started treatment from 
previously-treated TB cases, in comparison to 12 the year before. This 67% increase is an 
important result and suggests the revised RSS can be expected to improve detection of 
MDR-TB. 
WhatsApp groups played an important role in this study. Various groups created by the 
NTLP Manager such as ‘Vitendanishi’ for lab supplies, and the ‘Mwanza family’ created 
by the RTLC in Mwanza, served to enhance timely communication with laboratory 
personnel and the DTLC group in Mwanza. These groups allowed the ground staff 
responsible for sending out specimens to resolve concerns in a timely manner and eased 




turnaround times. Since the success of this approach in Mwanza, the WhatsApp group 
platform has now been replicated in other regions among DTLCs, RTLCs and laboratory 
teams. Use of WhatsApp groups may also be a useful approach to address other 
communication issues in the TB programme and beyond.  
The study had some limitations due to poor record keeping, particularly in the historical 
data, which made some comparisons of performance difficult. For example, due to poor 
data recording in 2016/2017, the turnaround time is only based on eight samples where 
the median turnaround time was 62 days. However, to a certain degree, this poor record 
keeping was also symptomatic of the poorly performing RSS prior to the pilot. The revised 
RSS has led to improved record keeping which can hopefully be maintained. The evidence 
from this study shows why this improved record keeping is important as it can have a 
direct effect on patients getting onto appropriate treatment and in a timely manner.  
There was great variability by month in the number of specimens transported for testing 
(Figure 30). This was due to operational reasons, for example towards the end of May 
2017, there was a nationwide employees’ education certificate inspection for 
irregularities which led to the termination of several laboratory staff and clinicians.  This 
exercise had a negative impact on the study. In addition, in December 2017 and February 
2018, fewer specimens were received which might have been due to staff shortages and 
some being on holiday which led to some specimen batching.  This suggests that without 
these difficulties even better results might have been possible.   
An extension to this research could include a modelling approach to provide additional 
insight (134).Data from this study could be used to support an operational model of 
alternative algorithms for a revised RSS. Such an operational model could be designed to 
include assessment of cost and benefits from both a patient and health system 
perspective.(135). A modelling approach might also help in understanding which parts of 
the revised RSS provide the greatest benefit overall, and which were less significant, and 
therefore may not be worth pursuing if they require additional resource. There was 




the qualitative assessment (Chapter 6), to mirror the assessment completed before the 
pilot (Chapter 4), was of greater priority for this research study. 
It is clear from this study there is even more to do to improve the RSS. For example, even 
with the focus of the revised RSS, 13% of laboratory forms had missing laboratory 
reference numbers and 3% missing addresses, although these were much lower than in 
2016/17.  Also, there were significant numbers of samples in 2017/18 that were not 
processed for a variety of reasons (i.e. in total 75 out of 471, 15.9% – see Figure 29). 
However, this again was much lower than in 2016/17. Our study focused on previously-
treated cases only. All the interventions looked at could have equal value to new cases, 
although the level of DR would be expected to be much lower.  
In the National Strategic Plan (NSP), it was estimated that the annual burden for MDR-
TB was 699 and 725 for 2016 and 2017, respectively. The actual DR- TB cases notified 
were 197 and 200, so there is still a significant detection gap which potentially a revised 
RSS could help address (7,31,136).   
5.6 Conclusion 
The revised RSS led to an increased number of specimens received and tested at the 
CTRL. The use of WhatsApp within the NTLP network led to close follow-ups and timely 
response to concerns during the piloting. The revised system has shown the ability to 
reduce delays in diagnosis and in addition there has been a notable increase in numbers 
starting MDR-TB treatment. The shorter transit and turnaround times are important in 
the diagnosis of MDR-TB and TB control. These positive results suggest a larger scale 
study involving more regions should be considered to determine whether these benefits 










This chapter addresses research questions (e) as referred to in the introduction section 
in 1.9.3. – Does the revised routine surveillance system reduce barriers to the effective 
performance of the system? (Qualitative). 
It describes the qualitative evaluation of the revised RSS described in chapter 5 and 
piloted in Mwanza region after the introduction of a number of interventions. The study 
explored health care providers’ perspectives of the revised RSS through FGDs and IDIs. 
The revised system was intended to address the barriers identified in the qualitative 
study described in chapter 4 (45). The implementation plan for the revised RSS is 
illustrated in Figure 32. This chapter covers the qualitative analysis of Step 3. 
Figure 32 Revised RSS implementation plan 
 
A summary of the key elements of the revised RSS intervention and how these addressed 




This study sought feedback from stakeholders of their perception of the revised RSS for 
previously-treated TB cases introduced in Mwanza, Tanzania. It also sought to facilitate 
comparison by stakeholders between the before and after RSS.  
 
6.2 Study Overview  
6.2.1 Objective 
To evaluate the effectiveness of the revised Routine Surveillance System for previously-
treated TB cases piloted in Mwanza, Tanzania from a stakeholder perspective. 
(Comparison before and after intervention). 
6.2.2 Research Question 
Does the revised routine surveillance system for previously-treated TB cases reduce 
barriers to the effective performance of the system? (Qualitative). 
6.2.3 Study approach 
A qualitative study was conducted from 1st May to 30th July 2018 after the pilot of the 
revised RSS had been in place for 12 months. The study involved both FGDs and IDIs as 
had been used in the earlier study described in chapter 4. Two trained RA conducted the 
FGDs and IDIs in the selected study sites. A topic guide was used to guide the FGDs and 
IDIs along with open ended questions. The focus was to elicit feedback from the key 
stakeholders in Mwanza and the CTRL on the revised RSS, especially in respect to 
successes and related challenges in order to facilitate comparison between the RSS in 
place before the intervention and the revised RSS.  
6.2.4 Study sites 
The study sites were in the Mwanza region where the revised RSS described in Chapter 




Nyamagana, Sengerema, Misungwi, Magu, Kwimba and Ukerewe. People of Mwanza 
mainly depend on small-scale farms, animal husbandry, fishing and to some extent 
mining for their livelihood.  
The region has a total of 384 health facilities, of these 15 are hospitals, 44 are health 
centres and 325 dispensaries. At the time of conducting this study the region had 80 
diagnostic facilities with 5 that had Xpert available. All facilities have been participating 
in quality improvement programs on AFB smear microscopy method through Proficiency 
Testing (PT) programme whereby random representative slides are sent by DTLC and 
rechecked blindly by a controller at district level. In the pilot RSS specimens from 
previously-treated cases were referred from peripheral sites to the nearest Xpert sites 
for testing as described in chapter 5, Figure 25.    Positive culture slopes from Bugando 
zonal TB culture laboratory were also referred to the CTRL for susceptibility testing.   
The region receives funds from the government and implementing partners for TB, and 
TB/HIV activities. The following partners are involved: Health Basket Fund, KNCV, 
AGPAHI and Global Fund through NTLP. 
Mwanza region is too big for a researcher to assess every district and village; therefore, 
four districts were selected as being representative of the region. Each district is 
overseen by a District Medical Officer, a District Laboratory Technologist and the DTLC 
who are responsible for all TB activities in the district.  All districts selected had access to 
Xpert technology. The selected districts were Kwimba, Magu, Sengerema and 
Nyamagana as shown in Figure 33. Health districts reflected Tanzania’s decentralized 






Figure 33: Mwanza study sites 
 
Before participant recruitment the PI sought and received permission from the TB Programme and the medical administrative 







Kwimba District has a total population of 44,964 people (By National Bureau of Statistics 
2012) (114). and occupies an area of 3,903 square kilometres. It is bordered to the west 
by the Misungwi district and to the north by the Magu district. Most residents of Kwimba 
are the Sukuma tribe and are engaged in subsistence farming of rice, sweet potatoes, 
cassava, millet or maize. Administratively, Kwimba District is divided into five divisions, 
30 wards and 119 villages. Of the 30 wards only 4 have local post office services and only 




The district has a total of 56 health facilities - 50 government owned, 2 parastatals and 4 
private sector facilities. Out of the 56, 2 are hospitals, 6 health centres and 48 
dispensaries. There are 8 centres that provide TB laboratory services. The district has 1 
Xpert site situated at Gundu district hospital. 
According to the NTLP annual report of 2016, TB notifications were 577. This included 5 




Magu District has a total population of 299,759 people (By National Bureau of Statistics 
2012),(114)  with a total area of 4,795 sq. kilometres. It is bordered to the north by Lake 
Victoria and Busega district, to the east by Bariadi district, to the south by Itilima 
district, Maswa district, Kwimba district and Misungwi district, and to the west by the 
city of Mwanza, which consists of Nyamagana and Ilemela districts. Administratively, the 
district is divided into four divisions, 27 wards and 82 villages. Of the 27 wards, 12 have 
local post office services and 15 have access to electricity. Magu district is one of the 
poorest districts in Tanzania due to persistent unfavourable weather conditions. The 
major sources of livelihood in the district are farming and animal husbandry (accounting 
for over 90 percent).  
The district has a total of 48 health facilities; 42 government owned, 1 parastatal, 1 faith-
based organisation and 4 private facilities. Out of 48 health facilities there is 1 hospital, 
5 health centres and 42 dispensaries. 11 health facilities provide TB laboratory diagnosis 
services.  The district has 1 Xpert site situated at Magu district hospital. The district has 
relatively high mortality of TB, TB/HIV and MDR-TB. In 2016  TB notifications were 393, 
of which 9 were previously-treated TB cases (137). A big challenge in the district is the 





Nyamagana district has a total population of 363,452 people (By National Bureau of 
Statistics 2012) (114) and covers an area of 256 square kilometres. It is bordered to the 
north by Ilemela district, to the east by Magu district, to the south by Misungwi 
district and to the west by the Mwanza Bay of Lake Victoria. Part of the region's capital, 
the town of Mwanza, is within Nyamagana district. The regional referral hospital and 
Bugando TB Zonal Culture Laboratory are in this district. The fish Industry is an important 
income generating activity in Mwanza City, it provides employment, food as well as 
income to the communities.  
Administratively, Mwanza city council comprises of 18 wards and 175 streets. All wards 
have local post office services and access to electricity. 
The district has a total of 56 health facilities; 16 government owned, 3 parastatals, 9 faith-
based organisation and 28 private facilities. Out of the 56, 11 are hospitals, 13 health 
centres and 32 dispensaries. There are 10 TB diagnostic centres.   
The district has 2 Xpert sites situated at SekouToure and Bugando Hospital. The district 
has relatively high mortality of TB, TB/HIV and MDR-TB. This is one of the districts where 
various implementing partners support different health interventions (68% are TB or 
HIV/AIDS related). In 2016  TB notifications were 1,036, of which 27 were previously-
treated TB cases  (137).  
The district faces challenges as it is experiencing fast population growth by both natural 
increase and migration. As a result, there many different ethnic groups living in the city. 
HIV/AIDS is a significant social, cultural and economic problem in the district. 
Sengerema district 
Sengerema district has a population is 639,103 and 90% of the population live in rural 
areas with only 10% in the urban areas. (114). The district covers 8,817 square 




5,482 square kilometres are covered by the water of Lake Victoria. The district is 
bordered to the north and east by Lake Victoria, to the south by Geita region and to the 
southeast by the Misungwi district. The majority occupations are agriculture, livestock 
keeping and fishing.  
Administratively the district is divided into 5 divisions, 25 Wards, 123 registered villages 
and 758 hamlets (Vitongoji). The district has a total of 56 health facilities; 43 government 
owned, 1 faith-based organisation and 2 private facilities. Out of the 46, 1 is a hospital, 4 
health centres and 41 dispensaries. The district has Xpert situated at Sengerema district 
hospital. Out of the 56 health facilities, 15 provide TB laboratory diagnosis.   
In 2016  TB notifications were 816, of these 29 were previously-treated TB cases (137). 
The biggest challenges of the district are transportation and electricity, almost all the 
diagnostic centres are using solar power. 
  
6.3 Study Method  
6.3.1 Methodology used and justification  
As with the earlier qualitative study described in chapter 4, a mixed approach using FGDs 
and IDIs was considered the most appropriate. FGDs would be a good way to gather a 
group of participants from a site to discuss the implementation of the revised 
surveillance system in comparison to the previous system. An FGD would allow 
participant interaction to agree and disagree, thus stimulating discussion which would 
assist in revealing respondents’ real perceptions. As in the earlier study, IDIs were chosen 
as a method appropriate for discussions with senior individuals within the health care 
programme and implementing partners supporting the NTLP. The perceptions of these 
individuals would be important to gather but being part of an FGD might restrict 




6.3.2 Sampling procedure  
The sampling approach to participant selection for both FGDs and IDIs was the same as 
described in detail in chapter 4 section 4.3. To facilitate this, prior information about the 
aim of the study and selection criteria were provided to the regional TB coordinator. The 
PI and the senior research assistant verified participants’ eligibility. The selection of the 
study participants considered the health care providers working with the TB clinics, the 
courier persons involved with specimen transportation (who worked closely with the 
bodaboda riders), TB programme staff, laboratory staff at both the regional and national 
levels and implementing partners within the TB Programme (120).  
6.3.3 Inclusion Criteria 
Health professionals working in TB clinics, including regional administrative authority 
staff, TB programme staff, laboratory staff at both the regional (Mwanza) and national 
levels (CTRL). Implementing partners supporting the TB Programme. 
6.3.4 Exclusion Criteria 
a) Non-health care service staff  
b) Non-TB health care professionals 
c) Not present during the pilot study 
 
6.3.5 Participants and sample Size 
The trained RA was responsible for finalising the recruitment of the study participants 
and ensured that participants felt comfortable with responding to the types of questions 
that would be involved. Participants for the FGDs were recruited through the selected 
study sites. The recruitment was based on purposeful sampling where a maximum 
variation sample was sought  (120,127).  This ensured a diverse range of views with 
respect to their roles, seniority and experience. The research assistant informed 




of the interview, the importance of confidentiality and the informed consent process. 
Informed consent documents were translated into Kiswahili, the most used language. 
Participants were informed of their freedom to withdraw from the study at any time 
without prejudice. They were made aware that the information collected would be 
treated with care and participant confidentially would be maintained.  
A total of 45 participants (13 females and 32 males) were selected. 35 individuals 
participated in the FGDs (10 females and 25 males). There were 6 FGDs and each group 
contained 5 or 6 participants with a mix of individual roles as shown in Table 22.  
Table 22: List of participants of FGDs 
Site Participants job roles No. of 
participants 
Group  Level  
Kwimba DOT-nurse, DTLC,  
Lab technician, TB clinician, 
TB/HIV officer x 2 
6 
(3 females,  
3 males) 
GR1 District 
Magu Courier person, DOT-nurse,  
DTLC, Lab technician,  
Quality Officer, TB/HIV officer 
6 
(2 females, 
4 males)  
GR2 District 
Sengerema Courier person, DOT-nurse, 
DTLC, Lab technician, 





Nyamagana DOT-nurse, DTLC, 
Lab technician, Quality Officer, 
TB clinician, TB/HIV officer 
6 
(4 females, 
2 males)  
GR4 District 
CTRL 1 Data manager, Lab attendant, 




 5 males) 
GR5 National 










(10 females, 25 
males) 
  
Keys: DTLC-district tuberculosis and leprosy coordinator; TB-tuberculosis; HIV-human immunodeficiency virus; Lab- laboratory; CTRL-
Central Tuberculosis Reference Laboratory 
 




Table 23: List of Participants, study sites and IDI coding 
Keys: RTLC- regional tuberculosis and leprosy coordinator; DTLC-district tuberculosis and leprosy coordinator; TB-tuberculosis.; Ag-
acting; MSH-management science for health; HIV-human immunodeficiency virus; IP-implementing partners 
 
6.4 Study preparation  
6.4.1 Research team and responsibilities  
The research team was the same as described in chapter 4. I was the team leader and PI 
with overall responsibility for the study. In particular, I was responsible for the design of 
the study; support to and quality assurance of data collection; training and management 
of the research team; and writing up of the research in this thesis.  
The study research team consisted of a senior research assistant with experience of 
qualitative research and a RA. Both were involved in conducting IDIs and FGDs. The 
senior research assistant ensured the careful translation of documents such as the 
consent sheets, topic guides and transcripts of IDIs and FGDs. The second RA also 
Study sites Participant job roles  Group Gender Level 
Nyamagana RTLC GR7 Male District 
Magu DTLC GR8 Male District 
Sengerema DTLC GR9 Female District 
Kwimba TB/HIV coordinator GR10 Male District 
MoHSW Ag. Director diagnostic  GR11 Male National 
NTLP Programme Manager GR12 Female National 
 MDR-TB coordinator GR12 Male National 
CTRL Ass. Lab Manager GR13 Male National 
Partners MSH GR14 Male International 
Partner 





undertook some transcription and translation of the recorded IDIs and FGDs. Both the 
research assistants collated the data with my close supervision.  
A senior laboratory person was able to accompany the RA while conducting IDIs and 
FGDs. In order to facilitate openness, I did not take direct part in most of the interviews 
and discussions. Instead, the senior laboratory person helped provide participants with 
an opportunity to speak out and give their ideas openly in order to accomplish the 
objectives of the study.  
My PhD supervisors supported this research as follows: - 
a) Dr Ivor Langley (LSTM) provided technical input and proof-reading 
support of the write-up of this research. 
b) Dr Eleanor MacPherson (LSTM) provided technical input on qualitative 
design and layout. She trained me on the qualitative methods and how 
to conduct the qualitative study.  
c) Dr Esther Ngadaya (NIMR) supported me in Tanzania throughout the 
study to ensure good progress was maintained.  
6.4.2 Training   
As this study was similar to the one described in chapter 4 and the personnel were the 
same, no additional training on the approach was required. Supervision was provided 
throughout the study period by the PI as required. 
The PI provided background to the study; how the revised RSS was undertaken; selection 
criteria and procedures; data analysis requirements; ethics and confidentiality; and the 
data collection tools to be used for this study. The PI together with the RAs went through 





6.4.3 Development of tools  
Hyman et al. explain that, one major caveat of using pre-existing questions is the 
potential result of low data quality if measures are unreliable. However, if ‘recycled’ 
questions are accurate measures of the concept of interest (and many will have been 
pre-tested to ensure this), the degree of validity is likely to be high, resulting ultimately 
in obtaining data of higher quality  (139). For this reason, the study tools were based 
around those used in Chapter 4 which had proved to be reliable. Amendments and 
additions to these were made to enable capture of perceptions comparing the previous 
RSS with the revised RSS. The study tools were developed and finalised after receiving 
inputs from supervisors. The data collection tools consisted of topic guides designed for 
FGD and IDI as shown in Appendices 15 and 16 respectively. They were used to 
guide interviewers and participants through the key themes and issues to be covered 
according to the study objectives.  
6.4.4 Confidentiality and consent  
The RA was trained on how to maintain confidentiality. Issues of confidentiality were also 
addressed at the time of data collection. To ensure anonymity and the respondents’ job 
security, the responses from the interviews were treated with confidentiality during the 
study period. No participants or site names were used; instead, special codes were used 
during the interviews and in documentation (124). Consent forms were provided in 
writing a day before the interview to give time for participants to understand the 
information related to the study. The consent form was the same as described in chapter 
4, see Appendix 6 Swahili version and Appendix 7 in English.  
6.5 IDIs and FGDs conducted  
6.5.1 Overview  
IDIs and FGDs took place between 1st May and 30th July 2018 in Mwanza region and at 
the CTRL in Dar es Salaam. The IDIs and FGDs were audio-recorded in order to capture 




study participants at the meetings. Participants were informed that the sessions would 
be recorded, and the recording would be kept for up to seven years. A notetaker took 
notes during the FGDs and IDIs and observed the participants’ responses. The research 
assistant ensured that confidentiality was maintained throughout the study. 
In-depth interview with key informants (IDIs)  
The IDIs involved TB programme staff, the regional administrative authority and the 
implementing partners supporting the TB Programme. IDIs were conducted at a location 
convenient to the individual being interviewed, generally this was an office in Mwanza 
region or at the CTRL. For international partners this was the partners offices.  
 Focus group Discussion with health care providers (FGD) 
FGDs were conducted in the four districts in Mwanza and the CTRL. All FGDs were 
conducted in health facilities with Xpert technique, with some of the participants being 
ferried from their health centre to the meeting. The FGDs in Mwanza region were 
conducted early in the morning before individuals started coming for TB services. At the 
CTRL the participants preferred late afternoon when they had finished dealing with 
specimens. 
6.5.2 Data handling 
At the end of each day, the RA was responsible to collate all recordings and written notes. 
Data was downloaded from the digital tape recorder to a password-protected laptop and 
then transferred to a secure external hard drive placed in a locked cabinet in the Head 
of the CTRL’s office. The protection of participants’ information through the application 
of appropriate ethical principles is important in all research studies (138), therefore all 
data were anonymized as soon as all expected interviews had been transferred and 
confirmed by the data manager. The Participants name or site was not used instead each 
participant in the FGDs was coded as group number; level in health system code; female 






1. FG-GR1-DT-F1  
FG- focus group discussion  
GR1- group 1  
DT- district level 
F1- F – female - participant number 1 
 
2. FG-GR5- NL –F26 
FG- focus group discussion  
GR5- group 5   
NL- national level 
F26 - F -female- participant number 26 
 
IDI participants were similarly coded see Table 23. Examples of the participant’s labelling 
for IDIs were as follows: 
Examples  
1.  IDI-GR13-IP-F1 
IDI- In-depth Interview 
GR13- site name 
IP- Implementing partners 
F1 - female participants number 1 
 
2. IDI-GR8-DT-M2  
IDI- In-depth Interview 
GR8- site name 
DT- district 
M2- male participants number 2 
 
6.5.3 Data analysis 
As with the qualitative study undertaken before the implementation of the revised RSS 
and described in chapter 4, NVIVO 10™ was used in the qualitative data analysis for the 




The analysis included four steps. The first step involved familiarisation with the data by 
the PI and the research assistant who together listened to the recordings and went 
through all the transcripts. The second step involved data coding with key themes and 
subthemes across the data set. The third step involved checking for frequency of key 
messages. In the fourth step categories and major themes were developed and classified. 
NVIVO 10™ software was used for organising, coding and analysing the qualitative data.  
The PI together with the senior RA went through the assembled analysis alongside 
quotes from participants in the FGDs and IDIs to make sure the resulting themes were 
grounded in the data. The key themes and observations are described in the next section 
alongside quotes from participants in the interviews and discussions. The data 
interpretation and analysis came to an end once there was no new information to be 
discovered (i.e. the theoretical saturation point had been reached) (127).  
 
6.6 Study findings 
This chapter presents the key themes and subthemes generated from the FGDs and IDIs 
conducted alongside representative quotes from the participants.  
The revised RSS was piloted in the Mwanza region (described in chapter 5) where 
specimens were collected routinely from health facilities without an Xpert machine and 
transported using bodaboda to the Xpert site for testing. Specimens were sent to the 
CTRL via EMS for LPA testing.  
The purpose was to identify DR-TB early and minimise delays in the dissemination of 
results. The findings explored how the revised RSS was understood and whether the 
participants observed any effect on accelerating operations; specimen transportation, 
availability of laboratory supplies, improvement in documentation (form filling), 




system had addressed the issues reported in the initial qualitative study (Chapter 4). 
Lastly, they explore the success and challenges observed between the two systems.  
Knowledge (awareness) of the revised RSS implementation  
Participants understood the NTLP policy on the submission of specimens from 
previously-treated cases to the CTRL. They declared that it was not clearly understood 
before. They gave several explanations and demonstrated how the system operates and 
how they were familiar with the system. The following quotes illustrate this:  
 ‘’Yes, we have heard of RSS, through mentorship provided. It is the system to 
monitor drug resistance by sending all previously treated TB specimens to the 
CTRL for culture and drug testing.” (IDI-GR7-M1-DT,2018) 
 ‘‘Routine Surveillance is a system that is used through the TB programme and 
the National Laboratory to perform further tests for the whole country on 
culture and DST. But this procedure is being administered under the control 
of TB coordinators. It would be ideal to make the revised system function well 
for our Tanzanian patients.” (FGD- GR5-F25-NL,2018) 
Barriers experienced with the revised system 
Despite the successes of the revised RSS, participants identified some challenges still 
hindering its operation. The majority of the participants were familiar with the RSS, but 
a few were not familiar with the system. The following quote illustrate this: 
A male participant declared that, “I’ve heard of it, but I do not know how it 
works and what does it target, but I heard in Mwanza, it is done at the 
SekouToure.‘’ (FGD_ GR2-M8-DT,2018) 
Although the revised RSS was found to be beneficial for fast-tracking results. It was 
reported that sometimes there is a delay in posting the specimens. The following quote 
illustrates this: 
‘’They send samples from the peripheries to the district and the Ngudu station 
as a hospital takes them to the post office. Looking back at the specimen 




the results after several months. Here we were sent through the normal way 
because the EMS goes through a long channel.” (FGD-GR3-M15-DT, 2018) 
It was reported that sometimes the wrong container for specimen collection (15 ml 
instead of 50 ml) was supplied. The following quotes illustrate this:  
‘’When we were out of stock, we ordered through the RTLC. The challenge 
was that the falcon tubes were not the right ones that you would give the 
patient to cough in and put a sample; there were 15 ml falcon tubes which 
were brought and if you give it to the patient, they would not be able to put 
the sample in there, it would spill, that is not the special one for 
transportation.” (FGD-GR1-M6-DT,2018) 
‘’In my day-to-day performance, I do not have the challenges I encounter at 
the moment I do not think there is a big challenge other than what has been 
said about the availability of consumables on time.” (IDI-GR8-M2-DT, 2018)’’ 
The geographical locations for some residential areas were reported to be a challenge 
because patients missed visits, especially during the rainy season when the roads are 
impassable. The following quote illustrates this: 
‘’In our region, the majority of patients are from the neighbouring region. 
There is Shinyanga, at the border with Shinyanga, there is Mwamashimba 
facility which borders Shinyanga rural and Kahama. If you look at the distance 
between patients’ villages and the Health Centre, they are huge, especially 
the Diagnostic Centres such as Mwamashimba facility.” (FGD-GR1-M3-DT, 
2018) 
A male participant mentioned facing a challenge when it came to working with staff from 
other departments in hospital due to lack of collaboration. The following quote illustrates 
this:  
‘’Another challenge is that the media we use for making culture is sometimes 
challenging. You would find that hospitals do not provide sufficient co-
operation in the acquisition of items such as media making eggs. But I know 
the programme has a media plan, I know the programme plans to enable us 




delays to prepare culture for the patients. It is not all the gears, others are 
always available, only a few.” (IDI-GR12-M7-NL, 2018) 
Perception of communication within the TB network   
The majority of the respondents affirmed that the TB network has improved and 
simplified the communication but also enabled the facilities to get electronic results on 
time. They also noted that the intervention that has been made serves to reduce 
workload at the CTRL by increasing the number of culture zonal laboratories. The 
following quotes illustrate this: 
‘’It is a good network, especially when there is active communication, 
extremely useful and if possible, should improve even more.” (IDI-GR10-M4-
DT, 2018) 
‘’I think TB networking is getting better, especially that now there is an 
establishment of zonal reference laboratories across the country. It reduced 
the workload at the CTRL.” (IDI-GR12-F6-NL, 2018) 
‘’Zones laboratory have received some samples from their regions, so I have 
a good impression that the network as good if sustained.” (IDI-GR12-F6-NL, 
2018) 
Some felt that improvement of the communication within the network helped to 
minimise shortages of laboratory supplies and rectify any problem that needs immediate 
attention. The following quotes illustrate this: 
‘’Network is good, especially when there is active communication, especially 
useful and if possible, should improve even more.” (FGD-GR4-F19-DT, 2018) 
‘’My point of view is that things are going well, although we said we do not 
get enough number of samples but I think when it comes to the network I see 
that the services are improving because the CTRL itself deals with making 





‘’TB Networking is good where there is an availability of connection that 
works well. For example, just like I was telling you, we sent a sample to the 
reference laboratory, by sitting here I get to see the results through the 
system. I log into the system I get the results earlier.” (IDI-GR9-F3-DT, 2018)  
The improved network has facilitated better communications among facilities where 
sometimes if one facility runs out of medical supplies or equipment they could request 
from nearby facilities. The following quote illustrates this:  
‘’TB Networking covers a lot of things; you know you can interact with a 
district or other regions. Suppose that the challenge was we have a deficiency 
of cartridges for GeneXpert, you see, when I do not have the cartridges, I could 
borrow from another district or other health facilities or help me transport 
the sample, when I suspect that my patient is an MDR, sending to Sekou Toure 
or Bugando.” (FGD-GR2-M10-DT,2018) 
Despite improvement on communication it was noted that it was still a challenge in some 
sites. The following quotes illustrate this: 
‘’Communication at some point was reported to be a big challenge, few 
participants reported to face network issues which hinder communication as 
they were not able to be linked into TB network.” (FGD-GR1-F5-DT, S2018) 
‘’It was also reported that it has been difficult to communicate with the 
patients who do not have mobile phones and others have mobile phones but 
the location where they live the network is fluctuating.” (FGD 2018) (FGD-
GR3-M18-DT,2018) 
Training, supervision and mentorship in terms of capacity building 
During the FGDs, some males and two females suggested that training plays a role in the 
improvements offered by the revised system in many aspects. They came to understand 
the operation of the revised RSS after being trained and are able to explain this to their 
colleagues. The following quotes illustrate this:  
‘’Yes, the RSS as I said in the beginning, is based on our patient's category 




provided helped us to understand the system clearly.” (FGD-GR2-M7-DT, 
2018) 
‘’Some of the participants declared that training and setting standards 
improved the way we work and increase our knowledge about the TB 
programme. The programme provided various training: for example, we had 
training courses on culture and sensitivity, by making us create an example of 
sending feedback online.” (FGD-GR6-M33-NL, 2018) 
‘’We have been able to increase skills and knowledge about TB testing and 
through the modern methods introduced to the programme we get the 
opportunity to recognise them, the guideline is very useful for their daily 
work.” (IDI-GR14-M9-IP, 2018) 
‘’Through trainings and setting standards through National guidelines would 
improve the way we work and increase our knowledge about the program 
and TB testing.” (IDI-GR11-M5-NL, 2018) 
Mentorship during supervision was found to be efficient. The following quote illustrates 
this:  
‘’Some female participants said that they involved us on mentorship and 
therefore they are mentored and through these mentorships, we are building 
capacity for them to be able to perform their work properly.” (FGD-GR4-F20-
DT, 2018). 
Specimen transport mechanism  
The bodaboda was used to transport sputum specimens between the study sites in 
Mwanza; from peripheral health facilities to the Xpert sites. The focus was to increase TB 
case detection and to detect more rifampicin-resistant (RR) cases from sites without 
Xpert machines and hasten the feedback of results to the requester. The study 
anticipated minimising hassle and cost to the patients. Specimen transportation from 
Mwanza to the CTRL was through EMS. The same systems were used to send back results. 




to be beneficial, as came out clearly during interviews with some participants. The 
following quotes illustrate this: 
‘’To be honest this bodaboda issue is exceptionally good, I mean to say, we 
received result quicker, we know the status of the patient early; that’s why I 
said this system is good.”  (FGD-GR3-M16-DT, 2018) 
‘’Yeah! RSS has reduced the waiting time, in fact, it has dramatically 
shortened the time. In the beginning there was the problem of delayed 
results, but sample shipment at present and in the past is quite different; it 
was taking too long to get the results.” (IDI-GR10-M4-DT, 2018) 
The existence of a smooth transportation system of specimens minimised batching as 
the following quotes illustrate: 
‘’The revised system avoids batching of specimens and was instead sent as it 
comes using EMS and the revised laboratory request forms are well filled.” 
(FGD-GR5-M33-NL, 2018) 
‘’There are other groups to National level, for example, we have a group of 
WhatsApp that has involved the Central level and Zonal Level people.” (IDI-
GR13-M8-NL,2018). 
Safety and Packaging of Specimens  
During the interviews, the participants reported receiving an orientation on how to 
prepare the sample and were also provided with the guidelines. The following quotes 
illustrate this:   
‘’They trained us about the importance of the triple package. Any trained 
personnel must adhere to the rules. We displayed in the work area, it shows 
when the samples should be transferred and how the labelling is done before 
it is sent to the post office.” (FGD-GR2-M12-DT,2018) 
‘’Participants acknowledged the efforts made by the CTRL team as the 
majority of staff working with the TB units were oriented on preventive 




conscious about TB infection and tried to minimise the risk of contamination.” 
(GD-GR6-M35-NL,2018) 
Participants noted reduction in the rate of specimen rejection and contamination, 
supported by improved communication that played a part in better sharing of 
information. The following quotes illustrate this:   
‘’Yes, there were samples that were rejected, because of leakages, not 
packaged well, but now the contamination rate has gone down. I think the 
RSS has managed to achieve somehow in the sense that it directs people on 
how to do it. Previously, the contamination rate was high and now it has 
decreased.” (FGD-GR4-F23-DT,2018) 
‘’Previously, some samples were rejected because of poor packaging but after 
staff were oriented, the rate of contamination has been reducing. I think it’s 
because of close communication.” (FGD-GR1-M2-DT,2018) 
Diagnostic method and centralisation of TB laboratory services  
Some of the participants said that the method used for the revised system improved the 
feedback of results. It hastened the process and minimised hassle for the patients. The 
following quotes illustrate this:  
‘’Yes, it takes 48 hours to get the results. Previously, culture took more than 
two months, of course, and it is eight weeks if negative. But now if it is 
‘’positive and has to be tested for rapid DST it means we get results within a 
month or two months. This is good.” (FGD-GR3-M13-DT,2018) 
‘’Actually, these are technological advances, at least there are some tests 
carried out with a lot more urgency than it was previously.” (FGD-GR4-M21-
DT,2018) 
A female participant affirmed that the use of molecular techniques at CTRL minimised 
delay in results. The following quote illustrates this:  
‘’This is because of the use of the rapid DST (LPA) methods for early 




tool, reducing the specimen processing time and resulting in timely 
transportation.” (IDI-GR14-F10-IP, 2018). 
  
6.7 Summary discussion 
A revised RSS was piloted in Mwanza region with the aim of addressing some of the 
weaknesses observed in the existing RSS through the quantitative and qualitative 
analyses described in chapters 3 and 4. The revised system sought to take care of several 
aspects reported as impeding smooth RSS operations and resulting in delays to DST and 
failure to identify some DR-TB cases. Following a successful pilot, the opinions of the 
revised RSS were sort from stakeholders. The general impression observed from the 
study participants is that the revised RSS is a big improvement over the previous RSS. In 
particular, in providing test results in a timely way and enabling appropriate patient 
management.  Several features were highlighted by the participants, for example the 
majority of the TB programme staff were trained on the specimen packaging and were 
aware of the RSS and the way it operates. The specimen transportation arrangements 
have now been improved, enabling specimens and results tracking. The findings also 
show that the CTRL is now able to provide prompt feedback and clarity as necessary. 
Inter-facility communication has been established through social media such as 
WhatsApp, which has strengthened the communication in the network, punctually 
resolving problems such as stock-outs and queries on forms and samples received or 
sent. Participants added that it has become easier for them to start patient’s treatment 
on time. The process of getting the results has improved efficiency in monitoring and 
controlling TB patients’ conditions. Data are received on time and, through this revised 
system, the number of reported MDR-TB cases has been increasing because of the 
documentation and the reporting system improvements.  
Despite all the successes of the revised RSS, the study encountered challenges. The 




which become more difficult during rainy season. Facility accessibility, specimen 
transportation and communication limitations such lack of internet connectivity are still 
a challenge for some facilities such as Gundu, Magu and Misungwi.  
Our study indicates that the majority of hospitals and health centres were equipped for 
general laboratory services including TB diagnosis. However, there was evidence that 
many dispensaries lacked functioning microscopes and some essential equipment such 
as weigh scales for reagent preparations. The diagnostic centre was reduced from 80 to 
72 due to lack of laboratory personnel and poor infrastructure. At some point there was 
a shortage of falcon tubes for specimen’s transportation and at the CTRL equipment 
breakdown at molecular sections. Frequent power cuts also led to a number of 
specimens not being processes or spoiled. 
There were some challenges with participation in the FGDs and IDIs especially in Mwanza 
region in some facilities like Misungwi where they were informed and agreed but we 
could not find the key people (DTLC and TB/HIV staffs to run an effective FGD). In the 
end we had to interview the DOT nurse using an IDI.  
6.8 Conclusion 
In conclusion, according to those engaged with the revised RSS in Mwanza and CTRL the 
revised RSS has delivered many improvements compared to the existing system. In 
particular, in reduced delays to getting DST results which should therefore result in 
increased detection of MDR-TB. This is an incredibly positive outcome and suggests the 





Chapter 7  DISCUSSION  
 
 
7.1 Introduction  
This chapter presents a summary of the key study outcomes of ‘’Creating an effective 
RSS for TB in Tanzania.’’ It reviews the methods and findings in the light of the literature 
and the context of a LMIC with a high burden of TB. It then outlines the potential 
implications of the study to other LMICs and what further research may be necessary.  
 
The study aimed to answer five research questions: a). What is the scale of the 
inadequate performance of the current RSS for previously treated TB cases in Tanzania?  
b). What is the stakeholder perception of the current RSS for previously treated TB cases 
in Tanzania? c). What new design of RSS for previously treated TB cases might overcome 
many of the weaknesses in the current system.  d). Does the newly designed and revised 
RSS improve the performance of the system, in particular by reducing the time from 
sputum collection at the district health facility to communication of the drug 
susceptibility testing results by the CTRL back to the district? e). Does the revised RSS 
reduce barriers to effective performance of the system?  
 
7.2 Summary of the design and methods used for the research. 
The research used a mixed method approach that included both quantitative and 
qualitative research methods. Firstly, quantitative data was collected and analysed for 




(described in chapter 3). Following this, qualitative data was collected from key 
stakeholders in a sample of regions in Tanzania. This aimed to understand their 
perceptions of the effectiveness of the RSS. This used FGD and IDI as appropriate 
(described in chapter 4). Findings from the quantitative and qualitative research were 
then linked and used to design a revised RSS for previously-treated TB cases to seek to 
address the issues identified by the research. This redesigned RSS recognised the rapid 
molecular technique Xpert MTB/RIF is in the process of implementation across the 
country in place of microscopy as the primary TB diagnostic tool. The revised RSS was 
then implemented as a pilot in one region (Mwanza) of Tanzania. A before and after 
quantitative comparison was then made of key output parameters such as the number 
of cases referred, transit time for samples from the periphery to the CTRL, turnaround 
time of DST in the CTRL, and the number of MDR-TB cases detected (described in chapter 
5). Finally, a qualitative assessment using FGDs and IDIs was conducted with key 
stakeholders impacted by the revised RSS, to determine perceptions of whether the 
revised RSS had addressed the issues observed in the earlier qualitative analysis 
(described in chapter 6).  
 
7.3 Key findings of the research alongside observations from the 
literature 
Specimen referral numbers with the existing RSS 
The initial quantitative study into the current RSS showed that, out of 8,482 previously 
treated TB cases notified across the country for the three years investigated, only 2,750 
(32.4%) were received at the CTRL for DST. This implies that, the NTLP goal for the RSS of 
100% of previously-treated TB cases being routinely investigated for drug resistant was 
far from being achieved. This infers that cases of drug resistant are likely to have been 
missed and surveillance by the TB programme was not fully undertaken. This finding 
corresponded well with the previous findings of an audit of programme data where it 




submitted to CTRL for culture and DST (46). In the follow-on qualitative study it was 
found that the system of TB specimen transportation in Tanzania was a major problem 
in remote health facilities as there were no postal services and no reliable and frequent 
means of transport (45). 
Time taken to transport and process specimen with the existing RSS 
Drug sensitivity testing is required for successful treatment of TB patients who may have 
drug resistance. Isolation of the mycobacteria from sputum samples within 24-48 hours 
is recommended (76). Studies have shown that, sputum specimens kept at room 
temperature beyond 3 days without preservatives, suffer a significantly low yield of 
isolation of MTB (140). In the initial quantitative study, analysis of the laboratory data 
collected for the three years showed significant delays in specimen transportation for 
culture and DST. The median transit time from sputum collection to arrival at the CTRL 
was over 7 days, which may have an impact on the specimen culture yield. According to 
the WHO, sputum specimens that are transported longer distances must be delivered as 
soon as possible, but no later than 48 hours from time of collection  (37). However, 
laboratory networks in many high-TB-burden countries like Tanzania experience 
technical and physical resource challenges that make it impossible to comply with these 
WHO guidelines (141).  
The turnaround time for the different tests at the CTRL only achieved the recommended 
time for microscopy in 82.4% of cases, 42.4% of cases for culture and just 2.8% of cases 
for DST. This means that more than 50% of the culture specimens and more than 95% of 
the DST specimens processed were unable to generate reliable results in a timely manner 
with consequent delays in patients commencing appropriate treatment, which in turn is 
likely to affect treatment outcomes. This also correlates with the follow-on qualitative 
study which showed result delays were one of the aspects raised in the majority of 
interviews with health care workers. The current RSS was seen as poor in relation to the 
feedback and communication of the DST results from the CTRL to the peripheries. The 




procedures, and only one TB DST laboratory being available in Tanzania. Park et al. (47) 
comment that the centralization of drug sensitivity testing has led to overwhelming 
workload at the CTRL, significantly contributing to ineffectiveness of the system in the 
country. Our study is in line with  Harries et al. who revealed that, problems often exist 
at all stages of the system from specimen transportation, processing and documentation 
(48). Likewise, the study findings correspond well with those reported from a study 
conducted by Harries et al. in Malawi (76). The authors emphasize an appropriate 
collection and transportation of sputum specimens from remote survey settings to a 
quality-controlled TB culture laboratory is essential to ensure accurate results that can 
contribute to national and global surveillance of drug resistant. The effects of delay in 
transporting the sputum specimen have been well discussed in previous studies. 
MDR-TB detection rates with the existing RSS 
In the initial quantitative study, the observed MDR-TB rate of previously-treated cases 
that did receive DST was surprisingly high (72 out of 373 i.e. 19.3%). WHO estimates for 
Tanzania in 2016 were 4.7% of previously treated cases (136). The reason for this 
difference is unknown, but there are three possible explanations. Firstly, that the WHO 
estimate is an underestimate which is possible as it was only an estimate and is not based 
on a recent DRS which is currently being updated. Secondly, that the observed figure in 
this study is an overestimate, potentially because those cases actually tested are not a 
random sample of all previously treated cases. They are potentially the ones that districts 
are most concerned about and actually have a higher probability of MDR-TB. The third 
possible explanation is that specimens could have been contaminated due to the short 
comings of the RSS. It could equally be a combination of all three reasons above. 
Key stakeholder perceptions of the existing RSS  
Additional observations on the existing RSS from the qualitative study with key 
stakeholders included comments on poor communication between the CTRL and the 
peripheries, weak supervision and staff shortages that contributed to low staff 




availability of new diagnostic technology for DST, problems with funding and incentive 
payments, and a general failure to follow good practices. These and the other key themes 
and subthemes observed from the FGDs and IDIs have been described and linked in 
chapter 4, Figure 20. Some of these observations appear to be new, but others have also 
been observed in the literature. For example, Royce et al. noted that, delays due to many 
“handoffs” of specimens through different levels of health system and unintended 
consequences of health worker incentive payments, can mean even if specimens reach 
the laboratory they may not be of adequate quality (80). Further, Daum et al. observed 
the scaling up of the coverage of rapid diagnostic techniques (e.g. Xpert) across the 
country could increase case detection, early treatment and help reduce further 
transmission, but this needs to be supported by accurate reporting and effective routine 
surveillance systems (104). Shewade et al. in a qualitative study in India observed many 
similar issues related to drug sensitivity testing. For example, lack of identification of 
patients eligible for DST and lack of assured specimen transport after patient 
identification (142).  
Design of a revised RSS for previously-treated TB cases 
It has been possible to design and pilot a revised RSS for previously-treated TB cases 
(described in Chapter 5). The revised RSS piloted in Mwanza region, Tanzania aimed to 
address many of the issues raised in the earlier qualitative study, as well as taking into 
account availability of rapid diagnostic tools using molecular testing services such as 
Xpert and LPA. It is believed that this is the first time such a comprehensively revised RSS 
has been designed, piloted and results published (143). Previously studies have looked 
at individual aspects of the RSS for example transport (47), but never in such a 
comprehensive manor and including new diagnostic technologies such as Xpert.  
Increase in the number of previously-treated TB cases receiving DST with the revised 
RSS 
It was observed during the pilot in Mwanza of the revised RSS that the number of 




which had been received under the previous RSS.  Additionally, the revised RSS led to 
93% of the specimens received at the CTRL being examined in comparison to just 64% in 
the previous year. This was probably a result of the reduction in missing information on 
the laboratory request forms received. However, despite improved transportation 
arrangements for the revised RSS, the study observed less than 50% of all culture-
positive slopes for previously-treated TB cases underwent DST, meaning drug resistant 
cases are still probably being missed. More work is clearly still required to identify how 
to increase universal DST for previously-treated cases in Tanzania. 
Reduction in transit and turnaround times for DST with revised RSS 
The primary outcomes of the study were the impact of the revised RSS on specimen 
transit time and the time for DST results to reach the requesters (overall turnaround 
time). The revised RSS pilot has shown significant improvements compared to the 
existing RSS. For Mwanza sites, the transit time in 2017/2018 had a median of 10 days 
(IQR 6, 15) with 21% taking more than 21 days. In comparison in 2016/2017, the median 
was 12 days (IQR 3, 54) with 44% taking more than 21 days.  Unfortunately, due to poor 
data recording in 2016/2017, the turnaround time was only available for 8 specimens, 
however for these 8 the median turnaround time at the CTRL was 62 days. The use of 
molecular techniques reduced the turnaround time median to 7 days during the pilot 
period of the revised RSS. In addition, the use of Xpert at local sites in Mwanza enabled 
specimen to be transported to a site within Mwanza region in less than three days in 
most cases, thus enabling a RIF resistant result to be available much sooner than 
previously.  An important reason for the reductions in transit time were the use of an 
improved EMS system and bodaboda services. This improvement is contrary to previous 
studies in Zimbabwe and Malawi where no improvement was detected (42, 48).  
Increase in number of MDR-TB cases identified through revised RSS 
An increase from 12 to 20 in the number of MDR-TB cases diagnosed and started on 
treatment from previously-treated cases in Mwanza was observed. Although these 




encouraging. WHO estimated in 2017 only around 22% of MDR-TB cases were 
successfully placed on treatment (144). Potentially the revised RSS could go some way to 
closing this gap. 
Improved communication between the periphery and the CTRL with the revised RSS 
Use of the social media tool WhatsApp played an important role in this study. Various 
groups were created by the NTLP Manager such as Vitendanishi for laboratory supplies 
and the Mwanza family created by the Mwanza’s RTLC to enhance communication with 
laboratory personnel and the DTLCs in the region. These groups helped the ground staff 
responsible for sending out specimens to resolve concerns quickly and eased results 
dissemination, consequently shortening both transit and hence the overall turnaround 
times (143).  
Social media use has increased over recent years, enabling millions of users to share 
immediate data, information and reports. (145), (146). Woods et al. explain how 
WhatsApp and its use as an alternative learning tool to improve clinicians’ access to 
specialised management of complicated HIV/TB cases (145). The analysis found the 
majority of participants had gained new clinical confidence from group participation. The 
study findings supported the use of WhatsApp in a medical setting as an effective means 
of communication, long distance learning and support between peers and specialists. 
Our findings are also consistent with the understanding raised by Shenouda et al. that, 
smartphones are a tool appropriate for prescribing, coordinating clinical work and an 
alternative means of communication especially through instant messaging. (147). Lester 
et al. acknowledge that short message services is the most widespread digital 
communication mode, with the capacity to improve the quality of care in people with 
active TB and LTBI (148). The study concluded that, the increasing range of technologies 
available to assist treatment adherence is conducive to the goal of establishing holistic, 
patient centred differentiated care models for TB.  
Muhjazi et al. showed that, compromised delivery of, and poor access to, TB diagnostic 




emergencies. A Whatsapp group was established to connect the central programme with 
TB workers at the governance level. This allowed workers to send patient reports 
including data spreadsheets from their mobile phones whenever they could get an 
internet connection. They also observed communications can often be severely 
interrupted in health centres which have no electricity or internet most of the time, an 
experience we also found in our study (149). Denkinger et al. noted that, the use of 
mobile phone technologies opened up opportunities for the integration of mobile 
phones as health intervention tools in many aspects of care for patients with TB, which 
will lead to improvements in health service delivery, patient care and patient satisfaction 
(146).  
Lestari et al. observed that people in close contact with tuberculosis should have 
screening and appropriate management, as an opportunity for active case detection and 
prevention (150). In order to bridge the wide policy-practice gap behaviour change is 
needed across the three levels of the healthcare system—policymakers, healthcare 
providers, and patients. Use of new communication tools alongside application of 
continuous quality improvement cycles using routinely collected data is a way to engage 
clinic staff in understanding their own data to seek to motivate behaviour change (150).  
Perception of stakeholders with the revised RSS compared to the previous RSS  
Following a successful piloting, the opinions of the revised RSS were sought from 
stakeholders through IDI and FGD (described in Chapter 6). The general impression 
observed from the study participants is that the revised RSS is a big improvement over 
the existing RSS in providing test results in a timely manner and enabling appropriate 
patient management.  It was clear the revised RSS was much appreciated by the health 
care workers. It was noticeable that the training provided seemed to play a major role in 
the progress of the revised system and this was commented on by many of the health 
care providers who came to understand its importance and implementation better. 
Stakeholders also noted that the CTRL is now able to provide prompt feedback and clarity 




such as WhatsApp, which has strengthened the communication in the network, 
punctually resolving problems such as stock-outs and sharing information about 
different TB programme events. 
Despite the revised RSS working better in many ways, there were still systemic 
constraints that stakeholders considered needed consideration. Stakeholders suggested 
that DST services needed to be further decentralised and the mode of communication 
between the CTRL and peripheries could be improved further. It was felt that laboratory 
request forms needed to be captured electronically and checks should be established to 
minimise unnecessary errors. Similar issues of the effect of poor record keeping was 
observed in South Africa by Mngomezulu et al. where they identify that poor record 
keeping contributed to the low levels of bacteriological coverage reported (152). These 
shortcomings need to be addressed to improve patient care and programme 
management. 
 
7.4 Reflection on the study design and methods used 
The design of this study incorporated both quantitative and qualitative research methods 
employed before the pilot implementation of a revised RSS, and after in a matched 
approach. Qualitative research has been used many times before in research related to 
health systems including TB. For example, in identifying how to improve TB services 
(151), to explore  the experiences and perceptions of patients and healthcare 
professionals in Peru  (153), in the development of integrated laboratory services (154), 
and in identifying barriers for TB case finding in Ethiopia (155). 
The mixed methods approach of using both quantitative and qualitative analysis has also 
been used before in research related to TB. For example, in a study focusing on 
identifying reasons why patients are lost to TB treatment follow-up in Japan (156), a 
study reviewing the performance of the TB programme in Liberia (157), a study looking 




and another study in Tanzania researching acceptability of community and health facility 
based DOT for TB (163). The approach might be considered as falling within the wider 
context of Implementation Research which the British Medical Journal (BMJ) defines as 
“the scientific inquiry into questions concerning implementation the act of carrying an 
intention into effect, which in health research can be policies, programmes, or individual 
practices (collectively called interventions)”(158). Implementation research generally 
uses a mixed methods approach including both quantitative and qualitative approaches 
and has been advocated previously by researchers working in the field of TB (159). In our 
study the qualitative and quantitative aspects of the research are discussed in separate 
chapters but cross-linking of ideas between the approaches was done. For example, 
incites derived from the qualitative part explained some of the quantitative findings. In 
addition, many of the overall study findings were consistent across the quantitative and 
qualitative results, for example in observing the delays to getting DST results and the 
resulting impact on MDR-TB diagnosis.  
The qualitative research performed both before and after the intervention focused on 
health worker perceptions of the RSS and did not include any interviews of patients using  
the health system, unlike some other qualitative research discussed in the literature 
(153). This was primarily because we already understood the RSS was not delivering for 
patients in providing rapid DST. We were focused on understanding why the current RSS 
was not delivering on its objectives. The RSS is probably not something patients of the 
health system would have the detailed knowledge of to make a useful contribution to 
the research but are clearly impacted by its poor performance. In the future it would be 
interesting to conduct qualitative research with the users of the health system following 
the introduction of the revised RSS, to understand whether patients are experiencing the 
service they require, or might expect, in detection of drug resistance.  
A combination of FGDs and IDIs were used as qualitative methods of data collection in 
this study. This is because the methods complemented one another in terms of 




provide a good social context to gain a deep understanding of a subject and enable the 
researcher  explore the stakeholders perceptions (160). The combination of the two 
approaches enabled some participants to discuss their observations with their peers in 
the FGDs, whilst other generally more senior individuals were able to privately voice their 
concerns and observations with the research team. Alternative qualitative methods were 
considered, but it was felt they would not give the quality and breadth of data required. 
For example, although Surveys might have allowed more people’s views to be 
considered, they would not have enabled a clear description of the RSS to have been 
provided beforehand and would not have enabled clarification via queries and questions 
to be provided easily. Also, in something as detailed as the RSS the concern would be 
response might have been low.  
 
7.5 Operational limitations of the study  
There were a number of operational limitations to this study that were observed. 
First: the historical routine data captured electronically was found to be incomplete due 
to poor form filling that led to some difficulties in analysing information. For example, in 
the number of previously-treated case specimens recorded in most of the specimens 
received in 2011 which were not accompanied by appropriate forms or registers, and 
even those sent were incompletely filled. In 2012, 2013 there were improvements in the 
documentation, hence the increased numbers recorded compared to 2011. Even so, 
some information in one or more of the relevant fields (including results and personal 
demographic information) was missing in 2012 and 2013 data which made it exceedingly 
difficult to verify the data so had to be discarded.   Poor record keeping sometimes made 
comparisons of performance difficult. However, to a certain degree, this poor record 
keeping was also symptomatic of the poor performing RSS. The revised RSS record 




evidence from this study shows its importance as it could have a direct effect on patients 
getting appropriate treatment and in a timely manner. 
Second: In the qualitative studies many of the experienced laboratory staff were not 
available for key informant interviews as a result of high staff turnover. The initial 
sampling of personnel for FGDs assumed achieving appropriate number of participants. 
(164). In most of the selected districts the number were less than recommended 
resulting in exclusion of some sites. Time for the key informant interviews was also 
limited due to their tight schedules and therefore some interviews were unavoidably 
hurried.  However, despite these limitations, a good range of stakeholders were still 
included that gave a broad range of views and perceptions. 
Third: During the pilot study of the revised RSS in Mwanza there were great variations in 
the number of specimens received by month (Chapter 5, Figure 30). This was mainly due 
to operational reasons, for example towards the end of May 2017, there was a 
nationwide employees’ education certificate inspection for irregularities which led to the 
termination of several laboratory staff and clinicians, which unfortunately had a negative 
impact on the pilot. In addition, in December 2017 and February 2018, fewer specimens 
were received which might have been due to staff shortages leading to specimen 
batching. Without, these difficulties it would be expected the pilot would have 
performed even better. However, such difficulties are not unusual, so potentially it is not 
unreasonable to expect in routine practice such problems.  
Fourth: The pilot study only referred specimens tested by Xpert in Mwanza to the CTRL 
for confirmatory LPA testing when Rifampicin resistance was detected, so potential cases 
with INH resistance could have been missed as Xpert, currently only has the capacity to 
detect Rifampicin resistance. However, studies have shown RIF resistance is highly 
correlated with INH resistance, therefore the effect of this limitation is expected to be 




Fifth: Despite all the successes of the revised RSS, the study encountered challenges. The 
geographical location of patients’ residence, leading to delays in specimen submission 
which become more difficult during rainy season. Facility accessibility, specimen 
transportation and communication limitations such as lack of internet connectivity were 
a challenge for some facilities such as Gundu, Magu and Misungwi. In addition, at some 
point there was a shortage of falcon tubes for specimen transportation and at the CTRL 
frequent power cuts also led to a number of specimens not being processes or spoiled. 
However, all these are real-world routine problems that any RSS has to deal with in 
becoming as effective as possible. 
Sixth: In the post pilot qualitative study there were some challenges with participation in 
the FGDs and IDIs especially in Mwanza region. In some facilities like Misungwi 
participants were informed and agreed to take part, but some important individuals 
could not be found to take part in an effective FGD. In the end additional DOT Nurses 
were interviewed using an IDI to ensure representation from all facilities. 
Despite all the difficulties and limitations, the study produced many useful and valuable 
findings. It is believed these findings give a real insight into the issues surrounding the 
existing RSS for TB in Tanzania and highlight how a revised RSS can address many (if not 
all) those issues to deliver improved outcomes for patients and the health system.  
 
7.6 Wider implications of the study 
Many low- and middle- income countries (LMIC) with a high burden of TB face similar 
problems to Tanzania (167, 168, 169). For example, limited capacity for DST with one 
Central Reference Laboratory (CRL) for the whole country with inadequate access due to 
several barriers. These barriers include lack of programme awareness amongst 
physicians, limited supplies, and unreliable transport (47). Laboratories performing 
culture and DST are often inadequate and overloaded (48,166). Likewise, rapid transport 




resulting in losses due to contamination or growth failure (166). Poor infrastructure and 
unsustainable logistics are also contributing factors (71,166). This study suggests that 
real improvement can be delivered in contexts like those in Tanzania that would increase 
DR-TB detection and reduce delays for patients in starting appropriate DR-TB treatment. 
This is the first study that the author is aware of that has taken such a comprehensive 
approach (including the use of quantitative and qualitative methods alongside a pilot 
study) to address the issues around RSS for TB in a low-income country. Lessons from 
this study undoubtedly have many practical applications to other similar countries with 
a high burden of TB. 
The study focused on previously-treated TB cases only, however all the interventions 
could have equal value to new cases, though the level of drug resistance would be 
expected to be much lower.  
The findings of this study could assist the NTLP in its operational plans and funding 
allocations. Potential interventions that could be considered are to establish national 
guidelines for specimen packaging and referral arrangements to counteract 
contamination effects; increased awareness among district coordinators on the 
importance of sending specimens within the recommended timeframe, decentralization 
of culture and DST services, and roll out of more appropriate rapid TB laboratory testing 
techniques such as Xpert MTB/RIF.   
The design and research methods used in this study have shown appropriate data 
collection and analysis using both quantitative and qualitative methods, are important in 
contributing to knowledge, understanding, identifying solutions and piloting 
interventions in health care. It is a potential approach for other studies involving health 




7.7 Reflections on the research being conducted by the Head of 
the CTRL 
The research described and written up in this thesis was conducted by the Head of the 
CTRL with responsibility for all the TB laboratory functions in Tanzania (described in 
section 1.5.1). This has both strengths and disadvantages.  
 
In relation to the design of the study, being the Head of the CTRL had many benefits. As 
the Head of the CTRL I had direct experience and understanding of the routine operation 
of TB control processes and strategies in Tanzania, including the RSS. In addition, I had   
direct experience of the outcomes of these processes, whether good or bad. For 
example, in my job I received frequent feedback from the regions concerning result 
delays from the CTRL, shortages of supplies and staff, difficulties in linking data between 
the CTRL and the wider TB network, equipment breakdown, and poor implementation 
of external quality assurance. Equally, the CTRL staff complained that the specimens 
received were not sent on time, were few in numbers, and often with incomplete TB 
laboratory request forms. This allied to the low levels of MDR-TB detection in Tanzania 
and the many previous unsuccessful attempts to address the issues, gave me real 
motivation to complete a research study into the RSS as I could see there were serious 
problems that needed addressing.  
 
My role as Head of the CTRL gave me the awareness that individuals involved in the TB 
programme could potentially provide great insight into what was going wrong, and 
hopefully help identify ways to fix it. This was a major motivation behind the mixed 
methods design involving completing a qualitative study with key stakeholders alongside 
the quantitative analysis using the available data to verify the extent of the issues. In my 
role, as Head of the CTRL I was also well placed to identify the key individuals to include 
in the research and the dynamic interactions between these individuals. Potentially 
however, being so close to the issues could have led to concerns about highlighting my 




collection and analysis. I needed to keep reminding myself, and my colleagues, that we 
are doing this for the betterment of the patients and improving the programme 
outcomes. In addition, a rush to finding solutions was avoided by the design and 
structure of the qualitative research, which was completed first before the design of the 
pilot intervention was even considered. Close and supportive supervision and training 
from my academic supervisors at LSTM enabled me to use approaches to the qualitative 
research that I had previously had little experience of using (e.g. use of focus group 
discussions and in-depth interviews). There was a concern that being in a senior position 
over many of the individuals involved in the FGDs and IDIs could have resulted in some 
individuals being reluctant to speak out. This was avoided as much as possible by 
employing research assistants to conduct the FGDs and IDIs and ensuring the 
confidentiality of the whole process. This did mean that I could not take part in the 
interviews themselves which was a disadvantage, but through the design of clear topic 
guides and recording of the interviews it was still possible to be fully engaged in the data 
collection and subsequent analysis. The need to hire two research assistants during the 
study was an additional cost, but the fact that this helped to ensure unbiased data 
collection made the additional expense essential. 
 
In relation to the design and execution of the pilot interventions, my role and experience 
helped ensure it was feasible to implement and was a great help in getting approval and 
buy-in from management and colleagues alike in Dar es Salaam and Mwanza. On the 
other hand, it is possible that more innovative and creative interventions might be 
identified by individuals less engrained in the current processes. To address this, external 
partners of the Tanzanian TB programme were included in the IDI’s conducted before 
and after the pilot of the interventions (i.e. MSH, PATH and KNCV). 
 
Data analysis was greatly helped by me being the Head of the CTRL as it gave me direct 
access to all the TB programme data systems and the resources to support the analysis. 




analysis and identifying where additional work and clarification was required. Effective 
interpretation of the results is key to any research. The fact I was so familiar with the 
existing processes and performance of the TB programme was a great help in 
interpreting the results. However, it was essential that there was external challenge to 
these interpretations to avoid misinterpretation and failure to identify new themes that 
may not fit with my preconceived ideas. This challenge, for example, assisted greatly in 
interpretation of the qualitative research described in chapter 4 and the design of the 
revised RSS described in chapter 5.  
 
In conclusion, this research has benefitted from me being the Head of the CTRL. This 
arises from the in-depth knowledge of the current processes and people of the TB 
programme in Tanzania, and the authority my position gave me. However, there are 
some issues that this could have caused, such as an over emphasis on preconceived 
ideas, lack of innovation, or bias introduced in qualitative data collection from the 
authority of my position in the organisation. It was important to realise these dangers 
and put in place measures to ensure the quality of the research by, for example, 
engagement of hired research assistants, partners, and academic supervisors to give an 
external dimension. Finally, a clear benefit of my role will be in taking the results and 
learnings of this research forward in implementing changes to the RSS and in the further 
research I am now better equipped to complete. This makes me very proud that my 
dedication and commitment to this research has paid off.  
 
7.8 Further Research 
It is clear from this study that there is more research to do. For instance, even with the 
focus of the revised RSS, 13% of the laboratory request forms had missing laboratory 
reference numbers and 3% missing addresses, although much lower than in 2016/17.  
Similarly, there were significant numbers of specimens in 2017/18 that were not 




that might identify how to close these and other gaps in performance would be 
worthwhile.  
The WhatsApp platform used as a communication tool in the pilot study was recognised 
as a great success. This has begun to be replicated in other regions among DTLCs, RTLCs 
and laboratory teams and has proved an extremely useful means to address many 
communication issues in the TB programme and beyond. Potentially, there are other 
aspects of work in the TB programme where such an approach could benefit. Further 
evidence is required to evaluate the feasibility, equity and effectiveness of mobile phone 
interventions for TB control (170). However, one area that seems ripe for use of such 
technology is in reporting laboratory results and a web-link to send laboratory data to 
the NTLP.  
The revised RSS was shown to reduce delays in diagnosis and increase the number of 
drug resistant cases detected. The shorter transit times and turnaround times are 
important in the diagnosis of MDR-TB and TB control. These positive results suggest a 
larger scale study involving more regions should be considered to determine whether 
these benefits are robust and sustainable across similar settings. Such a study could 
include a modelling element in order to assess the impact of a revised RSS on health 
system costs and to evaluate cost effectiveness.  
 
7.9 Conclusions  
The study findings provide a basis for identifying potential methods of improving the 
routine surveillance system and thereby providing more timely and appropriate 
management particularly for patients with potential MDR-TB. Based on these findings 
there is an urgent need to address the identified shortfalls of the existing RSS in order to 
provide improved feedback to peripheral centres and patients, and to increase MDR-TB 




In conclusion, the revised RSS led to an increased number of specimens received and 
tested at the CTRL. The use of social media within the NTLP network led to close follow-
ups and timely response to concerns during the piloting. The revised system was shown 
to reduce delays in diagnosis and increase the number of drug resistant cases detected. 
According to those engaged with the revised RSS in Mwanza, and at the CTRL, the revised 
RSS has delivered many improvements compared to the existing system. In particular, 
the shorter transit times and turnaround times are important in the diagnosis of MDR-
TB and TB control. This is a very positive outcome and suggests the revised RSS has 
significant scope for a roll-out across Tanzania. The research should lead to further 
research to determine whether the benefits identified in Mwanza, Tanzania are robust 
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Appendix 6: Informed Consent Form for Focus Group Discussion -Swahili Version 
 
A: Form ya ridha 
Jina la mchunguzi: Basra Esmail Doulla   
Jina la Taasis: National Tuberculosis/Leprosy Programme and Liverpool University
   
Jina la Ugunduzi: Unchunguzi wa Mfumo wa Kuchunguza sampuli za wagonjwa wa kifua 
Kikuu  
Tarehe ya kupitishwa:    
PIN ya Mshiriki: 
 
Ridhaa ya kushiriki katika Uchunguzi wa mfumo wa kuchunguza Mpango wa kifua kikuu 
Utangulizi 
Fomu ya idhini katika uzuria Kikao cha majadiliano (FGD) na mchakato wa mahojiano 
kuhusu mfumo wa kuchunguza kifua kikuu. Fomu hii itatumika katika sehemu mbili za 
mahojiano kati ta mahojiano ya mtu Mmoja nay a makundi kwa wafanyakazi wa sekta ya 
Afya.  
Unaruhusiwa kuchagua sehemu ambayo ungependa mahojiano haya yafanyike, na 
mahojiana yatachukuwa muda usiozidi saa moja. Upo huru kuuliza swali lolote na 
utajibiwa. Pia upo huru kujitoa katika mahojiana wakati wowote bila kuathiriwa. Taarifa 
utakazotowa hapa zitahifaziwa kwa siri na zitatumika kwa lengo husika tu. Usitoe 
taarifazozote zile zitakazo kutambulisha wewe, jibu maswali yanayo husiana na utafiti 
huu tu. Takwimu utaazo toa zitarekodiwa, tutawapa hapa namba, hatutatumia jina la 
mtu, pia unaruhusiwa kujitoa katika mahojiano wakati woowte ule bila kutoa sababu 
yeyote ile. Takwimu utakazotoa zita haribiwa baada ya miaka mitano. Tunaomba 
mzingatie usiri wa mahojiano. Pia tutawapa vinywaji na chakula pia. Mahojiano 




mfumo wa uchunguzi kwa kina. Pia atawapatia fomu ya ridhaa ya kushiriki katika 
mahojiano. Mnaruhusiwa kuuliza swali lolote lile, na utapewa ufafanuzi wa kina. 
Angalizo: 
Wakati wa mahojiano na washiriki twakimu zenu itasikilizwa na mjumbe wmingine 
ambaye pia ni mtafiti kwa ajili ya kuhakiki. 
Fomu ya Ridhaa ya Mahojiano ina sehemu mbili: 
Sehemu A: Inaelezea maelezo muhimu na madhumuni ya uchunguzi. 
Sehemu B: Kibali cha maadili kwa washiriki na ridhaa ya kushiriki katika utafiti 
Sehemu A: Yatakayokuwa anaelezwa Mshirika  
Jina langu ni -------------------------------------------- nafanya kazi katika Wizara ya Afya na 
Ustawi wa Jamii (MoHSW) kupitia NTLP tungependa kukukaribisha kushiriki katika 
kuratibu mfumo wa kuchunguza kifua kikuu (TB) ujulikanao kama Routine Surveylance 
System (RSS) katika mitandao ya maabara hapa nchini. 
Tunania ya kuelewa vitu vinavyochangia kudorora kwa mfumo huu wa kuchunguza kifua 
kikuu hapa nchini, sababu za specimen kutofika au kuchelewa kufika katika maabara kuu 
pamoja na kubaini matatiza yanayo ambatana na kutofika au kuchelewa kwa sampuli 
kufika katika maabara kuu ikiwa ni pamoja na madhara yanayoweza kutokea. Pia 
tungependa kusikia uzoefu wa waratibu wa kifua kikuu na ukoma katika mikoa husika 
kabla sampuli hazijatumwa Maabara kuu ya kifua kikuu Tanzania kwaajili ya uchunguzi. 
Pamoja na hayo tunge penda kupata maelezo ya viashiria vilivyokua vinafuatilia utendaji 
wa mfumo huu wa kuchunguza kifua kikuu siku za nyuma. Mshiriki Msaidizi ataongoza 






Faida za Utafiti huu? 
Tungependa kujua maoni yako kama mhudumu wa afya kuhusu mpango wa kudhibiti 
kufua kikuu (KKK),pia tungependa kujua uzoefu wako,vikwazo na changamoto kaika 
utekelezaji wa shuguli za mfumo wa kuchunguza kiffua kikuu. 
Hatuna mpango wa kuzungumza na wafanyakazi wote katika kitengo cha kupambana na 
kifua kikuu katika kituohiki cha afya. Wewe ni mmoja wa walio chaguliwa kutowa maoni 
yao katika utafiti huu kama upo tayari.  Ushiriki wako unaweza kuwakilisha wafanyakazi 
wote katika kituo hiki cha afya. Majibu tutakayo pata kutoka kwako yatachambuliwa 
kupata majibu ya ujumla kuhusiana na uelewa wa wafanyakazi wa afya katika mpango 
wa kupambana na kifua kikuu, changamoto na vikwazo vinavyo sababisha kudorora kwa 
mfumo wa kawaida wa ugunduzi wa kifua kikuu pia vitafahamika. Tunaamini kuwa kama 
tutapata ufafanuzi juu ya Routine Surveylance System (RSS) katika mitandao ya maabara 
hapa nchini.? 
 
Kwanini Nimealikwa Katika Majadiliano? 
 
Umealikwa katika mahijiano kwa sababu unafanya kazi katika kitengo cha KKK. 
Unamuhudumia mgonjwa na unachukuwa sampuli zake kwa uchunguzi Zaidi katika 
kiliniki za kKK(TB). Mahojiano haya ytatoa ufafanuzi muafaka. Jisikie huru na toa maoni 
yako kwa uhuru. Kama hutotaka kushiriki katika mahojiano haya ni  sawa pia. Unaweza 
kutuuliza maswali yoyote uliyonayo wakati wowote. Pia tunakuhakikishia usiri wa majibu 
utakayo tupa wakati wote. 
 
Utafiti unahusika na nini? 
Kwa kushiriki katika utafiti huu tutapenda ushiriki kwa hiari katika mahijiano mojawapo 
na utachukuwa tariban lsaa moja mpaka mawili. utapata faida ya moja kwa moja kwa 




wagonjwa hapa nchini. Pia tutaomba ridhaa yako ya hiari kwa kususainia kibali hiki cha 
kushiriki. 
Haki zako kama mshiriki katika Utafiti huu? 
Ushiriki wako katika utafiti huu ni wa hiari kabisa na unaweza kukataa kushiriki au 
kusimamisha ushiriki wakati wowote bila kutowa sababu yoyote. Kuondoka kwako 
hakuta hathiri utafiti huu. Hivyo upo huru kutoa taarifa zako au kukataa kutoa. 
Utachukuwa Muda gani? 
Utachukuwa takriba miezi miwili hivi pia titakutumi barua ya mwaliko wa kushiriki 
Kuna hasara gani kwa kushirik? 
Hatutegemei kuwa na hasara kwa kushiriki kwako katika utafiti huu. Aidha unaweza 
kuogopa kwa ajili ya ajira yako, lakini hatutatumia jina lolote la mshiriki, ila tutatumia 
namba ya uchunguzi (study number). Kila mahijiano yatakuwa ya usiri kabisa na msaidizi 
wa uchunguzi atakuwa anakumbushia usiri wakati wote. 
Faida Za Kushiriki katika utafiti ni nini? 
Ushiriki wako unaweza kuwakilisha wafanyakazi wote katika kituo hiki cha afya. Majibu 
tutakayo pata kutoka kwako yatachambuliwa kupata majibu ya ujumla kuhusiana na 
uelewa wa wafanyakazi wa afya katika mpango wa kupambana na kifua kikuu, 
changamoto na vikwazo vinavyo sababisha kudorora kwa mfumo wa kawaida wa 
ugunduzi wa kifua kikuu pia vitafahamika. Tunaamini kuwa kama tutapata ufafanuzi juu 
ya Routine Surveylance System (RSS) katika mitandao ya maabara hapa nchini. 
 
Je Kuna Malipo? 






Timu ya utafiti itahakikisha kwamba, taarifa zote na matokeo ya uchambuzi vitahifaziwa 
kwa usiri mkubwa. Taarifa zako zitakuwa zinatambuliwa kwa number tu. Na hakutakuwa 
na uhusiano wowote kutoka kwenye namba ya dodoso na fomu ya ridhaa jina lako 
halitahitajika kujaza fomu hii. Taarifa zitakazo andikwa katika majarida ya kisayansi 
hayata jumuisha taarifa zitakazo kutambua wewe kwa jina l au nafasi yako. Taarifa zako 
zitapitiwa na timu inayofanya utafiti huu tu, hakuna mtu mwengine yeyote atakaye 
ruhusiwa kupitia taarifa zako. 
Katika kutoa ridhaa ya kushiriki katika utafiti huu pia unatoa idhini ya kukubaliana na 
yaliyo ainishwa hapo juu. 
KushirikianaTakwimu 
Hakuna kitu kitakacho kuhusisha wewe na takwimu zitakazo patikana. Takwimu zitapelekwa 
kwa Mpango wa KKK, na Viongozi wa Wilaya na kujadiliwa kabla ya kusambazwa kote(publish) 
Uhalali wa Kujitoa 
Unaruhuiswa kujitoa katika mahoiano wakati woowte bila kutoa sababu zozote zile. Na 
wala haitadhuru kazi yako. Wala ushirikiano wako na Mpango wa KKK. Maelezo yako 
bado yatakuwa ni ya usiri kabisa. 
Kibali cha Mahadili 
Utafiti huu umewasilishwa katika Chuo Kikuu cha Liverpool School of Tropical Medicine 
na Medical Research Coordination Commettee (MRCC) yaani Kamati ya utafiti wa 
magonjwa katika wizara ya afya na maendeleo ya jamii. Barua ya Idhini ya kufanya utafiti 







Sehemu B: Kibali cha Ridhaa 
Nimeelezwa kuhusu dhumuni la utafiti na faida itakayopatika na utafiti huu. Nimeelewa 
na hiari yangu nakubali kushiriki katika mahojiano ya hiari. Fomu ya idhini katika uzuria 
Kikao cha majadiliano (FGD) na mchakato wa mahojiano kuhusu mfumo wa kuchunguza 
kifua kikuu. Na kwamba ninaweza kuacha kushiriki wakti wowote ule. 
 
Mshiriki 
Mshiriki: Natoa ridha ya kushiriki katika mahojiano. Mshiriki Nemekubali/ 
sijakubali (weka alama panapostahili)  
ndiyo hapana 
 
Saini ya Mshiriki Tarehe na wakati wa ridha: 
  
Jina la Mtafiti Msaidizi Tarehe  
  
 
Naelewa kuwa sual hili ni muhimu kwa mtafiti msaidizi kurikodi majadialiano kwa kutumia 
chombo cha kurikodia. 
Mtafiti Msaidizi Tarehe na wakati wa ridha: 
  
 
Ambaye atajibu maswali kuhusiana na Utafiti huu. 
Kama unahitaji maelezo yoyote ya ziada, kuhusiana na utafiti huu, tafadhali jisikie huru 




Bi. Basra Doulla 
Mtafiti Mkuu 
SLP: 65324 
Dar es Salaam 
Simu: 0773 230 778 
 
 
Kwa maswali yoyote kuhusu haki zako kama mshiriki: 
Kama kuna maswali yoyote kuhusu haki zako kama wa utafiti huu, na kama ungependa 
kuwasiliana na mtu mwingine zaidi ya timu inayo endesha utafiti huu wasiliana na watu 
walio ainishwa hapo chini., Kama unataka kutoa malalamiko yako kuhusu utafiki huu 
unaweza pia kuwasiliana na watu walio ainishwa hapo chini. 





Appendix 7: Informed Consent Form for Focus Group Discussion -English Version 
 
A: Informed Consent Form 
Investigator’s name: Basra Esmail Doulla   
 Name of Organization: National Tuberculosis/Leprosy Programme and Liverpool University
   
Title: Impact of Introducing an Effective Routine Surveillance System for Drug Resistance 
Tuberculosis in Tanzania  
Date: 
Study Number:   
 
Introduction 
This Consent form will cater for both interviews with the participants from the Focus 
Group Discussion (FGD) and in-depth interview with the IDI process. However, each 
interview will be conducted separately.  Before the interviews engaged, courtesy call will 
be undertaken both at the national and regional administrative and health authorities. 
The principal investigator (PI) or trained research assistance (RA) will explain the aim, 
study objectives and expected benefits of the study to the authorities in detailed. The 
same information will be presented to participants in Kiswahili, the National language. In 
order to ensure respondent’s job security, no name or any identification of the 
participants will be required; instead study number will be used. In addition, the RA will 
undertake the consent process, since participants are literate; the consent will be given 
in writing one day before the interview to provide room for the participants to 
understand the information relating to the study. The RA will ensure confidentiality and 
emphasis that, none of the responses will impact on the employment of the participants 
given participant will be discussing their work practices.7,8 
 
7 Qualitative Method For Health Research; Judith Green and Nicki Thorogood (2005) 
 






The study RA will separately administer and conduct the interview after obtaining 
consent both oral and written from the participants. RA will inform the participant that, 




During FGD the focus group discussions the participant’s responses will be heard by other 
researchers.   
This informed consent form has two sections:  
Section A: Information sheet explaining the information of the study to be undertaken 
Section B: Certificate of Consent for the participant to sign if you agree to take part in 
this study 
 
Section A: Information Sheet 
My name is --------------------------------------------, working with the Ministry of Health and 
Social Welfare (MoHSW) through the National Tuberculosis/Leprosy Programme (NTLP) 
would like to invite you to participate in an interview on routine surveillance system (RSS) 
on TB laboratory networking. You do not have to agree now, please take your time to 
read the consent form for better understanding. Before you make your choice, you can 
discuss among yourselves and feel calm with about the research. You can also ask any 
question for clarification or if you need more details do not hesitate to do so.  I would 
also like to introduce the study research assistant (RA) who will undertake this interview.  
What is the Aim of the Study? 
The main purpose of the RSS in Tanzania is to monitor the program performance at 




assessing patient response to individual TB drugs, monitoring the trend of multidrug 
resistance tuberculosis (MDR TB) in the country, and identifying individuals with drug 
resistance and informing the districts so they can start patients on appropriate treatment 
as early as possible. We are interested in understanding the factors contributing to lower 
performance of RSS, reasons for specimen does not reach or delay to reach to the central 
laboratory together with associated risk factors.  Also, we would like to hear experiences 
with the implementation of RSS from regional and district TB health workers. We believe 
this will give a better understanding to know the description of available historic 
indicators that monitor the performance of the RSS?  
 
Why have I been invited to participate in the study? 
 
You have been invited to take part in this study because you are working under TB clinic/ 
department; you are dealing with the TB patients and sputum specimen for diagnosis 
processes in one way or the other. By interviewing health workers working at the TB 
department/clinic, we anticipated to know your views on the TB programme as health 




What will the study involve? 
 
This study will involve your participation in a FGD. We will ask you to take part in one of 
the session of the FGD as one of the health worker working under TB department. We 
would also require you to consent to your participation in the study. 
 





If you agree to take part, you will be requested to participate in FGD which will last about 
50 to one hour. The discussion will be led by the RA.  During the discussion you and other 
participants will be asked to discuss about your   daily practice as TB staff, will include 
questions around your perception towards TB program’s performance, knowledge of TB 
and how is TB networking relates to the routine surveillance. We would like to record 
this discussion. This tape will be kept confidentially and will be used for writing reports.  
 
For how long will this study last? 
 
This study will take two – three months. During that time, we will invite you to participate 
in one of the FGD.  
 
Are there any risks of taking part in the study? 
 
We do not anticipate having major risks.  However, the participants might be scared and 
find uncomfortable on their responses might have impacted on their employment. In 
order to ensure respondent’s job security, we will ensure that, no name or any 
identification of the participants will be taken; instead study number will be used. It is 
important that, whatever is discussed during FGD will be kept confidential, participant will 
be advised not to discuss with anyone who was not taking part in the FGD. However, 
ensuring confidentiality during FGD will be difficult, but RA will always remind the 
participants the significance of sustaining confidentiality.   
 
What are the benefits to taking part in the study? 
 
 There will be no direct benefit to you of participating in this study. However, by 
participating in the FGD you will have a direct benefit by getting an opportunity to 




help in the future planning and implementation strategies for better patient’s 
management.  
Reimbursements 
You will not receive any financial or incentive in taking part in this study. However, 
refreshment will be provided (snacks and drinks) at the middle of the discussion. 
 
Confidentiality  
The researcher team will ensure that, all information and the results of the analysis will 
be kept confidential. Your information will be identified by a study number only. Data 
that maybe reported in scientific journals will not include any information that identifies 
you by name or working position. This information may be reviewed by authorized 
representatives of the study only.  In giving consent to participate in this survey you are 
also agreeing to the above conditions. 
 
Sharing the results 
 
Noting you tell us today will be shared with anyone outside the research team; nothing 
will be attributed to you by name. There will be a debriefing with TB staff at your region 
to discuss study results, this will be announced. Following the debriefing we will publish 
the results so that other interested people in the regions will learn from the research 
findings.  
 
Right to refuse or withdraw 
 
Your participation in this focus group/interview is entirely voluntary and you can refuse 
to participate or stop at any time without stating any reason. Your withdrawal will not 
affect the collaboration with the programme.  You are willing to agree your information 





This focus group/interview has been submitted to the University of Liverpool School of 
Tropical Medicine and Medical Research Coordination Committee (MRCC) of the MoHSW 
and an approval letter has been granted by the NTLP to conduct this study. 
 
Section B: Certificate of Consent 
I have been informed about the aim of the study and expected benefit and I fully 
understand these. I deliberate agree to take part in the study. I also understand that my 
participation does not have any monetary or incentive reward and that I have the right 
to withdraw from the study at any point of time without notice and my identity will not 
be disclosed. 
Respondent (Participants):  




Participant’s signature Date of signature  
  
Interviewer’s signature Date of signature 
  
 
I understand that it is particularly useful for the researcher to record the discussion with 






Participant’s signature Date of signature 
  
 
Who can answer your questions about the study? 
If you require more information, related to the study, please feel free to contact the 
investigator details listed below: 
Ms. Basra Doulla 
Principal Investigator 
P O Box 65324 
Dar es Salaam  
Telephone: 255773 230 778 
Email: Basra.Doulla@liverpool.ac.uk / bedoulla@gmail.com  
 
 
For any concern about your rights as participant in the study, contact: 
If you wish to ask questions about your rights as a study participant to someone other 
than the researchers or if you wish to voice any problems or concerns you may have 
about the FGD,  











Appendix 9: Specimens Rejection Form  
 
SAMPLE REJECTION FORM 
 
 
Patient Name/ Date  
Sample ID collected 
 
 Date and Time sample Received at CTRL 
 
The above sample has not met the criteria of a good specimen for the tests requested and 
processing this sample will give unreliable results. Therefore, we cannot submit the specimen 
for further analysis.  
You are advised to collect another specimen from the patient if possible.  
 
REASON FOR SAMPLE REJECTION 
                    Criteria for Sample Reception* 
Criteria for Sample Reception Met Not Met :(reason for rejection) 
Sample collected in proper container   
Sample properly sealed/not leaking   
Sample properly labelled at least with name/patient ID 
and Date of collection 
  
Nature of the sample delivered is appropriate for tests 
requested 
  
Volume of samples requiring culture must be at least 
1.5ml and above (ideal volume is 5ml) 
  
Sample was delivered with a request form   
At least patient name on both request form and sample 
container should be in agreement 
  
 
* For each of the criterion, tick the appropriate column if it has been met or not met 
 
We apologize for any inconvenience this has caused. 
CTRL Tech. Name/Sign                    Date: 
NB: Photocopy this form and the Laboratory Request form, staple the copies and keep in CTRL 








ACKNOWLEDGEMENT OF READING AND UNDERSTANDING THIS SOP 
Name Signature Date 
   
   
   
   
 
1. Title 
Standard operating procedure for specimen’s transportation of sputum from regions to the 
central tuberculosis reference laboratory 
 
SOP Approval 
 Name Signature  Date 





S. Mfaume  
    
Authorized by Dr Mutayoba     
Date withdrawn: 
Approved changes 
Change approved by Brief description of the change 
  
Annual Changes and Reviews 








2. Objective and Scope 
3. Purpose 
Sputum specimen’s collection, package, and transportation procedure to the CTRL 
 
4.Abbreviations 
5. Task and Responsibility 
Responsibility: 
Laboratory Technician from the respective regions  
he/ she can delegate to laboratory   personnel handling samples; will be responsible for    
following the shipment procedure 
 
Safety and Environment 
All samples should be well labelled 
The box should have the mark of potential hazards 
 
6. Procedure 
1. Sputum specimens for eligible subjects is collected in a sterile universal container or 50 
ml wide-mouth polypropylene falcon tube, 30 x 115 mm with screw cape.  
2. information of specimen is recorded in special dispatched book   
3. Sputum specimens will be labelled and packed into transport boxes or in boxes 
containing materials that can absorb leakage during transportation.  
4. The specimens will be accompanied with the well filled TB lab request forms with 
patient’s details  
5. A person at CTRL is informed immediately by message (sms), WhatsApp/email during 
specimen’s shipment 
6. Transportation is either by courier EMS, private bus, or courier boy  






Appendix 11: Reviewed Tuberculosis Laboratory Request Form  
  
Ministry of Health and Social Welfare 




Request and Reporting form for Xpert, LPA, TB Culture and Drug Susceptibility Test (DST) 
 
Patient TB District number ____________      Patient identification study number ____________  
Surname and first name of patient: _________________________________________   Age: ______ Sex: _____ 
Ward / Department: __________________  Address: _________________________________________ 
*HIV-status: Pos  / Neg  / Unknown    _________________________________________ 
          Region: _____________________ 
TB Disease type and treatment history 
Site:   Pulmonary      History:  New (never treated before for ≥1 month)  
    Extra pulmonary (specify):_______________      Relapse      
                  Failure     
Previous treatment:   Cat.1            Return after default 
        Cat.2            Chronic excretor     
       Cat.4 (second-line drugs)         MDR contact 
        Other _________________      Uncertain 
Origin of request: Region ID: _______________ District ID: _________Local laboratory name: ________________ 
Date of specimen collection ____/____/20____ Date of specimen processed ____/____/20____Lab serial number 
______________ 
Local laboratory Results:   Smear result: 1st ____        2nd ____    specimen  
Microscopy technique used:  Ziehl-Neelsen     Xpert MTB _____________ 
        Fluorescence      Rifampicin______________ 
Request for testing at the Reference laboratory: 
Reason:  Diagnosis       Specimen:  Sputum   
     Follow-up at ____ months DURING treatment        Sputum in preservative, type CPC  
       Follow-up at ____ months AFTER treatment    other specify: __________________ 
Requested tests:  Microscopy  Culture  DST  LPA  MGIT  GeneXpert 
Person requesting examination:   Name: _________________________________ Position: ________________ 
* Information that can be disclosed optionally  ID = identification number or code  
 
Reference laboratory results: 
Date received at Reference Laboratory ____/____/20____ Date of specimen processed ____/____/20____ 
Reference Laboratory serial number: _______________ 
Microscopic examination: LPA Results: R S Date Test results____/______/20_____ 
 Neg 1-9 1+ 2+ 3+    Ziehl-Neelsen   
   Fluorescence         
INH   
       Rif   
 
      Date Culture result inoculated ____/____/20____; Time________ 
Contaminated Neg 







1-9 colonies  
actual count 
10 – 100 col 
1+ 





         
DST Results:   will follow 
     Phenotypic method used ________________________   DST Batch: ________________ 
      Genetic method used ___________________________ 
  Legend:  S = Susceptible;       R = Resistant;       ND = Not done 









Pos Neg Contaminated Date results 
















































              
  
          
              
  
          
              
  
          
              
  










ACKNOWLEDGEMENT OF READING AND UNDERSTANDING THIS SOP 
 
NAME SIGNATURE DATE 
   
   
 
1. Title 
Specimens reception and accessioning 
 
 2. OBJECTIVE AND SCOPE 
This SOP will describe the reception and the allocation of the accession number of specimens 
in CTRL. This will help maintaining patient confidentiality, preventing specimens mix up, 
ensuring specimens integrity, and overall quality handling of specimens. It is imperative that 
SOP Approval 
 Name Signature  Date 





S. Mfaume  
    
Authorized by Dr. Mutayoba     
Date withdrawn: 
Approved changes 
Change approved by Brief description of the change 
  
Annual Changes and Reviews 





all personnel in the CTRL follow this SOP appropriately. This procedure is the first step in 
preparing patient specimens for processing, storing, and transferring to appropriate department 
of the CTRL for testing. 
 
3.ABBREVIATIONS 
 NTLP  National Tuberculosis and Leprosy Programme 
 CTRL  National Tuberculosis Reference Laboratory 
 LRFR   Laboratory Request Form Reconciliation form 
 SOP   Standard Operating Procedure 
 
4. Tasks, responsibilities and accountabilities  
  
Tasks Responsible Accountability 
Specimens collection  Authorized laboratory staff  Head CTRL 
Specimens registration Authorized laboratory staff  Head CTRL 
   
5. Safety and environment 
 
1. Wear gloves when handling specimen, and treat all the specimens as infectious material  
2. Label all specimens with laboratory serial number corresponding to the lab request from 
container as well as reception register. For study specimens label with a study 
identification number.  
3. Try to complete reception of specimens while the person who delivered them is still 
present so that he can carry back some information if available. 
4. Documentation of any corrections made should be noted on the laboratory request form 




1. Laboratory register 
2. Pens; blue or black and red and Fine Tip Markers 
3. Gloves 
4. Laboratory Coat 
5. Specimens racks 
6. Laboratory Request Form file 
 
Step procedure. 




and are delivered to the laboratory. 
2. The specimens must be shipped to the laboratory under conditions that are 
appropriate for subsequent processing, culture and testing.   
3. Each specimen MUST be accompanied by a TB lab request form or its equivalent 
for research specimens. 
4. Unpack the patient specimens and the TB lab request form. Match each specimen 
with the corresponding request form and make sure that the identifiers on the 
specimen’s containers match those on the request form. 
5. Check the criteria for acceptation of a specimens (see SOPs P001_v1.0 Specimens 
Rejection criteria). In case of rejection, follow the procedures mentioned in 
P001_v1.0 Specimens Rejection criteria 
6. If the specimens are acceptable, the date and time that the specimens were received 
at CTRL and the initials of the personnel handling the specimens, specimen’s 
appearance and volume are noted down on the lab request form. 
7. Transfer all the information in the reception TB laboratory register  
8. Record the Laboratory serial number with four digits eg 0001 and the numbers 
must be serial disregard of the origin of the specimens, from the request form, TB 
lab reception register, and on all specimen containers/ slides. 
9. Record the specimens’ laboratory number and the patient’s information in the 
Primary Culture Laboratory register in which subsequent monitoring will be 
done. 
10. Put all received specimens on a suitable rack and send the specimens to the Tb lab 
3rd floor 
11. If specimens have been received later in the evening, store appropriately in a 
fridge at 2 - 8°C or cooler place till the next morning.  
12. Dispose packing waste (cotton wool, gauze etc) in the biohazard bag/container 
under the specimen’s reception table.  
 
7. Related documents 
Authorization list 
Safety manual 
8. Related forms  
CTRL lab request form 
 
9. References  
ISO 15189 Guidelines for clinical laboratories 
 





Appendix 14: Standard Operating Procedure for Sputum Specimen Collections  
 
ACKNOWLEDGEMENT OF READING AND UNDERSTANDING THIS SOP 
NAME SIGNATURE DATE 
   
   
 
1. Title 
Standard Operating Procedures for sputum specimen’s collection in the tuberculosis 
laboratories  
 
2. Objective and Scope 
This SOP describes the correct method of obtaining a good quality sputum specimen from 
a TB suspects for the diagnosis of TB disease. The method is only applicable to adults 
only  
Purpose 
This procedure provides instructions for the collection sputum.   
 
SOP Approval 
 Name Signature  Date 






    
Authorized by      
Date withdrawn: 
Approved changes 
Change approved by Brief description of the change 
  
Annual Changes and Reviews 




3. Abbreviations and definition 
AFB  Acid Fast Bacilli 
TB  Tuberculosis 
SOP Standard Operating Procedure  
 
4. Task responsibility and accountability 
Task Responsibility Accountability 
Collection instructions  Lab staff at reception desk Lab supervisor  
Container provision  Lab staff at reception desk  Lab supervisor  
Container labeling and 
registrations 
Lab staff at reception desk Lab supervisor  
Specimens 
acceptance/rejection 
Lab staff at reception desk Lab supervisor  
Specimens provision TB suspect Lab staff at reception desk 
Specimens processing All Lab staff  Lab supervisor  
 
5.0 Safety and environment 
Instruct the patient with the following recommendations: 
• Collection must be done in open area away from other people  
• Use of handkerchief while coughing, sneezing, talking, to avoid aerosol formation  
• Avoid spiting outside the container  
• Gloves and laboratory coat must be worn when performing this procedure.  
 
All specimens must be regarded as potentially infectious 











Collection, Labeling and Registration 
1.1 Have all the needed specimen collection tools on hand Refer to specimen test 
catalog. 
1.2 Wear gloves and laboratory coat. 
1.3 Label patient details on the container including: Health facility name, date, 
patients name, Age, gender and physical address  
1.4 Fill in the laboratory request form, patient’s details must match with those on 
the container. 
1.5 Explain the specimen collection procedure to the patient 
1.6 Provide patient with the screw-capped container 
1.7 Instruct patient to cough deeply and spit up sputum (phlegm) into the screw-
capped sputum container. 
1.8 Instruct patient to seal the specimen container tightly. 
1.9 Ensure the sputum in the container is sent to the laboratory. 
1.10 Label each specimen immediately with identifying information – patient 
identificationnumber, date and time of collection. 
1.11 Fill out lab request/report form for each specimen with date, time and 
initials of collector.  
1.12 Check that lab serial number  on the specimen container matches with 
that on the lab request form. 
 
  
NOTE: This labeling and matching is the primary responsibility of the collector and 
must be done carefully and precisely.  
1.13 Place collected specimens in a transport container at an appropriate 
temperature, awaiting transport to the laboratory. 
1.10 Dispose of gloves and wash hands after each specimen collection/handling. 
Materials 





• Screw-capped sputum 
containers 
• Disposable Gloves 
• Laboratory coat 
• Soap 
• Permanent marking pens 
 





1.11 Enter specimen information into clinic/phlebotomy specimen register book 
             1.12 Send specimen to the laboratory. 
 
 
7. Related Documents 
 
 











Appendix 15: Topic Guide for Focus Group Discussion 
 
Target: Focus Group Discussion (FGD) for (Health workers working at the TB clinics, 
departments at the regional level, TB Programme staff and the Central tuberculosis 
reference laboratory staff).  
Before commencing the Focus Group Discussion (FGD), you will seek permission to 
conduct this study at the selected study sites and capture key demographic data on each 
of the participants this includes: sign written consent form.   
 
Focus Group Discussion ………………. …. ……….. Designation……………………………  




Topic 1: Objectives 
To understand what factors leads to inadequate performance of the routine surveillance system 
(RSS) in Tanzania for previously treated TB cases before and after intervention of the pilot study 
in Mwanza region.  
What is the scale of the inadequate performance of the current RSS?  Probe if there was any 
difference before and after intervention?  
What factors do stakeholders in the process believe are affecting performance of RSS? 
 
Topic 2: Introduction to the discussion 
Introduce the study objectives and explain the aim of the FGD- will be discussion on the factors 
leads to inadequate performance of the RSS in Tanzania for previously treated cases and 
perception of the TB health workers and other stakeholders in relation to the RSS and the pilot 
study conducted in Mwanza region  
Emphasise the importance of confidentiality and ensure respondent’s job security, no name or 
any identification of the participants will be required during FGD. (all matters that will be 
discussed in this private room will be held in confidence) 




Explain that there are no wrong answers or right answers 
Ask each participant to introduce themselves. 
All discussion will be tape recorded 
Participant will have allowed withdrawing from the study at any given time without notice.  
 
Topic 3: Tuberculosis routine surveillance system 
How do TB health workers involve in the RSS? (Probe; what is the role of the health workers in 
RSS, what do they think of the current method and the pilot study? what is their perception on 
the TB Programme and the reference laboratory?) 
 
Describe how RSS is implemented in your health facility? (Probe; if health workers know about 
the RSS, and what type of specimen needs to be send, algorithm and safety) if it in Mwanza region 
probe if they know the revised RSS.  Probe if revised RSS would be continuing?  
What do health workers think are challenges in implementing the routine surveillance system? 
How about the revised RSS? (Probe issues related to:  related causes that contribute to TB 
diagnosis is it patients or programme, feedback of the results, specimen handling and support 
from TB Programme). 
What could be done differently to make it better, what could be of beneficial to the community? 
(Probe for both systems current and revised RSS) 
Does the clinic transport specimen to another laboratory? Who does the specimen 
transportation? (Probe; how is it transported?) 
What perception of the health workers toward TB reference laboratory? What do they think it 
could be done better or sustain? (Probe; Issues around TB networking, results turnaround time 
and the performance). 
 
Topic 4: Relationship the workload 
Where does your patients come from probe;( how many patients per day per clinic, if heavy clinic, 
why, issues around health education and who does the TB screening) 
What perceptions do the health workers feel towards patient management? (probe; compared 






Topic 5: Knowledge on Tuberculosis 
How do health workers become aware of new TB diagnostic strategies? (Probe; from the 
programme, training, internet, collaboration with the TB programme, how is it disseminated). 
What do health workers know about TB transmission? (probing on ways it is transmitted, ways 
it is prevented, explore questions relating to TB diagnosis)  
What knowledge do the health workers have on RSS? (probe; after intervention, do they still feel 
the same? how it works, collaboration with the reference lab, specimen to be transported, 
frequency). 
 
Topic 6: Ending the discussion  
Before we break up, is there anything else you think would be useful for programme to know? 
Do you have any questions about any aspect of this interview? 
OK, thank you very much for your help and active participation. 
 
Try to leave the discussion in a positive way thanking everyone for her participation.  Make sure 
you stay behind in case any one wishes to speak further.  Make sure you are assured them 
nothing will jeopardize their professions.9 
Note: 
When introducing this topic, it is important to be very sensitive as we are talking on people’s 
careers.   No participant should be forced to respond to these questions.  Again reassure 
participants that there are no wrong answers to these questions.  If people do not want to 
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Appendix 16: In depth Interviews Discussion Guides for Evaluation study 
 
1. Target: Participants (members of the National Tuberculosis/Leprosy Programme (NTLP), 
Programme Manager, Programme staff, Donor Representative Agencies (DRA) supporting 
tuberculosis (TB) interventions in the country. The Ministry of Health and Social Welfare at 
the Department of Preventive Services where TB programme is under the directorate.   
 
2. Objectives 
To determine what factors leads to inadequate performance of the routine surveillance system 
(RSS) in Tanzania for previously treated cases after intervention. (Probe if there is any difference 
before and after pilot study conducted in Mwanza region), explore area which shows or not show 
any changes? 
• What is the scale of the inadequate performance of the current RSS before and after 
intervention? Probe what do they prefer, is there any changes for the better? 
• What factors do stakeholders in the process believe are affecting performance of RSS? 
o To explore stakeholders’ perceptions of the successes and challenges in the TB 
Control Programme in Tanzania  
• What evidence exists in support of the factors above? 
o To identify stakeholders‟ own roles and contributions to the TB Control 
program in Tanzania   
 
Participants ………………. …. ……….. Designation……………………………  
Organization ………………………………………………………………………….  
Interviewer…………………………………………….  
Date…………….……………. 
 
 
